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1.1 General introduction 
Anovulation is a major cause of female reproductive dysfunction and can be iden-
tified in approximately 18-25% of couples presenting with infertility (Hull et al., 
1985). Oligomenorrhea (arbitrarily defined as menstrual periods occurring at 
intervals betvveen 35 days to 6 months) or amenorrhea (menstruation intervals 
longer than 6 months) are common features. \Vhether and ho\v frequent there 
occasional bleedings are associated \vith preceding ovulatory cycles is not known. 
The occurence of ovulation can be established applying basal body temperature 
charts, the assessment of serum progesterone levels, or through the observation 
by ultrasound of co !laps of the pre-ovulatory follicle. While ovulatory cycles may 
be observed occasionally in oligomenorrheic ·women, ovulatory cycles are unlike-
ly events in amenorrhea. 'vVell-designed longitudinal follow-up studies concern-
ing the incidence of spontaneous conception in oligomenorrheic patients are lack-
ing. Follov,.·-up studies performed thus far report only on pregnancies in those 
women \Vho did not conceive spontaneously and subsequently seek the physi-
cian's help. Therefore, this population may be a negative selection of patients \Vho 
exhibit cycle abnormalities. Obviously, induction of ovulation is required in these 
anovulatory patients to achieve follicular maturation, subsequent ovulation and 
ultimately conception. 
The association betv,reen oligoamenorrhea, obesity, bilateral polycystic ovaries, 
and hirsutism was illustrated in 1935 by Stein and Leventhal (Stein et al., 1935). 
A primary ovarian defect \\ras inferred since bilateral vvedge resection of the ovary 
restored the cycle abnormality unexpectedly and 2 of 7 patients conceived (Stein 
et al., 1967). The wide variability of clinical and histologic fmdings associated 
with anovulatory state in PCOS resulted in the inability of the investigator to dis-
tinguish clinically significant and reliable characteristics of this syndrome 
(Goldzieher et al., 1963). Excessive androgen production was initially attributed 
to abnormal adrenal function. Hyperandrogenemia clue to diminished granulosa 
cell aromatase activity (responsible fOr the conversion of androgens to estrogens) 
of the polycystic ovaries (PCO) has subsequently been demonstrated (Axelrod et 
al., 1962). Abnormalities in the hypothalamic-pituitary-ovarian axis resulting in 
inappropriate FSH secretion along with luteinizing hormone (LH) hypersecretion 
has also been highlighted (Yen et al., 1970). Further insight in the abnormal phys-
iology of this disorder occurred vvhen hyperandrogenism \vas demonstrated to be 
LH dependent (Givens et al., 1974). A landmark discovery was the association of 
ovarian hyperandrogenism and various causes of insulin resistance (I"\ahn et al., 
1976) and subsequently, an association between polycystic ovaries, hyperandro-
genism and hyperinsulinemia was established (Burghen et al., 1980). 
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The ultrasound manifestation of polycystic ovaries was first illustrated by 
S\vanson and co-vvorkers who demonstrated symmetrically enlarged ovaries con-
taining numerous tiny cysts in various diameters ·which may be arranged in the 
periphery of an ovary (Swanson et al., 1981 ). The ultrasonographic diagnosis of 
polycystic ovaries became accepted after diagnostic criteria had been critically 
defined (Forster et al., 1988). Criteria for polycystic ovaries have- amongst many 
others- been investigated by our group applying transvaginal sonographic (TVS) 
assessment of the ovarian stroma echogenicity (arbitrarily classified from 1-3), 
ovarian volume (milliliters), and total number of follicles (both ovaries) (van 
Santbrink et al., 1997b; Pache et al., 1992). Polycystic ovaries has been defined as 
"mean ovarian volume 2:: 10.8 mL and/or mean follicle number per ovary 2:: 10" 
(van Santbrink et al., 1997b ). 
Ho\vever, criteria for PCOS diagnosis are not \\rell defined. Various endocrine 
abnormalities such as hyperandrogenemia, hyperinsulinemia, or high LH have 
been used for the definition ofPCOS (Fauser et al., 1997). We studied the incidence 
of features associated vvith PCOS in normogonadotropic anovulatory infertility 
(see below), including high testosterone (T <: 3.£ nmol!L) and/ or high 
androstenedione (AD<: 16.3 nmol!L) in combination with polycystic ovaries (van 
Santbrink et al., 1997b). 
1.1.1 Classification '![anovulatory infertility 
The clinical approach to ovulation induction in patients \vith ovarian dysfunction 
requires an understanding of the causes of anovulation. Classification of cycle 
abnormalities was originally described by Lunenfeld and lnsler (Lunenfeld et al., 
1974) and has been subsequently modified by the World Health Organization 
(\VHO) (Rowe et al., 2001) and European Society for Human Reproduction and 
Embryology (The ESHRE Capri Workshop Group. et al., 1995). According to this 
classification based on the assessment of gonadotropin and estrogen levels, 
patients are classified into three main categories (referred to as \i\'HO classifica-
tion; group l, 2, or 3). 
TVHO class I: Hypogonadotropic hypo gonadal anovulation (hypothalamic-pituitary 
dyifunction): \Vomen in this group, which accounts for 5-10% of anovulatory 
women, frequently present with amenorrhea. They have low or low-normal serum 
follicle-stimulating hormone (FSH) concentrations and negligible endogenous 
estrogen activity suggesting a central origin of the disease (i.e. decreased hypo-
thalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unre-
sponsiveness to GnRH). The causes of hypothalamic amenorrhea include stress or 
exercise-related amenorrhea, anorexia nervosa, and l{allman's syndrome (isolated 
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gonadotropin deficiency). Approximately 5-!0% exhibit hypopituitarism. 
Hl1-IO class 2: j_Vormogonadotropic norma-estrogenic anovulation (pituitar;'-ovarian 
'dysbalance'): \Vomen \Vith normogonadotropic normoestrogenic anovulation con-
stitute the largest group of anovulatory women encountered in clinical practice 
(60-85% of cases). These patients present with serum FSH (1-10 IU/L) and estra-
diol levels within the normal range (\'Vorld Health Organization. et al., 1993; Rowe 
et a/., 2001 ). The polycystic ovary syndrome (PCOS), characterized by chronic 
hyperandrogenic anovulation, comprise a significant proportion of these patients 
(20-25%) (Rowe et al., 2001). It constitutes the most common cause of WHO class 
2 anovulatory infertility Strictly speaking, the term normogonadotropic does not 
apply to some women since approximately 50% present with elevated LH. 'WHO 
2 (and to a lesser extent PCOS) represent a notoriously heterogeneous patients 
group, since different underlying causes might be involved which lead to a compa-
rable clinical manifestation i.e. chronic anovulation. 
fVHO class 3: Hypergonadotropic hypoestrogenic anovulation: The patients in this 
group account for 10-30% of cases of anovulation. These individuals present \vith 
high levels of gonadotropins and lo\V circulating endogenous estrogens levels sug-
gesting the presence of a nonfunctioning ovary. The primary causes represent 
auto-immune disorders, genetic abnormalities or not yet elucidated factors that 
constitute conditions in which the number of the primordial follicles drastically 
diminish prior to the timed menopause (premature ovarian failure). 
1.1.2 Incentive for development of a sub classification rif WHO 2 
Despite the extensive endeavor of investigators who have focused on the etiology 
of PCOS, no clear consensus has been reached concerning the validity of criteria 
used to diagnose this syndrome as vvell as its relevance for clinical practice (Franks 
et al., 1 995). \'Ve have previously demonstrated that a distinct overlap exists 
betv,reen three criteria used for polycystic ovary diagnosis based on ultrasound 
(van Santbrink et al., 199/b). Moreover, these sonographic characteristics overlap 
the endocrine parameters such as LH, T or AD (Pache et a!., 1991; Pache et a!., 
1993; van Santbrink el al., 1997b). If strict criteria are used for the diagnosis of 
PCOS, a large heterogeneous group of YVHO 2 patients \:vill remain unclassified. 
All this confusion underlies a seemingly never-ending discussion regarding appro-
priate criteria for PCOS diagnosis. Controversy \\rill continue as long as end-points 
are not defined. 
It is generally accepted that PCOS patients represent a distinct subgroup with 
lower pregnancy chances and an increased risl-~: for development of complications 
during ovulation induction such as ovarian hyperstimulation syndrome (OHSS), 
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multiple pregnancy, or miscarriages. Hovvever, reports in the literature are con-
flicting due to inclusion bias of population studied and the retrospective nature of 
most studies (Fauser et al., 1997). Reflecting the lack of consensus in defining 
PCOS, various criteria are used for PCOS diagnosis. This obviously affects the 
inclusion of the remaining group of vVHO 2 anovulatory infertility in the study. 
Some features of PCOS can be found in almost all \VHO 2 patients and there is a 
gap in the literature regarding the behavior of these patients during ovulation 
induction. 
In daily clinical practice, it does not seem to matter whether a vvoman is diag-
nosed as having PCOS, since all WHO 2 anovulatory patients start with first line 
anti-estrogen medication clomiphene citrate (CC). Altogether, less than 50% of 
vvomen \Vill conceive following CC and very little is known regarding the clinical, 
endocrine, and ultrasound characteristics of these patients. This becomes increas-
ingly important with the current trend to delay childbearing, since time lost with 
ineffective therapy will by itself decrease chances for subsequent therapeutic 
strategies. Since, the primary wish of infertile couples is the live birth of a child, a 
reasonable approach may be to screen anovulatory infertile women with this end-
point in mind. Screening of anovulatory infertile women should be performed 
prior to initiation of ovulation induction vvith the follmving aims: 
Assessment qflzealtlz risks; Although extremely rare, anovulation may be the frrst sign 
of a serious underlying disease , such as ovarian, adrenal or pituitary tumors. 
To assess whether ovulation induction is indicated. For instance, medical intervention 
to induce ovulation is useless in WHO S anovulation where ovarian function 
per se is defective due to exhaustion of the primordial follicle pool. 
Choice of most appropriate type if ovulation induction agent; For instance, pulsatile 
GnRH in hypogonadotropic hypogonadism and CC in 'vVHO group 2 anovu-
lation. It is still uncertain whether the addition of dexamethasone in cases of 
adrenal hyperandrogenemia may increase chances of ovulation or conception. 
Further studies should also establish whether and for which patients insulin 
sensitizing agents are indicated. 
Assessment of doses required; Currently, most clinicians start with the lowest possi-
ble gonadotropin dose (50 or 7 5 IU of FSH), and increase the dose slowly and 
prudently (so called, low-close step-up protocols) to minimize the chance for 
OHSS. This is a low risk but time consuming approach. vVere dose require-
ments knovvn for a given patient, then treatment strategies could be individ-
ualized. This approach \vould increase efficiency and render this treatment 
modality more cost-effective. Starting with the individualized accurate dose 
(predicted FSH threshold or response dose) in decremental FSH dose regi-
mens, ho\vever, vvould certainly improve safety. 
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Assessment qf chances for success or complications; Patients with low chances may be 
directly shifted to alternative treatment options (such as exogenous 
gonadotropins as first line treatment, or IVF rather than ovulation induc-
tion). Patients with high chances for complications should be monitored 
more closely. 
Assessment qf chances of long-term health risks; For instance, increased risks of devel-
oping type 2 diabetes later in life on the basis of insulin resistance, or pre-
sumed cardio-vascular risks and chances for developing endometrial cancer 
in PCOS. Very fevv data are available in the current literature, and it is much 
too early to assess whether any prospective measure may improve life 
expectancy. Results from appropriately designed prospective follow-up stud-
ies are awaited "'vith much interest. 
1.2 Treatment strategies in WHO 2 anovulatory infertility 
The anti-estrogen clomiphene citrate (CC) represents the first line treatment 
strategy in 'vVHO class 2 anovulatory infertility. Medication is cheap and compli-
cations are minor. Hovvever, the majority of patients fail to conceive follov.ring CC 
therapy. Generally, these patients will subsequently be treated with daily adminis-
tration of exogenous FSH. This treatment modality is associated with a higher 
ovulation and conception rate at the expense of a clear increase in the chance for 
complications such as multiple pregnancies or OHSS. The last step of treatment 
strategy is in vitro fertilization (IVF). A schematic presentation of the treatment 
strategies, ovulation induction protocols and possible treatment outcomes has 
been depicted in Figure l. In this section we describe in brief the ovulation induc-
tion protocols used in daily clinical practice. 
1.2.1 Anti-estrogens 
Clomiphene citrate consists of two isomers with mixed estrogen and anti-estrogen 
activities (Adashi et al., 1996). Many organs have estrogen receptors, and therefore 
CC may act at many sites in the body (Adashi et al., 1996). Although rising serum 
FSH levels due to CC interference with estrogen negative feedback may be held 
responsible for stimulating follicle growth (Jacobson et al., 1968; Miyake et al., 
1983; Kerin et al., 1985), other mechanisms of action have also been proposed 
(Butzow et al., 1995; Aclashi et al., 1996). 
Generally, clomiphene is initiated between day S and day 5 after a spontaneous 
or progestagen-induced withdrawal bleeding. The starting close is 50 mg/ day, 
orally, for 5 subsequent days after initiation of menstruation. Daily doses are 
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increased by 50 mg in the subsequent cycle to increase the endogenous FSH rise 
and induce follicle maturation. The highest recommended CC dose is 150 mg/ day 
which generally is used in the subsequent cycle after a given vVHO 2 patient per-
sist to remain anovulatory following 100 mg of CC. If ovulation occurs, the CC 
close used should remain unaltered for subsequent cycles. Some publications pro-
posed higher daily doses (Lobo et al., 1982a) or an extended duration of treatment 
(Fluker et al., 1996). 
II 
Ill 
Treatment of normogon. 
anovulatory infertility 
WH02 
(+/- PCOS) 
initial screening characteristics 
clomiphene 
ovul+ 
pregn+ 
ovul-
preg-
FSH 
ovul+ 
(response dose 
preg+/- response/com pi) 
!VF (surgery) 
pregn+ 
preg- (complications, 
dose regimen) 
Figure 1.2. Schematic representation cf classical 07)ulation induction treatment modalities (and 
outcomes) in normogonadotropic anovulatory ilifertility 
However, the additional benefit in terms of the number of live birth applying these 
alternative approaches may be negligible and should be investigated. There is not 
a common consensus regarding the duration of the CC treatment if a given WHO 
2 patient's cycle abnormality is restored. Hmvever, ovarian response in these 
patients should be monitored in a regular basis i.e. every 3 months. A menstrua-
tion chart or a body temperature chart may be used to monitor the cycle pattern 
during CC use at home. Ovulation following CC can also be monitored by;(!) The 
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assessment of a midluteal serum progesterone (P) measurement (levels >25 
nmol/L indicating ovulation). (2) Transvaginal sonographic monitoring of follicle 
growth until the appearance of a pre-ovulatory follicle (mean diameter, 218 mm) 
and subsequent follicle rupture after endogenous LH rise. 
1.2.2 Exogenous gonadotropins 
Since their introduction into clinical practice in 1958, exogenous gonadotropin 
preparations play a central role as the second line modality for ovulation induc-
tion in WHO 2 patients \Vho fail to ovulate or conceive during the previous anti-
estrogen medication (Schwartz et al., 1981; Lunenfeld et al., 1985; lnsler et al., 
1988; Kelly et al., 1990; Fauser et al., 1993; Franks et al., 1994; Fauser et al., 1997). 
The aim of this treatment modality is to approach normal conditions as closely 
as possible; i.e. maturation and ovulation of a single dominant follicle and subse-
quent singleton pregnancy. Characteristics of dominant follicle development 
during gonadotropin induction have been monitored using ultrasound and 
serum estrogen levels (\Vilson et al., 1982; Marrs et al., 1983; Messinis et al., 
1990; School et al., 1992). 
As indicated previously, this treatment modality is associated \Vith a higher 
chance for complications such as OHSS or multiple pregnancy. During the first 
decade of clinical use, various dose regimens, such as fixed, intermittent, or flex-
ible incremental or decremental closes, have been tested (Taymor et al., 1967; 
Thompson et al., 1970). Recently, various novel protocols, new FSH preparations 
and tools have been introduced to improve ovarian response monitoring and 
minimize the chance of complication. These novel protocols will be discussed 
later in the present chapter; 
1.2.3 Alternative treatment modalities 
Recently introduced insulin sensitizing agents such as Metformin may be used as 
an alternative approach in (insulin resistant) anovulatory patients particularly in 
women remaining anovulatory following CC (l{ocak et al., 2002). More recently 
aromatase inhibitors have been introduced and may be used as ovulation induction 
medication in the future (Mitv,.rally et al., 1902). Laser surgery and ovarian drilling 
may be used to restore the cycle and endocrine abnormality of these patients 
although there is insufficient evidence to demonstrate a significant effect in ovula-
tion or pregnancy rates (Farquhar et al., 2000). In vitro fertilization is the last 
option in the treatment of \VHO 2 anovulatory infertility. This is the most 
unknown area in terms of understanding ovarian response during treatment and 
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prediction of treatment outcome (complications and live birth) partly clue to a lack 
of prospective follow-up studies. In vitro fertilization is certainly the most expen-
sive strategy in terms of treatment costs per cycle. Diet and exercise may also be 
a different approach in restoring the ovarian abnormality and should be combined 
yv·ith most of the treatment strategies to increase the chance of spontaneous or 
stimulated ovulation and conception (Hollmann et al., 1996; Clark et al., 1998). 
l.S Success and complication rates of ovulation induction 
protocols 
Approximately 70-80% of WHO 2 anovulatory infertile women will ovulate after 
CC medication (MacGregor et al., 1968; Gorlitsky et al., 1978; Shepard et al., 1979; 
Hammond et al., 1983; Polson et al., 1989; Opsahl et al., 1996), whereas only 40-50% 
of ovulatory women will conceive (Gorlitsky et al., 1978; Hammond et al., 1983) 
following CC. However, CC remains the first line treatment strategy in normogo-
nadotropic anovulatory patients, because it is simple and inexpensive ·with little 
chances for side-effects or complications. l'vfeans of identifying women who will 
remain anovulatory follov,ring CC therapy have, until recently, been restricted to 
clinical experience and retrospective analysis indicating obesity and hirsutism to 
be negative factors (Lobo et al., 1982b). 
Although gonadotropin therapy has been shO\\'n to be fairly successful in terms 
of ovulation rates (reported in the literature between 60-100%) (\Vhite et al., 1996; 
Imani et al., 1998) and cumulative pregnancy rates (reported betvveen 20-75%) 
(vVhite et al., 1996; van Santbrink el al., 1995; Imani et al., 1999), complication rates 
are high (Fauser et al., 1997). The most prominent complications include multiple 
pregnancies and OHSS. 
The chance of success and complications in each treatment strategy varies. 
Relevant factors will now be discused separately; 
1.3.1 Patients related factors 
Variability in the F SH dose requirements due to distinct individual F SH threshold levels 
\Vomen diagnosed as hypogonadotropic hypogonadism, by definition, suffer from 
inadequate stimulation of ovarian function. FSH serum levels are belo\v the 
threshold, and growth of follicles is arrested at a stage where further develop-
ment becomes dependent on stimulation by gonadotropins. If FSH levels rise 
above the threshold, due to exogenous administration of gonadotropin prepara-
tions, ovarian response should be normal. Success and complication rates of 
gonadotropin induction of ovulation in these patients is certainly favorable 
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(Oelsner et al., 1978; Dor et al., 1980; Healy et al., 1980; Schwartz et al., 1980; 
Wang et al., 1980; Ginsburg et al., 1991)(Hull et al., 1991). 
The great majority of \VHO 2 patients who remain anovulatory following CC 
medication are the potential candidates for induction of ovulation Vv'ith exogenous 
gonadotropins. Major complications during gonadotropin ovulation induction 
include multiple pregnancies (Schenker et al., 1981 ), ovarian hyperstimulation 
(Golan et al., 1989), and a high rate of early pregnancy wastage (Shoham et al., 
1991b). In this regard, a profound individual variability in ovarian response to 
stimulation by FSH (so-called 'FSH threshold') was proposed in anovulatory 
patients indicating that only a small margin exists betv.reen an effective dose and a 
dose generating excessive ovarian response clue to multiple follicle development 
(Brown et al., 1978). Unfortunately, predictors for the FSH threshold of a given 
'WHO class 2 patient have not yet been identifwd. 
Various lines of evidence indicate that early follicle development is normal in 
\VHO 2 patients particularly in PCOS, whereas anovulation is caused by disturbed 
dominant follicle selection (Pache et al., 1992). This abnormal condition may be 
caused by disturbed intraovarian regulation ofFSH action (Fauser eta!., 1994), and 
therefore response to exogenous FSH may be different from normal. Hence, the 
presence or absence of ovarian abnormalities in patients may influence treatment 
outcome after exogenously administered gonadotropins. This may explain major 
differences in the FSH threshold and duration of stimulation needed to induce pre-
ovulatory follicle development in these patients. 
The FSH response dose (FSH threshold) may represent the severity of ovari-
an abnormalities in \\.THO 2 patients and may be associated Vl-'ith reproductive 
outcome such as live birth during gonadotropin ovulation induction. Major indi-
vidual variability in FSH threshold and ovarian response to stimulation by 
exogenous FSH underscores the requirement for regular and cautious monitor-
ing of ovarian response by ultrasound and/ or rapid serum E 2 assays (Schoot et 
al., 1992) and fme-tuning of exogenous FSH doses on an individual basis. 
Disparity in the FSH threshold level of \VHO 2 individuals result in significant 
variability in the duration of gonadotropin administration. Unaltered late follicu-
lar phase FSH serum levels in gonadotropin-induced cycles differ significantly 
from the follicular phase of the normal menstrual cycle. This condition may elic-
it growth of other cohort follicles and consequently, induce multiple follicle devel-
opment clue to extension of the FSH window. 
Oligomenorrheic patients might constitute a different subset of V/HO 2 
patients compared to amenorrheic subjects. Amenorrheic women may present with 
lovv or normal E 9 levels \;vhereas estradiol in oligomenorrbeic \\-'Omen is usually 
\vi thin normal range. There are several studies indicating that frequency of PCO 
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is different in amenorrheic compared to oligomenorrheic subjects (Devoto et al., 
1998; Hull eta!., 1987). Although LH pulse fi·equency and intervals are not differ-
ent, the mean pulse amplitude is significantly higher in amenorrheic patients com-
pared to oligomenorrheic subjects (Prelevi<; et al., 1990). 
Obesity frequently coincides with PCOS, and differences in pharmacokinetic 
characteristics of gonadotropin preparations (Mannaerts et al., 1993), as well as 
clinical outcome (McClure eta!., 1992) related to body weight, have been reported. 
Moreover, other concomitant endocrine disorders such as hyperprolactemia or 
adrenal hyperandrogenemia may also affect treatment outcome. 
Increasingly, the wish to establish a family is expressed later in life. Therefore, 
the population of \vomen seeking help for infertility is increasing in age. It has 
been documented that cumulative conception rates after gonadotropin induction of 
ovulation are distinctly different vvhen \\romen under the age of 35 are compared 
with older women (Dor et al., 1980; Ginsburg eta!., 1991). 
1.3.2 Medication related factors 
Several stimulation protocols have been introduced and applied in the clinic 
applying lovv-dose exogenous gonadotropins regimen to minimize the chance of 
complication. Conventional step-up dose regimens for gonadotropin induction of 
ovulation are characterized by initial daily doses of two ampoules (= 150 IU of 
bioactive FSH). Doses may be increased after 5 days in the event that ovarian 
response is judged to be insufficient. This protocol has been the preferred dose 
regimen worldwide since the early 19/0s. Estimation of ovarian response changed 
over time from physical examination (urine and later serum) to estrogen assays, to 
abdominal ultrasound, and more recently TVS. Improved accuracy of response 
monitoring resulted in superior treatment outcome. This treatment modality is 
effective, with a relatively high complication rate (Thompson et al., 1970; Oelsner 
et al., 1978; Dor et a!., 1980; Healy et a!., 1980; Wang et al., 1980). This is now 
believed to be related to FSH serum levels being too far above the threshold in a 
great proportion of patients. Ho\vever, fev,r studies have fOcused on FSH serum lev-
els and ovarian response during conventional step-up cycles (vVu et al., 1977; Healy 
et al., 1983; Mallya et al., 1993). 
This dose regimen is characterized by low initial daily gonadotropin doses 
ranging between one-half and one ampoule (38-7 5 !U of bioactive FSH), and doses 
are only increased by one-half ampoule per clay after 14 days, in cases of insuffi-
cient ovarian response (Seibel et a!., 1984 ). This treatment modality seems to be 
characterized by low complication rates, at the price of an extended duration of 
treatment and possibly a slightly diminished success rate (Seibel et al., 1984; Buvat 
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et al., 1989; Hamilton-Fairley et al., 1991; Shoham et al., 1991a; Dale et al., 1992; 
Cheng et al., 1993; Buckler et al., 1993; Dale et al., 1993; Herman et al., 1993; Balen 
et al., 1994; Strowitzki et al., 1994; Homburg et al., 1995). The FSH threshold for 
stimulation of ovarian activity is reached slowly and prudently, in an attempt to 
reduce the magnitude of serum FSH levels surpassing the individual threshold 
(Benet al., 1995). This means that in a given patient, gonadotropins are adminis-
tered for an extended period of time, clue to the individual profound variability of 
FSH threshold level. The amount of exogenous FSH will be increased after 14 clays 
of treatment in the event that a relatively high FSH threshold is operative. 
Pharmacokinetic studies have indicated that it takes approximately 5 days before 
steady state FSH levels are reached when similar gonadotropin closes are adminis-
tered daily through the intraperitoneal route (Mannaerts et al., 1993; Mizunuma et 
al., 1990). Therefore patients may be exposed to FSH levels that are too low to stim-
ulate follicle gro\vth for several weeks. It is uncertain \vhether ovaries may be sen-
sitized by extended exposure to subthreshold FSH levels. Similar daily serum FSH 
levels \vere measured preceding hCG administration in patients treated \vith lmv-
dose, step-up protocols (Dale et al., 1993). Hence, in the late follicular phase FSH 
serum levels remain above the threshold for an extended period of time, resulting 
in a \vide FSH windovv even vvhen lovv-dose step-up protocols are used. Improved 
treatment outcome, as compared vv·ith conventional step-up protocols, is likely due 
to the reduced magnitude of FSH levels surpassing the threshold \\,hen lov,'er ini-
tial doses are used. Improved monitoring of ovarian response should not be ruled 
out as an additional important factor responsible for improved safety of treatment. 
Our group has focused on establishing a protocol for gonadotropin induction of 
ovulation applying decremental doses once there is an onset of ovarian response 
following sonographic monitoring (so-called 'step-down' protocol) (Fauser et al., 
1993b ). The major goal has been to design a safe and effective dose regimen for 
gonadotropin induction of ovulation that mimics physiological circumstances as 
closely as possible (Schoot et al., 1992; School et al., 1993; Schoot et al., 1995; van 
Dessel et al., 1996). Readers are referred to the previous publications of our group 
for more detail (Schoot et al., 1992; Schoot et al., 1993; van Santbrink et al., 1995; 
School et al., 1995; van Dessel et al., 1996; Fauser et al., 1997; van Santbrink et al., 
1997a). In brief, we applied the following FSH dose regimen; i.e. a two-
ampoule/ day starting dose shortly after a spontaneous or progestagen-induced 
bleeding, followed by a decrease to one and one-half ampoules/day once a domi-
nant follicle can be visualized by TVS (at least one follicle > 10 mm) (van 
Santbrink et al., 1995; Fauser et al., 1997; van Santbrink et al., 1997a). The dose is 
further decreased to one ampoule/ day 3 clays after the first close reduction (van 
Santbrink et al., 1995). The stimulation duration is approximately 10 clays (medi-
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an) and from 234 stimulated cycles in only one or two large preovulatory follicles 
were observed in 95% of stimulated cycles (van Santbrink et al., 1995). As com-
pared with step-up protocols, a signifrcant reduction in late follicular phase E2 lev-
els and number of large and medium-sized follicles was observed in a randomized 
controlled comparative study performed by our group (van Santbrink et al., 1997a). 
Moreover, the pregnancy chances \vere not reduced compared to those indicated 
following the low-dose step-up dose regimens. The observed reduction in the 
duration of stimulation, as \'vell as a lo\ver total number of ampoules per stimula-
tion cycle, may represent significant benefits in terms of health economics 
(reduced drug costs per cycle, possibly a reduced number of visits to the clinic, and 
more ovulations in a given time period). The major problem of this approach is 
that the initial starting dose may be too high for a proportion of 'WHO 2 patients 
particularly those women with a low FSH threshold. For low-dose step-up regi-
men, hmvever, the major problem might be the duration of ovarian stimulation 
which is extended in patients with an augmented FSH threshold who start with 
an initial low-dose exogenous FSH. 
1.4 Statistical aspects of the development of a prognostic 
model 
The clinical end point in a prospective study for prediction of infertility treatment 
outcome may be ovarian response to medication, conception or ongoing pregnancy 
leading to live birth. At the end of follo·w-up in a prospective fashion, some patients 
have not yet reached the end point. Therefore, statistical methods have been intro-
duced to incorporate censoring, \vhich are based on the assumption 'non-informa-
tive drop-outs". The fact that a patient does not continue the fertility therapy does 
not indicate her chance of becoming pregnant since the statistical formula used in 
these methods are based on the assumption that the chances of becoming pregnant 
in all patients who did or did not reach the end point are comparable (Kaplan et al., 
1958; Cox et al., 1972). In this respect there is no problem with a given patient who 
voluntarily stops the fertility treatment. Hovvever, \vomen who are advised to stop 
the fertility treatment because of the adverse ovarian response are informative 
drop-outs. An excellent example for this condition is patients who remain anovula-
tory following CC vvho are advised to stop the first line medication and start vvith 
an alternative treatment modality such as induction of ovulation using exogenous 
gonadotropins. For this reason we focused on distinct outcomes (ovulation vs. con-
ception and life birth) in our studies focusing on prediction of CC outcome. 
So far only univariate analyses have been used in the studies on prediction of 
fertility outcome in the literature which does not take into account the dependen-
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cy bet\veen the candidate predictors. For this reason, multivariable analyses have 
recently been developed and used in the studies which have aimed to develop mod-
els for prediction of chances to conceive in norma-ovulatory sub/infertile vvomen 
(Eimers et al., 1994; Collins et al., 1995). For practical use, the model may be visu-
alized applying a score chart or a Nomogram. Finally, a prognostic model should 
be internally validated to correct the possible "overfitting". This is clue to the 
development of a multivariate model with many candidate potential predictors on 
a limited number of patients reaching the end point. 
1.5 Study objectives 
It V·muld potentially represent a significant step-fon;~..rard in the development of an 
individualized treatment strategy if patients with a very low chance for live birth 
after CC could be predicted beforehand. Alternative treatment approaches may be 
applied in patients \vho have a high chance of remaining anovulatory follm.ving CC 
or despite ovulatory CC-induced cycles do not conceive leading to live birth for 
reasons such as o·varian aging or altered endometrium receptivity. Literature 
regarding characteristics of these patients in vvhom CC medication is ineffective is 
scant. This becomes increasingly important at the present time since there is an 
increase in the number of patients \\·'ho would v.rish to have a child in a relative later 
age. Precious time might be lost \vith ineffective treatment in these patients, which 
in turn decreases chances of success for subsequent therapies. 
Prediction of ovulation induction outcome applying a nomogram may be a 
step-forward in individualized treatment protocols. The clinician may- after prop-
er external validation - apply these prediction models for decision making in 
choosing a treatment protocol which may be more effective and less expensive. 
This issue is becoming also more and more important in the daily clinical practice. 
Moreover, the social, financial, and economic consequences of a multiple pregnan-
cy (i.e. the recent report on overall live birth in a quadruplet in the US) after ovu-
lation induction should not be ignored. The tremendous consequences of a multi-
ple pregnancy should kept in mind and the aim sbou1d be reaching a singleton 
pregnancy which ends in a live birth. 
Step-clown regimens may involve a relatively high initial close of FSH followed 
by subsequent decremental steps. Particularly for those patients with a low FSH 
threshold level, the initial standard FSH dose may be too high. This could induce 
imminent ovarian hyperstimulation requiring cancellation of stimulation (Fauser 
et al., 1997). Adjusting the starting dose in women with a low FSH threshold 
would certainly reduce the incidence of multiple dominant follicle development 
and related complications during the step-down regimen. This could considerably 
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improve treatment outcome in both lo\'v-dose step-up or step-dovvn regimens and 
render this treatment modality safer and more efficient. Moreover, prediction of 
patients who are at high risk to develop multiple follicle growth and/ or OHSS may 
be a distinct step forward in reducing the incidence of complication rates after 
gonadotropin induction of ovulation applying step-up or step-down dose regi-
mens. Moreover, patients who have a poor chance to conceive after gonadotropin 
ovulation induction may be advised to omit CC therapy and directly start \Vith an 
alternative treatment modality (such as exogenous gonadotropins, insulin sensi-
tizing hormones, \\reight reduction, or in vitro fertilization) particularly in vvomen 
vvith an advanced age. 
From a clinical point of vie\v, it does not seem to matter \Vhether a patient is 
classified as PCOS or VVHO class 2, since all normogonadotropic anovulatory 
infertile patients start with first line therapy consisting of CC treatment for ovu-
lation induction. Therefore it may be more appropriate to exhibit a shift in atten-
tion and focus of various investigations from diagnosis to prognosis as long as no 
consensus has been reached regarding the definition and diagnosis of PCOS. 
Applying a distinct end-point (prognosis) such as live birth may be more reliable 
for the clinician and for the patient. This may render the treatment protocols more 
cost-effective in a century which financial issue of the hospital and the government 
has and is going to be more discussed. This "evidence based" approach might lead 
also to a ne\v sub-classification of the notoriously heterogeneous group of \VHO 
class 2 anovulatory women, v..rhich might add to our future understanding of this 
complex clinical picture. 
The prediction of outcome in ovulation induction strategies in \VHO 2 patients 
will be the scope of the present thesis. Ho\vever, ongoing investigation should elu-
cidate the probability of prediction of outcome of WHO 2 patients who do not 
reach live birth after CC or gonadotropin induction of ovulation applying a deere-
men tal dose regimen. 
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2.1 Introduction 
In a longitudinal follow-up cohort study we focused on the predictive value of ini-
tial clinical, endocrine, and sonographic screening for ovarian response (ovulation), 
success (conception as \\rell as live birth), and complications (such as multiple preg-
nancy or OHSS) following ovulation induction therapies. Various multivariate pre-
diction models have been developed. In this chapter, these models for the predic-
tion of ovarian response and clinical outcome following CC are discussed. This 
approach may provide valuable information regarding clinical and endocrine fac-
tors involved in ovarian dysfunction. Multivariate analysis allows to assess the 
inter dependence of these factors. Moreover, patients \vith low chances for success 
of ovulation induction may be identified in advance. 
The frrst part of the present prospective longitudinal follow-up study was 
designed to identify vvhether certain criteria assessed during standardized initial 
screening could predict the response to ovulation induction \'>'ith clomiphene cit-
rate (CC) in 201 patients presenting vvith oligomenorrhea or amenorrhea and 
infertility. Serum FSH levels were within the normal range (1-10 IU/L), and all 
patients underwent a spontaneous or progestin-induced \vithdrawal bleeding. 
Initial CC doses vvere 50 mg daily for .5 days starting on cycle day 3. In the case of 
an absent response, doses vvere increased to 100 mg and 150 mg daily in subse-
quent cycles. First ovulation \vith CC was used as the end point. After a complete 
follow-up (in the case of a nonresponse, at least 3 treatment cycles with daily CC 
closes up to 150 mg), 156 patients (78%) ovulated. The free androgen index (FA! 
= testosterone/ sex hormone-binding globulin ratio), body mass index (BMI), 
cycle history (oligomenorrhea vs. amenorrhea), serum androgen (testosterone 
and/or androstenedione) levels, and mean ovarian volume assessed by transvagi-
nal sonography were all significantly different (P < o.o 1) in responclet-s from those 
in non-responders. FAI \Vas chosen to be the best predictor in univariate analysis. 
The area under the receiver operating characteristics curve in a multivariate pre-
diction model including FAI, BMI, cycle history~ and mean ovarian volume was 
0.82. Patients whose ovaries are less likely to respond to stimulation by FSH due 
to CC treatment can be predicted on the basis of initial screening characteristics, 
such as FAI, BMI, cycle history (oligomenorrhea or amenorrhea), and mean ovar-
ian volume. These observations may add to ongoing discussion regarding etiolog-
ical factors involved in ovarian dysfunction in these patients and classification of 
normogonadotropic anovulatory infertile \Vomen. 
The second part of the present prospective follm.v-up study was designed to 
identi(y whether clinical, endocrine, or ultrasound characteristics assessed by stan-
dardized initial screening of normogonadotropic oligo/ amenorrheic infertile 
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patients could predict conception in 160 \\'Omen who reached ovulation after 
clomiphene citrate (CC) medication. Additional inclusion criteria were total motile 
sperm count of the partner above 1 million and a negative history for any tubal dis-
ease. Daily CC doses of 50 mg (increasing up to 150 mg in case of absent ovarian 
response) from cycle day 3-7 were used. First conception (defined as a positive uri-
nary pregnancy test) v,.'as the end point for this study. A cumulati·ve conception rate 
of 73% vvas reached \Vithin 9 CC-incluced ovulatory cycles. Patients who did con-
ceive presented more frequently with lower age (P < 0.0001) and amenorrhea (P < 
0.05) upon initial screening. In a univariate analysis, patients \vith elevated initial 
serum LH concentrations (>7.0 IU/L) had a higher probability of conceiving (P < 
0.01 ). In a multivariate analysis, age and cycle history (oligomenorrhea vs. amenor-
rhea) were identified as the only significant parameters for prediction of conception. 
These observations suggest that there is more to be gained from CC ovulation 
induction by younger v,romen presenting vvith profound oligomenorrhea or amen-
orrhea. Screening characteristics invoh·ed in the prediction of ovulation after CC 
medication in normogonaclotropic oligo/amenorrheic patients (body V1/eight and 
hyperandrogenemia, as shown previously) are distinctly different from predictors of 
conception in ovulatory CC patients (age and the severity of cycle abnormality). 
This disparity suggests that the FSH threshold (magnitude of FSH required for 
stimulation of ongoing follicle grov,rth and ovulation) and oocyte quality (chances 
for conception in ovulatory cycles) may be dift€rentia1ly regulated. 
The third part of the present prospective longitudinal follow-up study vvas 
designed to identify whether additional endocrine screening characteristics, all 
potentially involved in ovarian dysfunction in 182 normogonadotropic oligoamen-
orrheic infertile women, are associated with ovarian response, which may improve 
overall prediction of CC-resistant anovulation. Standardized endocrine screening 
took place before initiation of CC medication (50 mg/day; increasing doses up to 
!50 mg/day if required) from cycle days 3-1. Screening included serum assays for 
fasting insulin and glucose, insulin-like growth factor I (IGF-1), IGF-binding pro-
tein-! (IGFBP-1), IGFBP-3, free IGF-1, inhibin B, leptin, and vascular endothelial 
growth factor. Forty-two women (22% of the total group) did not ovulate at the 
end of follmv-up (a total number of 325 cycles were analyzed). Fasting serum 
insulin, insulin/ glucose ratio, IGFBP-1, and leptin were all significantly different 
in univariate analyses (P ::; 0.02), comparing CC responders vs. nonresponders. 
Fonvarcl step\vise multivariate analyses in combination \\rith factors reported ear-
lier for prediction of patients remaining anovulatory after CC revealed a prediction 
model including I) free androgen index (FA! = testosterone/ sex hormone-bind-
ing globulin ratio), 2) cycle history (oligomenorrhea or amenorrhea), 3) leptin 
level, and 4) mean ovarian volume. These data suggest that decreased insulin 
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sensitivity, hyperandrogenemia, and obesity, all associated vvith polycystic ovary 
syndrome, are prominent factors involved in ovarian dysfunction, preventing these 
ovaries from responding to stimulation by raised endogenous FSH levels due to 
CC medication. By using leptin instead of body mass index or waist to hip ratio, 
the previous model for prediction of patients remaining anovulatory after CC med-
ication could be slightly improved (area under the curve from 0.82-0.85). This may 
indicate that leptin is more directly involved in ovarian dysfunction in these 
patients. The capability of insulin and IGFBP-1 to predict patients who remain 
anovulatory after CC disappears when FA! enters into the model due to a signifi-
cant correlation between FAI and these endocrine parameters. This suggests that 
markers for insulin sensitivity (e.g. IGFBP-1 and insulin) are associated with 
abnormal ovarian function through its correlation with androgens, whereas leptin 
is directly involved in ovarian dysfunction. 
2.2 Predictors of patients remaining anovulatory during 
clomiphene citrate induction of ovulation in 
normogonadotropic oligo-amenorrheic infertility 
2.2.1 Introduction 
Chronic anovulation is a frequent cause of infertility~ and approximately SO% of 
these patients present with serum follicle-stimulating hormone (FSH) and estra-
diol (E2) levels within the normal range (WHO group 2) (World Health 
Organization. et al., 1993). The anti-estrogen clomiphene citrate (CC) is considered 
to be a successful treatment strategy in these patients. It has been documented that 
approximately 70-80 % of these \VOmen \\rill become ovulatory (MacGregor et al., 
1968; Gorlitsky et al., 1978; Shepard et al., 1979; Hammond et al., 1983; Polson et 
al., 1989; Opsahl et al., 1996), whereas 40-50% of ovulatory women will conceive 
(Gorlitsky et al., 1978; Hammond et al., 1983). 
Polycystic ovary syndrome (PCOS), usually referred to as chronic hyperan-
drogenic anovulation, represents a distinct proportion of \VHO group 2 anovula-
tory patients. It is uncertain to what extent PCOS patients are particularly prone 
to remain resistant to CC medication (Lobo eta/., 1982b; Adashi et al., 1996). 
Discussion continues regarding the validity of criteria used to diagnose PCOS 
(Franks et al., 1995) as \vell as its relevance for clinical practice. We have previously 
demonstrated that a distinct overlap exists betv,,een endocrine and ultrasound fea-
tures used by various authors (van Santbrink et al., l997b). If strict criteria are 
used for PCOS diagnosis, a large heterogeneous group of normoestrogenic 
patients vvill remain unclassified. 
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Thirty-five years after its first clinical introduction (Greenblatt et al., 1961), 
CC still remains the first line treatment strategy in normogonadotropic anovula-
tory patients. Although rising serum FSH levels due to CC interference with 
estrogen negative feedback may be held responsible for stimulating follicle grovvth 
(Jacobson et al., 1968; Miyake et al., 1983; Kerin et al., 1985), other mechanisms of 
action have also been proposed (Butzow et al., 1995; Adashi et al., 1996). A signifi-
cant proportion of treated women, however, do not respond. The aim of this study 
vvas to investigate \Vhether clinical, endocrine and sonographic characteristics dur-
ing initial screening of normogonadotropic anovulatory infertile \vomen may pre-
dict ovarian response to CC medication. This approach may help to define condi-
tions that prevent the ovary from responding to stimulation by increased FSH lev-
els and to further classify \VHO group 2 anovulatory patients. 
2.2.2 Subjects and Methods 
Subjects and study deszgn 
Approval for this study was obtained fl·om the human subject committee of the 
Dijkzigt Hospital/Erasmus University. Between February 1993 and September 
1996, 201 patients presenting ·with oligomenorrhea (interval bet\veen vaginal 
bleeding >35 days and< 6 months) or amenorrhea (bleeding interval >6 months) 
and infertility were recruited. Informed consent v,.'as obtained from all partici-
pants. All subjects \:vere referred directly by their general practitioner to our infer-
tility unit. None had received previous ovulation induction medication. Additional 
inclusion criteria were serum FSH levels within normal limits (1-10 IU/L) (van 
Santbrink et al., 1995; World Health Organization. et al., 1993), spontaneous 
menses or a positive bleeding response to progestagen \vithdrav,ral, normal serum 
PRL and TSH levels, body mass index (BMI; weight divided by the square of the 
patients height) more than 18, and age less than 40 years. 
Clinical, endocrine, and sonographic screening \\ras carried out before initiation 
of CC therapy. Clinical screening included infertility and cycle history, BMI, pre-
vious medication and/ or surgery. Endocrine screening included serum assays of 
FSH, PRL, TSH, LH, estradiol, androstenedione (AD), testosterone (T), sex hor-
mone-binding globulin (SHBG), cortisol, and clehyclroepianclrosterone sulfate. 
Fasting blood samples were taken randomly between 8:00-10:00 A.M. before to 
initiation of therapy. Venous blood samples were centrifuged v.-'ithin 2 hours after 
\Vithdrav,ral and stored at -20 C until assayed. Transvaginal sonographic screen-
ing included assessment of the ovarian stroma echogenicity (arbitrarily classified 
from 1-S), ovarian volume (milliliters), and total number of follicles (both ovaries), 
as described previously (van Santbrink et al., J997b; Pache et al., 1992). Serum LH 
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and FSH levels \Vere measured by immunoradiometric assay (Meclgenix, Fleurus, 
Belgium), and T, AD, SHBG, and dehydroepiandrosterone sulfate were determined 
using radioimmunoassay (RIA) kits (Diagnostic Products Corp., Los Angeles, CA), 
as described previously (Fauser et al., 1991; van Dessel et al., 1996), 
The treatment schedule and assessment of ovarian response \Vas as follows. CC 
medication \Vas initiated on clay S after spontaneous or progestagen-inclucecl vvith-
drawal bleeding. The starting dose was 50 mg/ day, orally, for 5 subsequent days. In 
the case of an absent response, daily doses vvere increased by 50 mg in the next cycle 
to a maximum close of 150 mg/ day in the following cycle. If ovulation occurred, the 
dose remained unaltered during subsequent cycles. First ovulation \vas used as the 
end point. The duration of follow-up for all patients included in the study was at 
least three treatment cycles. Ovulation \Vas assessed by midluteal serum proges-
terone (P) measurement (levels >25 nmol/L indicating ovulation) combined with 
transvaginal sonographic monitoring of follicle grovvth until the appearance of a 
preovulatory follicle (mean diameter, 218 mm) and subsequent follicle rupture, or 
by biphasic basal body temperature charts. Responders were defined as patients 
who ovulated during CC therapy, independent of the close administered. The num-
ber of treatment cycles and the CC close in which first ovulation occurred were 
recorded. Clomiphene-resistant anovulation (CRA) was defined as patients who do 
not ovulate despite receiving maximum treatment doses of 150 mg/day. 
Data analysis 
Distribution of characteristics in patient groups is presented as the mean ± stan-
dard deviation (SD). \Ve used the Mann-Whitney U test and the Wilcoxon rank 
sum W test for exploratory comparison of initial parameters betv,reen responders 
and nonresponclers. The univariate and multivariate relation \vith response to CC 
was assessed using logistic regression analysis. The following parameters \vere 
used in the analysis: BMI, ti·ee androgen index (FA!; T x 100/SHBG), serum T 
and/ or AD concentrations, serum LH levels, cycle history (oligomenorrhea or 
amenorrhea), cycle duration in case of oligomenorrhea, mean ovarian volume, and 
follicle number. Baclnvard stepwise elimination \Vas used for the multivariate logis-
tic analysis of prediction of patients being CRA, and P o; 0.10 was used as a cut-
off level fOr elimination of nonsignificant predictors from the prognostic modeL 
The area under the receiver operating characteristics (ROC) curve (AU C) was used 
to assess the discriminative ability of the logistic models. The AUC gives the pro-
portion of all pairs of patients (each pair consisting of one patient without and the 
other patient with a response to CC) in which the model predicts a higher proba-
bility of no response for the patient without response. The Statistical Analysis 
System program (SAS Institute, Cary, NC) was employed for data analysis. 
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Because selection and estimation vvas performed fOr S potential predictors on a 
dataset with only 45 events (CRAs), correction for overfilling was performed 
(Harrell, Jr. et al., 1996). The internal validity of the prognostic model was tested 
by a bootstrapping method in which the selection and estimation process was 
repeated 200 times. Each of these repetitions consisted of creating a new dataset 
(bootstrap sample) by drawing cases with replacement from the original data. The 
backward step\vise elimination process was performed on this dataset, yielding a 
set of selected predictors and parameter estimates (Van Houwelingen et al., 1990; 
Harrell, Jr. et al., 1996). Resulting model estimates of each bootstrap sample were 
evaluated on the original data, and a shrinkage factor \Vas estimated to correct for 
statistical overoptimism. The Hosmer-Lemeshovv goodness of fit test (Hosmer et 
al., 1989) has been used to check for lack of fit of the final model. The logistic coef-
ficients that were corrected by the shrinkage factor have been translated into an 
easy to use score chart. The scores vvere calculated by multiplying the shrunk coef-
ficients by 10 and rounding them off to the nearest Vi' hole number. 
2.2.3 Results 
The number of patients who did or did not ovulate after CC medication in increas-
ing doses of 50, 100, and 150 mg daily are depicted in Figure 1. Forty-five patients 
(22.5% of the overall study group) remaining anovulatory vvere considered having 
CRA. A total of 432. cycles were analyzed. 
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Figure 1 Distribution rifnorrnogonadotropic oligomenorrheic or am.enorrheic infertile women who 
do or do not ovulate following CC induction 9l mmlation in incremental dail)' doses 9l 50, 100, or 
150 mg,JOr 5 subsequent da;·s. A total number oj45 women (22.5% of the overall study group) 
remain anovulatory 
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From the total study group of 'W1 women, 91 (4,6%) were considered obese 
(BMI >26), 101 patients (5o%) presented with an elevated FA! (>1'.5), 85 patients 
(42%) presented with hyperandrogenemia (T 23.2 nmol/L and/or AD 216.3 
nmol!L) (Fauser et al., 1991; van Santbrink et al., 1997b), and in 125 patients (66%) 
polycystic ovaries (mean ovarian volume ~10.8 mL and/or mean follicle number 
per ovary 210) (Pache et al., 1992; van Santbrink et al., 199/b) were diagnosed. 
Finally, 105 patients (54%) presented with elevated LH (27.0 IU/L) serum levels 
(Fauser et al., 1991; van Santbrink et al., 1997b). 
In Table l, clinical, endocrine, and ultrasound characteristics are presented for 
the overall study group and separately for patients who did or did not ovulate after 
CC medication. Forty-four percent of patients presenting vvith amenorrhea ( 17 of 
39) were considered to have CR.l'l., whereas only 17% (28 of 162) of patients with 
oligomenorrhea showed no response. Statistical significance in univariate analysis 
with logistic regression analyses and ROC AUC of the initial parameters are 
depicted in Table 2. The AUCs for FA! and BM! were the highest (0.76 and 0.70, 
respectively). The ROC curve with the best performance (FA!) and that with the 
poorest performance (serum LH) are shown in Figure 2. 
Of the 201 patients, 187 had complete data on the variables used in the multi-
variate analysis. Using the back\varcl elimination procedure, 4 variables were 
selected in the final modeL 1) FA!, 2) BMI, s) cycle history (oligomenorrhea or 
amenorrhea), and ·l) mean ovarian volume. By using the combined information of 
these 4, variables, the AUC further improved to 0.82 (Table 2 and Figure 2). The 
bootstrap procedure revealed that these 4 predictors were selected in over two 
thirds of the bootstrap samples, whereas all other candidate variables were select-
ed in less than half of the samples, which illustrates the stability of the fmal model. 
The shrinkage factor was estimated from the bootstrap procedure to be 0.82, indi-
cating that when this study is replicated many times, the resulting coefficients of 
the final multivariate model are, on the average, 18% smaller. This v.ras incorpo-
rated in the calculation of the scores. The scores for different parameters are 
depicted in Table 3, and resulting probability scores fOr patients remaining anovu-
latory after CC medication are shovvn in Figure 3. The Hosmer-Lemeshow good-
ness of fit test showed no lack of fit of the final model to the data (P = 0.3). 
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TABLE 1. Clinical, endocrine, and ultrasound characteristics (mean ± SD) dur-
ing initial screening of 201 normogonadotropic oligomenorrheic or amenorrheic 
infertile women, and separated for patients who do (responders) or do not ovu-
late (CRA) after CC induction of ovulation 
Screening parameters Overall group CC responder CRA 
(n ~ 201) (n = 156; 71.5%) (n:::: 45; 22.5%) 
Clinical 
Age (yr) 28 ± 4<.4 28 ± 4•.5 27.5 ± 4.5 
Primary infertility (n) H5 (12%) 110(71%) 35 (78%) 
Amenorrhea (n) 39 (19%) 22 (H%) 17 (38%) 
Bleeding interval (days, 79 ± 62 70 ±56 113 ± 72 
in case of oligomenorrhea) 
BMI (kg/m2) 26.6 ± 6.2 25.5 ± 5.8 30.0 ± 6.6 
Endocrine 
T (nmol/L) 2.3 ± 0.9 2.1±0.9 2.7 ± 1.0 
AD (nmol!L) 16.5 ± 7.8 15.3 ± 6.5 20.5 ± 10.2 
SHBG (nmol!L) 53±31.7 57 ± S2.5 38.3 ± 23.8 
FA! (T X 100/SHBG) 5.9 ± 4.3 4.9 ± 3.4 9.3 ± 5 .. '3 
LH (IU/L) 7.8 ± 4.3 7.8 ± 4.3 8.2 ± 4.6 
FSH (IU/L) ·4.4 ± 1.4- 4.5 ± 1.4- 4.2 ± !.4 
E2 (pmol!L) 282 ± 233 296 ± 195 234 ± 78 
DHEAS (umol!L) 7.9 ± 3.8 7.9 ± .'3.7 7.9 ± 4 
TVS 
Total stroma scoreb s.o ± !.0 2.8 ± 1.3 3.3±1.1 
Mean ovarian vol (mL) 10.0 ± 4-.4- 9.2 ± 5.7 12.2 ± 5.8 
Mean fOllicle no. 11.5 ± 5 II± 6 12 ± 5 
a Comparison of CC responders ·us. CRA (by Mann-\Vhitney U test). 
b Arbitrarily defined as one to three per ovary (both ovaries added). 
2.2.4 Discussion 
P valuea 
NS 
NS 
0.0004 
<0.0001 
0.0001 
0.001 
0.001 
<0.0001 
<0.0001 
KS 
NS 
NS 
NS 
0.006 
0.0007 
KS 
It may be helpful for further classification of normogonadotropic anovulatory 
infertility and for evaluating pathophysiological factors involved in ovarian 
abnormalities in these patients to study in a longitudinal fashion \Vhether initial 
screening parameters may predict success, failure or complications of induction of 
ovulation. The present study was designed to investigate as a first step whether 
ovarian response after CC medication could be predicted. It is established in the 
literature that approximately 7 5% of patients will ovulate, and less than 50% of the 
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TABLE 2. Univariate and multivariate logistic regression analyses with score test 
and area under the ROC curve (AU C) of initial clinical, endocrine, and sonographic 
screening parameters in 201 normogonadotropic oligomenorrheic or amenorrheic 
infertile vvomen for the prediction of patients remaining anovulatory after CC 
induction of ovulation 
Parameters 
Univariate analyses 
r:'\I (T x Ioo/SHBG) 
BMI (kg/m2) 
l\'lean ovarian vol 
Hyperandrogenemia (elevated T and/or AD) 
Oligomenorrhea or amenorrhea 
lv1ean follicle no. 
Bleeding interval in case of oligomenorrhea 
LH (IU/L) 
Multivariate analysis 
Prediction model for CRAb 
a Area under the ROC curve. 
P value Auca 
<0.0001 0./6 
<0.0001 0./0 
0.0001 0.6/ 
0.0001 
0.0005 0.62 
0.1 0.58 
0.-42 0.5.'3 
0.5 0.52 
0.82 
b Combination of four initial screening parameters: FAT, BfvH, cycle history (oligomenorrhea or 
amenorrhea), and mean ovarian volume. 
total population will conceive after CC as first line medication. If patients remaining 
anovulatory despite CC therapy could be identified beforehand, ineffective and 
time-consuming CC medication could be prevented. This may be helpfi.1l, particu-
larly for vvomen of advanced reproductive age. Further studies, ho·vvever, are 
required to investigate \vhether alternative primary treatment options are cost 
effective. Moreover, ethiological factors involved in ovarian dysfunction could be 
identified in this heterogeneous patient group, as subjects v,rhose ovaries will or 
will not respond to increased FSH stimulation may be differentiated. 
For this first analysis of response to CC medication vve decided to focus on ovu-
lation rather than conception. Ovulation is biologically relevant and most closely 
connected to the desired effects of CC medication. Analysis of conception as the 
end point requires a comprehensive study of other potential confounders, such as 
tubal factor, sperm factor, and endometrial function. Four initial screening param-
eters (FA!, BMI, mean ovarian volume and cycle history) could be identified, pre-
dicting patients remaining anovulatory after CC medication. A combination of 
these parameters showed good predictive power, with a ROC AUC of 0.82. Several 
studies have been published recently regarding the use of a similar multivariate 
56 
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model for predicting chances for conception in infertile patients vvith regular 
cycles (Eimers et al., 1994•; Collins et al., 1995; Snick et al., 1997). Various 
researchers have investigated the predictive value of clinical and endocrine screen-
ing parameters for the response to CC. Only a positive correlation between body 
weight and the dose of CC required to induce ovulation has been established (Lobo 
et al., 1982b; Shoham et al., 1990). A recent study has indicated that increased BMI 
is the only initial parameter that is significantly different between responders and 
non-responders (!{ousta et al., 1997). To our knowledge this is the first time a mul-
tivariate prediction model has been applied in the treatment of anovulatory infer-
tility. \Ve could demonstrate that patients suffering from amenorrhea, obesity, 
increased ovarian volume, and elevated androgens (a complex of signs, symptoms, 
ultrasound and endocrine findings frequently referred to as PCOS) are most like-
ly to remain anovulatory after CC induction of ovulation. 
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Figure 2 Receiver Ojxrating Characteristics (ROC) Curve 9l serum LH concentration, FA! or the 
prediction model (FA!, B1'vfl, C)'cle histor;' and mean oDarian Dolume combined) for predicting clo-
miphene citrate resistant anomtlation (CRA) in a total groujJ rif 201 normogonadotropic oligome-
norrheic or amenorrheic injf:rtile women. 
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A model can be used to predict chances for an individual patient to remain anovu-
latory by calculating a total score on the basis of these initial screening character-
istics. Further studies should validate the prediction model in a new group of 
patients. The present study also suggests that LH concentrations do not predict 
ovarian response after CC medication in accordance vvith recent observations by 
others (Kousta et al., 1997). These data oppose the concept that elevated LH is 
implemented in ovarian dysfunction in these patients (Yen et al., 1980). However, 
the assessment ofLH levels in anovulatory patients is problematic due to effects of 
timing, immunoassays used and the pulsatile nature of LH release (Fauser et al., 
199Sa). 
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TABLEs. Score charts of four initial screening parameters of the fmal model for pre-
diction of patients remaining ano-vulatory after CC induction of ovulation in nor-
mogonadotropic oligomenorrheic or amenorrheic infertile \vomen (total scores, 0-53) 
Initial screening parameters 
FA[ (T x 100/SHBG) 
<2 
2-3 
S--4 
+-5 
5-6 
6-8 
8-11 
>11 
BM[ (kg/rn2 ) 
<20 
20-21.5 
21.5-23 
23-25 
25-'27 
2/-Sl 
Sl-35 
>35 
Mean uvarian vol (mL) 
<6 
6-1 
1-8 
8-9 
9-11 
11-13 
13-16 
>16 
Cycle history 
Oligomenorrhea 
Amenorrhea 
Total score 
0 
2 
s 
5 
6 
10 
14 
0 
2 
3 
6 
s 
12 
15 
0 
2 
2 
3 
5 
6 
9 
11 
0 
l.S 
a Encircle the scores related to each category of the screening parameters and add them togeth-
er. Correspond the total score to the score chart (Fig. s). As an example, a nevv amenorrheic 
patient had the following findings: FAI = 8.1, BMI = 29.4, and mean ovarian volume= IS ml. 
Scores are 10 for FAI, 8 for BMI, 9 for mean ovarian volume, and 13 fOr having amenorrhea. 
The total score is 40, and the corresponding probability to be CRA is 6:3%. 
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Together, these observations suggest that obese hyperandrogenic \vomen are less 
likely to respond to increased stimulation by FSH, suggesting that these factors 
are instrumental in follicle maturation arrest (Franks et al., 1998) and an increased 
FSH threshold (Polson et al., 1989). The correlation between BMI and ovarian 
response after CC treatment suggests that much emphasis should be focused on 
weight reduction. However, it should be realized that scientific proof for this 
approach is lacking, and that vveight reduction may not necessarily result in nor-
mal response. Previous v.rork from our group demonstrated indeed that long term 
androgen medication in female to male transsexuals induces polycystic ovary mor-
phology, characterized by increased ovarian size, augmented follicle number, and 
stroma hyperplasia (Pache eta!., 1991 ). Assessment of steroid levels in follicle fluid 
obtained from polycystic ovaries suggested that disturbed dominant follicle selec-
tion in hyperandrogenic patients may result from disrupted enhancement of FSH-
induced aromatase activity (Pache et al., 1992). This could be due to intra-ovarian 
dysregulation of FSH action, which precludes normal response (i.e. follicle growth 
and ovulation) after incremental FSH levels elicited by CC medication. Factors 
involved may include locally produced growth factors or insulin resistance (Giudice 
et al., 1992; Nestler et al., 1997a). Alternative explanations for a nonresponse after 
CC may include 1) an abnormal hypothalamic I pituitary response to steroid feed-
back resulting in an insufficient rise in FSH after CC, 2) individual differences in the 
FSH isohormone profile resulting in discrepancies in bioactive FSH concentrations 
despite similar immunoreactive FSH levels, 3) additional, as yet unidentified mech-
anisms responsible for at least part of CC actions. Recently reported CC-induced 
changes in the insulin-like growth factor system (Butzow et al., 1995) may be rele-
vant in this regard. It may be speculated that improved insight into any of these fac-
tors (intraovarian dysregulation (Fauser et al., 1997), hypothalamic I pituitary dys-
function (Berga et al., 1997), FSH heterogeneity (Ulloa-Aguirre et al., 1995), or the 
insulin-like growth factor system (Giudice et al., 1992)) may eventually result in 
additional predictors for the CC response. Further studies focusing on insulin 
resistance may also be of interest, as recent reports suggest that ovarian dysfunc-
tion may improve after the use of insulin-sensitizing agents (Sattar et al., 1998). 
Preliminary observations (lmani, B. and Fauser, B.C.J.M., unpublished observa-
tions) suggest that fasting insulin levels are increased in CRA patients. It requires 
further study to clarif}r \:vhether insulin resistance is a determining factor in an 
abnormal response to FSH independent from androgen concentrations, since the 
mc0ority of studies propose that insulin resistance is associated vvith PCOS through 
increased thecal cell androgen production (Nestler et al., 1997a). 
ln conclusion, this study demonstrates that it is possible to predict patients 
remaining anovulatory during CC induction of ovulation using criteria that are 
4{) 
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directly associated with PCOS, predominantly obesity and hyperandrogenemia. 
Further studies should establish v,rhether the occurrence of pregnancies after CC 
medication can also be predicted and \'vhether similar factors are involved. The 
identification of initial characteristics that predict the ovarian response to ovulation 
induction therapy may help to further classify the heterogeneous group of nor-
mogonadotropic anovulatory infertile \vomen. The present study suggests that 
hyperandrogenemia and obesity are crucial in inducing ovarian abnormalities that 
are less likely to respond to increased stimulation by FSH. 
2.3 Predictors of chances to conceive in ovulatory patients 
during clomiphene citrate induction of ovulation in 
normogonadotropic oligoamenorrheic infertility 
2.3.1 Introduction 
The synthetic antiestrogen clomiphene citrate (CC) represents an easy to use, 
convenient, inexpensive, and safe first choice medication in normogonadotropic 
oligo/amenorrheic infertility (WHO group 2) (\Vorld Health Organization. et al., 
1993). Life-table analysis of pregnancy rates after CC medication and prediction 
of treatment outcome have been the subject of extensive investigation 
(MacGregor et al., 1968; Gorlitsky et al., 1978; Shepard et al., 1979; Lobo et al., 
1982b; Hammond et al., 1983; Polson et al., 1989; Shoham et al., 1990; Opsahl et 
al., 1996; Kousta et al., 1997). Cumulative pregnancy rates after CC treatment 
between 37-97% have been reported (Gorlitsky et al., 1978; Shepard et al., 1979; 
Hammond et al., 1983). A positive correlation was established between body 
weight and the CC dose required to induce ovulation (Lobo et al., 1982b; Kousta 
et al., 1997). Moreover, recent studies have indicated that body mass index (BMI) 
is significantly higher in nonresponders (Polson et al., 1989; Kousta et al., 1997). 
Limited information is available, however, concerning the predictive value of ini-
tial screening characteristics for treatment outcome (Adashi et al., 1996), and pre-
vious investigators \vere unable to identify predictors for conception after CC 
induction of ovulation (Hammond et al., 1983; Shoham et al., 1990; !'1:ousta et al., 
1997). All the above-mentioned studies focused on the prediction of treatment 
outcome in the entire group of infertile patients \:vho started with CC medication. 
In contrast, \\.'e focused separately on the prediction of ovulation after CC admin-
istration (Imani et al., 1998) and the prediction of conception in ovulatory CC-
treated \vomen. This approach seems more appropriate, because statistical bias 
due to selective drop out from the study for reasons of persistent anovulation 
despite increasing doses of CC medication is eliminated. 
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Our group could recently establish that obese hyperandrogenic amenorrheic 
patients are more likely to be resistant to CC medication (lmani et al., !998). 'We 
nov,-' report on initial clinical, endocrine, and sonographic screening characteristics 
of normogonadotropic oligomenorrheic or amenorrheic infertile women achieving 
ovulatory cycles after CC medication in an attempt to identify factors predicting 
chances for conception in these patients. The separate focus on the prediction of 
conception and ovulation after CC treatment may allovv to differentiate among fac-
tors affecting oocyte quality independently from follicle development. 
2.3.2 Subjects and Methods 
Subjects and study protocol 
Between February 1993 and December 1997, !60 couples presenting with oligomen-
orrhea (bleeding intervals between 35 clays and 6 months) or amenorrhea (bleeding 
interval >6 months) and infertility attending our unit were included in the present 
study. Additional inclusion criteria vvere 1) serum FSH levels \vi thin normal limits 
(1-10 IU/L) (World Health Organization. et al., !993; van Santbrink et al., !995; 
Schipper et al., 1998) and normal serum PRL and TSH levels, 2) spontaneous menses 
or positive bleeding response to progestagen \vithdrawal, 3) ovulatory cycles after 
CC induction of ovulation, 4) BMI (weight divided by height squared) greater than 
18, 5) age between 19-40 years, 6) a total motile sperm count [TMC =ejaculate vol-
ume (milliliters) x sperm concentration (106 I mL) x percentage of progressive 
motile sperm] of the partner above I million (Ombelet et al., 1997), 7) negative his-
tory for any tubal pathology~ and 8) no indication for intrauterine insemination. 
Study approval was obtained from the human subject committee of the Dijkzigt 
Hospital/Erasmus University, and informed consent was obtained from all subjects 
included. A standardized clinical, endocrine, and sonographic screening took place 
befOre initiation of induction of ovulation v ... ith CC medication. 
Ovulation after CC treatment \vas assessed by midluteal serum progesterone 
(P) levels above 25 nmol/L, combined with transvaginal sonographic monitoring 
of follicle growth until visualization of a preovulatory follicle (mean diameter, > 18 
mm) and subsequent disappearance or biphasic basal body temperature charts, as 
described previously (lmani et al., 1998). Clomiphene citrate was administered at a 
daily dose of 50 mg (increased to 100 and !50 mg in subsequent cycles in the case 
of absent ovarian response) from cycle days 3-7 after initiation of spontaneous or 
progestin-induced withdra\val bleeding. Conception \Vas defined as a positive 
urinary pregnancy test (Clearview, hCG II, Unipath Ltd., Bedford, UK) more 
than S clays after the expected menses, and ongoing pregnancy was defined as 
sonographic assessment of an intrauterine gestational sac with positive heart beat. 
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Prediction rif Ovulation Ind!lction Outcome in Nornwgonadotropir Anovu!ator_y litfertili~y 
History and clinical screening included assessment of duration of infertility, 
whether infertility vvas primary or secondary, cycle history, previous medication 
and/or surgery, and B:\11. Endocrine screening included serum assays ofFSH, LH, 
estradiol (E9 ), testosterone (T), androstenedione (AD), sex hormone-binding 
globulin (SHBG), and P. Fasting venous blood samples were taken on a random 
day between 8:00-10:00 A.M., as indicated previously (lmani et al., 1998). Blood 
samples vvere centrifuged \Vi thin 2 hours after withdrmval and were stored at -20 
C until assayed. Serum LH and FSH levels were measured by immunofluoromet-
ric assay (Amerlite, Ortho-Clinical Diagnostics, Amersham, Aylesbury, UK), as 
described previously (Schipper et al., 1998). P levels were measured by radioim-
munoassay (RIA), as described previously (de Jong et al., 1974). Serum E 9 , T, AD, 
and SHBG levels were estimated using RIA kits provided by Diagnostic Products 
Corp. (DPC, Los Angeles, CA), as described previously (Fauser et al., 1991). Intra-
and interassay coefficients of variation \\rere less than 3% and 8% for FSH, less 
than 5% and 15% for LH, less than 16% and 17% for P, less than 5% and 7% for 
E2, less than 3% and 5% forT, less than 8% and 11% for AD, and less than 4% and 
5% for SHBG, respectively. Transvaginal pelvic ultrasound (Model EUB-4-15, 
Hitachi Medical Corp., Tokyo, Japan) was performed by a single observer (B. I.) and 
included the assessment of ovarian stroma amount and echogenicity (arbitrarily 
classified from one to three per ovary), ovarian volume (milliliters), and total num-
ber of follicles (both ovaries), as described previously (van Santbrink et al., 1995; 
Pache et al., 1992). Semen analyses were performed according to \VHO guidelines 
(1992) and comprised ejaculate volume (milliliters), number of spermatozoa per 
mL (106 spermatozoa/mL), percentage of progressive motile spermatozoa, and 
percentage ofnonnal forms (World Health Organization. et al., 1992). 
Data analysis 
A P value of 0.05 was chosen as the threshold level for statistical significance. Cox 
regression has been used for life-table analysis of conception rates during CC 
treatment (Cox et al., 1972). The number of ovulatory CC treatment cycles was the 
time variable for multivariate analyses. Censoring was defined as definitive dis-
continuation of CC therapy without conception or end of follow-up (February 
1998). To analyze the effect of the severity of the cycle abnormality on chances to 
conceive after CC treatment, \:ve arbitrarily divided the cycle histories of the 
patients into four categories; interval between periods of 5-6 weeks (n:::::: 56), 6-9 
weeks (n =50), 9-26 weeks (n = 25), and greater than 26 weeks (i.e. amenorrhea) 
(n = 29). The univariate relation was assessed between the variables listed in 
Table 1 and the time interval between the first ovulation after CC medication and 
conception using the Kaplan-Meier method (Kaplan et al., 1958) for categorical and 
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the Cox regression (Cox et al., 1972.) for continuous variables. The Log-rank test 
has been used to denote statistical significance in life-table analyses. The multi-
variate analysis \:vas performed with the method of fonvard stepwise selection to 
gain a better insight into the interdependence betvveen initial screening parame-
ters. This method can explain \vhy a variable that \vas significantly different in uni-
variate analysis \Vas not selected in the final model. The prognostic impact of vari-
ables ,..,,..as expressed as a fecundability ratio, which is equivalent to the hazard ratio 
in survival analysis. For instance, a fecunclability ratio of 0.9 for an unfavorable 
group means that the conception rate per ovulatory CC treatment cycle is 10% 
lovl''er compared to that in the favorable group. In some couples (n = 25), no sperm 
analysis was performed because of the short time interval betvv·een initiation of CC 
medication and conception. A statistical imputation technique has been applied 
using multiple conditional mean imputation to fill in these missing sperm param-
eters (Rubin et al., 1918). The value of semen parameters was estimated using the 
time until conception and patient characteristics related to sperm parameters in 
the nonmissing group. Data ·were analyzed using the commercially available soft-
ware package SPSS, Inc. (Chicago, IL). 
2.3.3 Results 
A total of82 women (51% of the ovulatory group) conceived, and 73 (46%) reached 
an ongoing pregnancy !!·01n the total of 160 patients fiJlfllling the in/ exclusion cri-
teria. Sixty-nine were singleton and 4 vvere twin pregnancies (data not sho\vn). 
Initial screening parameters of 9 patients who had a miscarriage after CC ( 11% of 
overall CC conceptions) \\rere not different from those of the remaining 73 patients 
v,'ho reached an ongoing pregnancy (data not shO\vn ). One woman \vho conceived 
(twin pregnancy) during her first CC treatment cycle \vas frequently monitored on 
an out-patient basis due to abdominal discomfort and enlarged ovaries. There \vas 
no case of severe ovarian hyperstimulation syndrome. 
The life-table analysis of cumulative conception rates (CCR) of patients who 
ovulated after CC are indicated in Figure 1 for the total group, and separately for 
different dose groups. A cumulative conception rate of 47% was reached within 
three cycles from first ovulation, and a CCR of /3% Y\/as reached within nine CC-
induced ovulatory cycles. Patients using daily closes of 50, 100, and 150 mg CC 
reached cumulative conception rates of 57%, 66%, and ss% \\'ithin 5 ovulatory 
cycles, respectively (P log rank= 0.25; Figure 1). At higher doses, chances fOr con-
ception and ongoing pregnancy are not statistically significantly reduced, 
although absolute CCR (n = IS) \-vere lovv in the 150-mg CC group. The overall 
mean duration of fOlJovi''-LIP \vas 4 ± 3 months and 3.2 ± 2.6 ovulatory CC cycles. 
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Initial screening characteristics of the overall group of patients \Vho ovulated after 
CC and separately for those women who conceived (n = 82) vs. those who did not (n 
='iS) are depicted in Table 1. Age, the severity of cycle abnormality (oligomenor-
rhea vs. amenorrhea), and cycle duration, arbitrarily classified in four categories (see 
also lVIaterials & J.i!Jet!zods), were significantly different in univariate analysis. Age 
(cut-off of SO yr), cycle history (oligomenorrhea vs. amenorrhea), and initial serum 
LH level (cut-off level of 7.0 IU/L) in univariate analyses for CCR are depicted in 
Figure 2. 
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oligo-amenorrheic irifertile patients who ovu)atedfOllowing CC medication. CCR's (including 
absolute nurnber of patients at risk and nzonber of events (~ conceptions)) are presented for the 
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Rank test P value. 
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The percentage of ongoing pregnancies per conception for patients with elevated 
(initial serum LH level ~7.0 !U/L) or normal initial serum LH levels were 84.8% and 
94.4%, respectively (?value for difference in proportion ongoing pregnancies= 0.16, 
and 95% confidence interval for difference= -3% to 23%). The cut-offvalue for nor-
mal (i.e. 7 .o IU /L) was chosen on the basis of a previous study fi·mn our group in 
normoovulatory controls (mean+ I SD) (van Santbrink et al., 1997b). 
A total number of !59 patients had complete data on the variables used in the 
multivariate analyses. Univariate analysis and fOrward stepvvise multivariate analy-
ses of all initial parameters fOr the prediction of chances to conceive in ovulatory 
patients treated with CC are depicted in Table 2. During the step\vise multivariate 
analysis for the prediction of chances to conceive, age, and cycle history ( amenor-
rhea vs. oligomenorrhea) entered into the model (step I and 2, respectively). The 
multivariate-acUusted fecundability ratio for age \'Vas 0.90 (95% confidence inter-
val, 0.85~0.95), and that for amenorrhea 0.54 (95% contldence interval, O.S2~0.9S). 
2.3.4 Discussion 
The present prospective follov\"·-up study was designed to evaluate vvhether ini-
tial screening characteristics of 160 normogonadotropic oligo/ amenorrheic 
infertile \vomen could predict conception during ovulatory CC-induced cycles. 
Although CC medication has been the focus of prevalent research, limited infor-
mation is available regarding the prediction of conception as treatment outcome 
(Ad as hi et al., 1996). He ported cumulative pregnancy rates vary between 31-97%. 
Most studies, hovv·ever, suffer from methodological difficulties and different 
inclusion/ exclusion criteria. For the first time, our group has focused on ovula-
tion and conception in separate steps, taking into account that a significant pro-
portion (23%) of patients \Vho remain anovulatory after CC medication (Imani et 
al., 1998) have no chance of conception. Inclusion of these patients in a study 
focusing on conception causes statistical bias. This separate focus may offer a 
better insight into the potential predictive po\ver of initial screening character-
istics in a heterogeneous group of normogonadotropic oligo/ amenorrheic infer-
tile women (vVHO class 2) for CC-induced follicle growth and ovulation, sepa-
rately from conception. 
In the present study, CCR of 63% within six cycles and 73% within nine ovu-
latory CC-induced cycles have been reached. Tvvo third of patients Yvho con-
ceived reached this end point within the first three ovulatory CC treatment 
cycles. This is in agreement with previous reports in the literature regarding CC 
(Garcia et al., 1977; Gorlitsky et al., 1978; Gysler et al., !982) and is similar to 
spontaneous conception chances in normoovulatory \vomen (Tietze et tll., 1968). 
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TABLE l. Initial clinical, endocrine, and ultrasound screening characteristics and 
sperm parameters of partners (median and range) of 160 normogonadotropic 
oligomenorrheic or amenorrheic infertile ·women who ovulated after CC induction 
of ovulation (overall group) and did or did not (CC failure) conceive 
Screening parameters Overall group Conceived CC failure 
(n = 160) (n:::::: 82; 51%) (n = 78; 49%) 
Clinical 
Age (yr) 28 ± 4 21 ± 4 29 ± + 
Infertility duration (yr) 1.9 ± 2.3 1.6 ± 1.+ 2.2 ± 2.9 
Primary infertility (n) 116 62 54 
Amenorrhea (n) 29 IS (62) II (.~8) 
Bleeding interval in +categories 
5-6 "\Veeks, n (%) 56 (3ti) 22 34 
6-9 Yveeks, n (%) 50 (S I) 29 21 
9-26 \Veeks, n (%) 25 ( 16) 13 12 
>26 weeks, n (%) 29 (I 8) 18 II 
BMI (kg/m2) 26 ± 6 26 ± 6 25 ± 6 
Endocrine 
LH (IU/L) 7.6 ± 4.2 8.2 ± 4.3 6.9 ± 4.0 
T (nmol!L) 2.3 ± 1.0 2.3 ± 1.0 2.3 ± 1.0 
AD (nmol/L) 15.0 ± 6.9 15.8 ± 1.9 14·.0 ± 5.1 
FAI' 5.4 ± 3.9 5.5 ± 4.1 5.1 ± 3.7 
SHBG (nmol!L) 56± 31 .')4< ± 21 58± 35 
E2 (pmol!L) 259 ± 115 229 ± 145 290 ± 198 
Ultrasound 
:Mean ovarian vol (mL) 9.3 ± 3.1 9.2 ± 3.7 9.4 ± S.l 
Mean fOllicle number 12 ± 5 12 ± 5 12 ± 5 
Total stroma scored .'3.2 ± 1.1 3.1 ± 1.1 3.3 ± 1.2 
TMCe 7.'3 (1.1-492) 15 ( 1.5-.'303) 72 (1.1-492) 
%Normal morphology 24(1-50) 20 (I-50) 25(1-50) 
Values are the mean ± SD. Underlined values are statistically significant. 
a Comparison of CC-conceivecl vs. CC failure ( uni,,rariate Cox regression). 
b Chances to conceive differ among four categories of bleeding interval. 
Cf~A..I = T X 100/SHBG. 
d Arbitrarily defined as one to three per ovary (both ovaries added). 
e Total motile sperm count 
f Computed vv·ith multiple imputation of missing values 
F7 
P valuea 
0.0001 
0.23 
0.40 
0.04 
o.o.s 6 
0.+6 
0.11 
0.85 
0.16 
0.20 
0.24 
0.10 
0.97 
0.4•8 
0.66 
o.sg/ 
0.3~ 
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This is also comparable to conception rates reported for exogenous gonadotropin 
induction of ovulation (Dor et al., !980; Hamilton-Fairley et al., !991; van 
Santbrink et al., 1995) in anovulatory infertile patients. These observations 
strongly suggest that the overall detrimental effects of CC on cervical mucus 
production or endometrial receptivity and subsequent implantation are limited 
with daily CC doses up to !50 mg. Although the CCR seems to be lower in the 
high dose CC group, this finding was not statistically significant. It should be 
noted that the sample size of this group is limited, so actual differences cannot 
be excluded. 
Previous studies were unable to identify predictors for conception in CC 
induction of ovulation in normogonadotropic infertile \Vomen (Hammond et al., 
1983; Shoham et al., 1990; Kousta et al., 1997). In the present study, age and cycle 
history (amenorrhea or oligon1enorrhea) vvere significantly different comparing 
patients who conceived vs. those who did not during CC-induced ovulatory 
cycles. Multivariate analyses revealed a fmal model including age and cycle his-
tory. The predictive power of age was the highest. The area under the receiver 
operating characteristics curve of the final model including these t\vo factors 
reached 0.68 (data not shown), which is substantially lower than that in the pre-
vious model predicting ovulation after CC (0.82) (lmani et al., 1998). For reasons 
of clarity, the forward stepwise approach was chosen (see Table 2). Backward 
stepwise analysis was also applied, resulting in the same final model (data not 
shown). Young patients have a higher probability to conceive during CC-induced 
ovulatory cycles. The fecundability rate of the patient decreases by approxi-
mately 10% per year. This is in agreement \Vith reports that indicate that age is 
an important factor for the prediction of chances for spontaneous conception in 
untreated normoovulatory subfertile patients (Eimers et al., 1994; lmani et al., 
1998; Scott et al., 1995). Similar findings have been reported for the prediction of 
chances to conceive following exogenous gonadotropin induction of ovulation 
(Dor et al., !980) and in vitro fertilization treatment (Templeton et al., 1996). 
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Figure 2 Univariate analysis cif cumulative conception rates in I 60 normogonadotropic oligoame-
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49 
Prnliction ~ldon!!jJhene citraft ovulation indurtio11 outcome 
TABLE 2. Forvvard stepwise multivariate analyses of initial screening character-
istics for the prediction of chances to conceive in 159 normogonadotropic oligo-
amenorrheic infertile \Vomen v,,ho ovulated after CC induction of ovulation 
Analyses steps 
Screening parameters 
Clinical 
Age (yr) 
Amenorrhea (n = 29) 
Bleeding interval (in four categ·ories) 
Endocrine 
LH (iUIL) 
FA!b 
AD (nmol!L) 
E2 (pmoi/L) 
Univariate: 
oa 
0.0001 
0.04 
0.05 
0.11 
0.20 
0.16 
0.10 
Multivariate 
2 
In model In model 
0.02 In model 
0.06 0.30 
0.36 0.26 
0.56 0.38 
o.ss 0.15 
0.26 0.39 
?\umbers are P values fOr inclusion in the model. Underlined numbers are significant at P < 0.05. 
a Only screening parameters ·with a univariate PSo 0.2 (see Table 1) are shovvn. In the univari-
ate analysis (step 0), three variables reach statistical significance (underlined). In step I of the 
multivariate analysis the variable \Jv·ith the highest prognostic infOrmation (age) is selected. 
After the first step, amenorrhea still reaches statistical significance and, therefore, is selected in 
the second step. Thereafter, no additional variable is statistically significant anymore, indicat-
ing that the model cannot be improved by selecting a subsequent parameter. 
b FA! = T X 100/SHBG. 
Amenorrheic patients exhibit a 2-fold higher probability to conceive after ovu-
latory CC cycles as compared to oligomenorrheic patients. Patients vvith longer 
bleeding intervals also exhibit higher conception chances. \Ve have been unable to 
find similar reports in the literature regarding induction of ovulation. The most 
likely explanation seems to be the follov,ring. Patients with amenorrhea have an 
extremely low probability to conceive \Vithout intervention due to anovulation 
before seeking help by a physician. Presumably, the major subfertility factor in 
these patients is chronic anovulation, which can be resolved temporarily by the use 
of CC medication. These patients are more likely to be at low risk for any other 
subfertility factor, such as tubal or sperm dysfunction. Some oligomenorrheic 
patients may have spontaneous ovulations (Minakami et al., 1988), and some of 
these \\'Omen may never seek medical intervention because of spontaneous 
pregnancies. Their benefit from ovulation induction is an increased chance for 
conception clue to an increased number of ovulations with a fixed interval in a given 
50 
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period of time. Similar observations \-vere made for pregnancy chances after artifi-
cial insemination with donor sperm in relation to the sperm quality of the partner. 
Donor insemination outcome is significantly better in cases \\·'ith very poor sperm 
quality (Emperaire et al., 1982). One should consider that amenorrheic patients also 
have a higher probability to remain anovulatory after CC, as demonstrated previ-
ously (lmani et al., 1998). In contrast, regular ovulatory cycles are easier to induce 
v,rith CC in oligomenorrheic patients but there is less chance of pregnancy. 
In the present study, patients with elevated initial serum LH levels have a sig-
nificantly higher probability to conceive once ovulatory cycles have been 
achieved by CC. A recent study also indicated higher initial LH levels in patients 
v,rho conceived after CC medication (1\ousta et al., 1991). In contrast, a poor 
treatment outcome has been observed in patients \Vith high LH levels during the 
follicular phase of CC-induced cycles (Shoham et al., 1990). It should be realized 
that we report on initial LFI levels before initiation of CC medication, rather than 
during CC-induced cycles. Indeed, elevated LH levels may normalize only dur-
ing CC-induced ovulatory cycles (Eden et al., 1989). These observations are in 
sharp contrast with reports regarding patients with elevated LH \vho perform 
poorly during gonadotropin induction of ovulation (Hamilton-Fairley et al., 
1991) or in vitro fertilization (Howles et al., 1986). \Ve previously showed that 
initial LH concentrations did not predict patients vvho would remain anovulato-
ry after CC medication (lmani et al., 1998). The present observation seems to dis-
pute previous beliefs concerning the detrimental effects of raised LH levels on 
oocyte maturation and capacity for fertilization. In addition, \\'e did not observe 
a higher spontaneous abortion rate in patients \vith high LH levels who con-
ceived after CC medication. This finding is also in contrast with previous reports 
on the effects of high LH concentrations on chances for spontaneous abortion 
after exogenous gonadotropins (Homburg et al., 1988; Regan et al., 1990). The 
predictive povver of the initial LH level is poor in case age enters in the final 
model, which may be due to a correlation of initial LH with age (data not shown). 
The mechanism of action of CC is not fully elucidated, and the role of LH in the 
pathogenesis of ovarian abnormalities remains open for speculation. As an exam-
ple, female siblings of male patients described with an activating mutation of the 
LH receptor (so-called familial male testotoxicosis) seem to be without a clear 
phenotype (Fauser eta!., 1999). 
Total motile sperm count is not a predictor in univariate or multivariate 
analyses of prediction of conception in the present study population. This is in 
agreement with the observation that a large overlap exists bet\veen semen 
characteristics of males from fertile vs. subfertile couples (Ombelet eta!., 1997). 
Moreover, it can be speculated that couples with better sperm parameters have 
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already conceived spontaneously before seeking medical intervention. 
In summary, it can be concluded that body weight and hyperandrogenemia are 
the predominant predictors for ovulation after CC treatment, whereas age and 
cycle history dictate pregnancy chances in ovulatory \\'omen. This stresses for the 
first time the important concept that follicle growth and oocyte quality (and sub-
sequent capacity to be fertilized in vivo) are differentially regulated during induc-
tion of ovulation, confirming observations during in vitro fertilization. 
2.4 Free androgen index and leptin are the most prominent 
endocrine predictors of ovarian response during clomiphene 
citrate induction of ovulation in normogonadotropic 
oligoamenorrheic infertility 
2.4.1 Introduction 
Clomiphene citrate (CC) is considered to be the first line strategy for ovulation 
induction in normogonadotropic anovulatory infertility (\VHO group 2) (\Vorld 
Health Organization. et al., 1993) since its clinical introduction almost 4 decades 
ago (Greenblatt et al., 1961 ). This synthetic steroid, characterized by its mixed 
estrogenic and antiestrogenic properties, is still extensively used. Approximately 
75% of treated patients will ovulate after CC medication (MacGregor et al., 1968; 
Gorlitsky et aL, 1978; Imani et al., 1998), and once ovulation is achieved, cumula-
tive conception rates are 75% \Vithin six consecutive CC cycles (Gorlitsky et al., 
1978; Shepard et al., 1979; Hammond et al., 1983; lmani et al., 1999). 
Polycystic ovary syndrome (PCOS), usually referred to as chronic hyperandro-
genic anovulation (Dunaif et al., 1992), is a common endocrine disorder and repre-
sents a significant proportion of normogonadotropic anovulatory infertility (van 
Santbrink et al., 1997b). Etiological factors involved in ovarian dysfunction in this 
heterogeneous patient group have not yet been fully elucidated. Various investiga-
tors reported on the prominent role of locally produced growth factors, such as 
insulin-like growth factors (IGFs) (Giudice et al., 1996; Cataldo et al., 1997; van 
Dessel et al., 1999) or vascular endothelial growth factor (VEGF) (Agrawal et al., 
1998a). Moreover, recent evidence suggests that decreased insulin sensitivity plays 
an important role in initiating ovarian dysfunction in these patients, possibly by 
stimulating thecal cell androgen production (Dunaif eta/., 1997; Nestler et al., 
1998). A significant proportion of patients with PCOS suffer from severe obesi-
ty (Dunaif et al., 1988; Pasquali et al., 1993), and therefore, leptin, the hormone 
product of the obesity gene (Zhang et al., 1991·), has been the focus of intense 
investigation (Cohen et al., 1996; Brzechffa et al., 1996; Rouru eta!., 1997; Laughlin 
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et al., 1997). It has been demonstrated that leptin can impair insulin action in hepa-
tocytes (Cohen et al., 1996). Although leptin does not appear to play a direct role 
in either hyperandrogenemia or hypersecretion of LH (Laughlin et al., 1997), 
abnormalities in its signaling may be involved in hypogonadotropic hypogonadism 
(Clement eta/., 1998) and in certain cases ofPCOS (Brzechffa et al., 1996). Finally, 
inhibin B, which has been shown to be produced by healthy antral follicles under 
the control of FSH in the early follicular phase of the normal menstrual cycle 
(Groome et al., 1996), may serve as a marker for the severity of ovarian dysfunc-
tion in PCOS patients (Pache et al., 1992; Anderson et al., 1998)._ 
\'v'e previously demonstrated that obese, hyperandrogenic, amenorrheic women 
are less likely to respond to stimulation by increasing endogenous FSH levels after 
CC compared to normal \veight, oligomenorrheic women presenting vvith normal 
androgen concentrations (Imani et al., 1998). This approach may have clinical 
implications in terms of health economics, but may also provide infonnation 
regarding factors involved in ovarian dysfunction in these women. \Ve novv report 
on the predictive power of additional endocrine screening of factors potentially 
involved in ovarian abnormalities in this patient population, including insulin sen-
sitivity, the IGF system, leptin, inhibin B, and VEGF. 
2.4.2 Materials and Methods 
Subjects and study protocol 
Between February 1993 and January 1998, 182 \vomen attending our infertility 
unit presenting with 1) oligomenorrhea (bleeding intervals betvv·een 35 clays and 6 
months) or amenorrhea (bleeding interval >6 months), 2) serum FSH levels with-
in normal limits (1-10 Il..J/L) (\Vorld Health Organization. et al., 1995; van 
Santbrink et al., !995) and normal serum PRL and TSH levels, s) spontaneous 
menses or positive bleeding response to progestagen vv·ithdrawal, 4) body mass 
index (BMI; weight divided by height squared) more than 18 kg/m 2, and 5) age 
bet\\reen 19-40 years vvere included in the present study. Study approval \\ras 
obtained from the human subjects committee of the Dijkzigt Hospital/Erasmus 
University, and informed consent v ... ·as obtained from all subjects. 
Standardized initial clinical, sonographic, and endocrine screening took place 
before initiation of induction of ovulation \\·'ith CC medication, as described previ-
ously (Imani et al., 1998). Clinical screening included age, infertility and cycle his-
tory, B:v!I, waist to hip ratio (\VHR), previous medication, and/ or surgery. 
Transvaginal sonographic screening included assessment of the ovarian stroma 
echogenicity (arbitrarily classified from one to three per ovary), ovarian volume 
(milliliters), and total number of follicles (both ovaries), as described previously 
Prediction qf clomiplwu citmft r!'imlation induction outcome 
(van Santbrink et al., 1997b; Pache et al., 1992). Endocrine screening included serum 
assays for FSH, PRL, TSH, LH, estradiol (Eq), androstenedione (AD), testosterone 
(T), and sex hormone-binding globulin (SHBG), as described previously (lmani et 
al., 1998). In addition, serum \vas assayed for fasting insulin and glucose, free and 
total IGF-1, IGF-binding protein-! (IGFBP-1), IGFBP-3, inhibin B, leptin, and 
VEGF concentrations. Fasting venous blood samples vv·ere taken on a random day 
between 8:00-10:00 A.M., before initiation of therapy Blood samples were cen-
trifuged within 2 hours after withdrmval and stored at -20 C until assayed. 
Hormone assa)'S 
Serum insulin levels v.'ere measured by immunoradiometric assay (IRMA; 
Biosource Technologies, Inc. Fleurus, Belgium), glucose levels by the hexokinase 
method (Gluco-quant, Roche Molecular Biochemicals, Mannheim, Germany) 
(Neeley et al., 1972), free IGF-1 levels by a two-site IRMA (Active, Diagnostic 
Systems Laboratories, Inc., vVebster, TX) direct assay Serum was incubated in 
tubes and decanted, and the tubes \\,ashed according to the manufacturer's instruc-
tions. Free IGF-1, bound to the tube, was detected by radiolabeled antibody as 
described previously (van Dessel et al., 1996). Serum IGF-Ilevels were measured 
using a tv.,o-site IRMA (Active, Diagnostic Systems Laboratories, Inc.), \vhich 
includes an extraction step to separate the IGF-I from its binding protein in 
serum. IGFBP-1 and IGFBP-3 levels were assayed using a two-site IRMA (Active, 
Diagnostic Systems Laboratories, Inc.) assay as described previously (van Dessel et 
al., 1996). The IGFBP-3 samples were diluted 1:100 before assay Dimeric inhibin 
B levels were measured using an immunoenzymometric assay (Serotec, Oxford, 
UK) (Schipper et al., 1998), leptin levels using a radioimmunoassay (RIA) (by means 
of reagents supplied by Linco Research, Inc., St. Charles, MO) (Lahlou et al., 1997), 
and VEGF levels by enzyme immunoassay (Cytokit RedTM EIA kits; Peninsula 
Laboratories, Inc., College Park, MD) (Agrawal et al., 1998b). Midluteal serum 
progesterone (P) levels were measured by RIA, as described previously (lmani et al., 
1999). Intra- and interassay coefficients of variation \vere less than 6.1% and 9.9% 
for insulin, less than 1.0% and 1.9% for glucose, less than 10 . .3% and 10.7% for free 
IGF-1, less than 3.4% and 8.2% for IGF-1, less than 5.2% and 6.0% for IGFBP-1, 
less than 3.9% and 1.9% for !GFBP-3, less than 8% andl4% for inhibin B, less than 
3.6% and 4.6% for leptin, and less than 7.8% and 12.2% for VEGF, respectively. 
CC ovulation induction protocol 
CC was administered at a daily dose of 50 mg (which was increased to 100 and 150 
rng in subsequent cycles in the case of absent ovarian response) from cycle days 
.3-7 after initiation of a spontaneous or progestin-induced withdrawal bleeding, as 
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described previously (lmani et al., 1998). Ovulation after CC treatment was 
assessed by midluteal serum P levels above 25 nmol/L combined \\rith trans-
vaginal sonographic monitoring of follicle grovvth until visualization of a pre-
ovulatory follicle (mean diameter, > 18 mm) and subsequent disappearance or 
biphasic basal body temperature charts, as indicated previously (lmani et al., 
1998). If ovulation occurred, the CC dose remained unaltered during subsequent 
cycles. The duration of follow-up for all patients included in the study was at 
least three treatment cycles. First ovulation after CC was used as the endpoint. 
Responders were clefmecl as patients who ovulated after CC, independent of the 
close administered. The number of treatment cycles and the CC dose in which 
first ovulation occurred were recorded. Clomiphene-resistant anovulation (CRA) 
was defined as patients \vho did not ovulate despite receiving maximum treat-
ment doses of !50 mg/ day. 
Data analysis 
P = 0.05 was chosen as threshold level for statistical significance in uni\'ariate 
analyses. For comparison of initial screening parameters of CC responders and 
non responders, we used the Mann-\Vhitney U test and \Vikoxon rank sum \V 
test. The univariate relation \Vith response to CC vvas assessed using logistic 
regression analysis. The following initial serum parameters were used in the mul-
tivariate analyses (forward stepwise selection of variables, P entry< O.JO)o fasting 
serum insulin and glucose, !GF-1, IGFBP-1, IGFBP-3, free IGF-1, inhibin B, lep-
tin, and VEGF in combination with parameters of the previous model for predic-
tion of patients remaining anovulatory after CC treatment including FAI, cycle 
history (oligomenorrhea vs. amenorrhea), BMI, and mean ovarian volume (Imani 
et al., 1998). The area under the receiver operating characteristics curve (AUC) 
was used to assess the discriminative ability of the tests, as described previously 
(lmani et al., 1998). Data were analyzed using the commercially available software 
package SPSS, Inc. (Chicago, IL). 
2.4.3 Results 
From the total number of 182 patients fulfilling the in/exclusion criteria and 
treated with CC medication, I 31 (72%) suffered from primary infertility, 43 
(24·%) from amenorrhea and the remaining 139 (76%) had oligomenorrhea. 
Eighty two (45%) women were obese (BMI, 226), 113 (62%) patients presented 
with an elevated FA! (FA! 24.0), and 67 (37%) patients presented with hyperan-
drogenemia (testosterone, 23.2 nmol/L; and/or androstenedione, 216.3 nmol/L) 
(Fauser et al., 1991; van Santbrink et al., 1997b). In 134 patients (74%) polycys-
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tic ovaries (mean ovarian volume, ;:::10.8 mL; and/or mean follicle number per 
ovary, 2:10) (Pache et al., 1992; van Santbrink et al., 1997b) were diagnosed. 
TABLE I. Endocrine findings (mean ± SD) upon initial screening of 182 nor-
mogonadotropic oligoamenorrheic infertile \Vomena and separately for patients 
who did (CC responders) or did not (CRA) ovulate after CC induction of ovulation 
Overall group 
(n = 182) 
Insulin (mU/L) 14.7 ± 10.4· 
Glucose (mmol!L) 4.3 ± 1.6 
Insulin/ glucose ratio 3.6 ± 2.5 
Inhibin B (ng/L) I 53± 102 
IGF -1 (ng/mL) 2:37 ± 97 
Free IGF-I (ng/mL) 2.8 ± 1.7 
1GFBP-1 (ng/mL) 2+.2 ± 18.1 
IGFBP-cJ (ng/mL) 3297 ± 693 
Leptin (ng/mL) 21.6 ± 11 
VEGF (ng/mL) 4·.8 ± 2.9 
CC responder 
(n = 142; IS%) 
13.6 ± 9.5 
4.2 ± 1.0 
3.4 ± 2.3 
156 ± 103 
242 ± 99 
2.8 ± 1.6 
26.4 ± 18.5 
3320 ± 71+ 
19.3 ± 15 
4.9 ± 2.9 
CRA 
(n = 40; 22°/cJ) 
19.0 ± I.':l.O 
·1.8 ± 2.9 
4.4 ± s.o 
J4.9 ± 99 
218 ± 8:3 
3.0 ± 2.0 
16.7 ± 1+.5 
3240 ± 622 
30.4 ± 20 
4.3 ± .'3.1 
P value b 
0.009 
c 
0.05 
0.001 
0.003 
a Remaining characteristics: age, 28 ± 4.5 yr; BMI, 26.5 ± 6 kg/m2; T, 2.4 ± 0.9 nmol/L; FAI, 
6.2 ± 4.2; LH, 7.9 ± 4.4 IU/L; FSH, 4.5 ± 4·.6 IU/L; E 2, 258 ± 17·1 pmol!L; and mean ovarian 
volume, 9.8 ± "L2 mL. 
b Comparison of CC responders vs. CRA (by Mann-\Vhitney U test). 
c Not significant. 
Finally, 9S patients (51%) presented with elevated LH levels (2:7.0 IU /L) (Fauser 
et al., !991; van Santbrink et al., 1997b). From the total group of patients, '10 (22%) 
\\,omen remained anovulatory despite the maximum CC dose. A total number of 
S25 CC cycles were analyzed (205 ovulatory and 120 anovulatory cycles). 
Endocrine screening characteristics of the overall study group and separately 
for patients who did or did not ovulate after CC medication are presented in Table 
1. Fasting insulin level, insulin/ glucose ratio, and serum leptin levels vvere signif-
icantly higher and IGFBP-1 levels significantly lower in CRA patients. P values 
after univariate analysis with logistic regression analyses, odds ratio, 95% confi-
dence interval, and the receiver operating characteristics AUC of additional initial 
endocrine screening parameters are depicted in Table 2. Again serum insulin, 
insulin/glucose ratio, IGFBP-1, and leptin levels were significantly different 
between patients who did vs. those who did not ovulate after CC treatment. Results 
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of multivariate analyses for prediction of patients remaining anovulatory after CC 
induction of ovulation are depicted in Table 3. Using a forward stepwise selection 
procedure, various significant predictors during univariate analysis (such as 
insulin, IGFBP-1, and BMI) disappear, and four variables were eventually select-
ed: 1) FA!, 2) cycle history (oligomenorrhea vs.amenorrhea), 3) leptin, and 4·) mean 
ovarian volume. The association of FAI, leptin and insulin with other endocrine 
and clinical features vvas analyzed in more detaiL Correlations between FAI and 
BMI, leptin, insulin, and IGFBP-1 are depicted in Figure I. Correlations between 
initial serum leptin levels and BMI, \VHR, and insulin are shown in Figure 2. 
Correlations between initial serum insulin levels and BMI, SHBG, and IGFBP-1 
are shown in Figure 3. For all figures, individual correlations are shov,rn separate-
ly for CC responders and nonresponders. With exception of leptin, correlations 
betvveen all other factors depicted in the figures \\'ere significantly stronger in CC 
nonresponders than in responders (data not shown). 
2.4.4 Discussion 
The present prospective follo\v-up study \vas designed to evaluate \'vhether initial 
screening of insulin sensitivity, the IGF system, leptin, inhibin B, or VEGF could 
predict the ovarian response to CC medication in normogonadotropic oligoamen-
orrheic infertile women. \Ve recently reported (lmani et al., 1998) that obese, 
hyperandrogenic, amenorrheic women, a complex of signs and symptoms fre-
quently referred to as PCOS (Dunaif et al., 1992), are more likely to remain anovu-
latory after CC medication. As a first step we focused on screening of the most per-
tinent clinical, endocrine, and sonographic characteristics of these patients (lmani 
et al., 1998). Further endocrine parameters potentially related to ovarian dysfunc-
tion in these vvomen are the focus of the present study. Decreased insulin sensitiv-
ity I hyperinsulinemia or augmented free IGF-l may be involved in the patho-
physiology of this heterogeneous syndrome by directly stimulating thecal cell 
androgen production (Dunaif et al., 1997; van Dessel et al., 1999; Nestler et al., 
1998). Serum leptin levels \vere also assessed in these patients, as it has been sug-
gested recently that this is a reliable endocrine marker for obesity. Abnormalities 
in its signaling patlnvay may be involved in hypogonadotropic hypogonadism 
(Clement et al., 1998) and eventually in certain cases of PCOS (Brzechffa et al., 
1996; Rouru et al., 1997). In addition, leptin may directly modulate insulin activity 
in obese individuals (Cohen et al., 1996). lnhibin B is produced by healthy early 
antral follicles under the control of FSH in the early follicular phase of the men-
strual cycle (Groome et al., 1996) and may therefore be used as a marker for the 
severity of ovarian abnormalities (i.e. the sensitivity to FSH and assessment of the 
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number of healthy, rather than atretic, follicles in polycystic ovaries) and the like-
lihood of ovaries to respond to ovulation induction (Anderson et al., !998). Finally, 
VEGF levels were assessed in these patients, as recent reports suggest that this 
protein may serve as a marker for changes in ovarian stroma of PCOS patients 
(Agrawal et al., J998b; Agrawal et al., 1998a). 
TABLE '2. Univariate logistic regression analyses, odds ratio, 95% confidence 
interval, and area under the ROC curve of endocrine screening parameters in 182 
normogonadotropic oligoamenorrheic infertile vvomen for the prediction of 
patients remaining anovulatory after CC induction of ovulation 
Univariate analyses Odds ratio (95% CI I ) p2 value 
Insulin (mU/L) !.05 (!.01-!.08) 0.005 
Glucose (mmol/L) 1.21 (0.97-1.50) 0.07 
Insulin/ glucose ratio 1.16 (!.01-1.32) 0.03 
Inhibin B (ng/L) 0.99 ( 0.99-l.OO) 0.5 
IGF -1 (ng/mL) 0.99 (0.99-1.00) 0.2 
Free IGF-I (ng/mL) 1.06 (0.86-1.30) o.s 
IGFBP-1 (ng/mL) 0.96 (0.93--().98) 0.01 
IGFBP-3 (ng/mL) 0.99 (0.99-1.00) 0.6 
Leptin (ng/mL) !.OS (1.01-1.06) o.ooos 
VEGF (ng/mL) 0.92 (0.79-1.07) 0.4 
1 Confidence interval. 
2 Univariate logistic regression analyses with likelihood ratio test (Bold = P < 0.05). 
3 Area under the ROC curve. 
AUC3 
0.6"1 
0.51 
0.61 
0.53 
0.56 
0.51 
0.61 
0.54 
0.70 
0.58 
The present study demonstrates that serum insulin, insulin/ glucose ratio, 
and leptin levels are significantly higher and, in contrast, IGFBP-1 levels are 
lo\\'er in patients who remain anovulatory after CC. \Vhen a multivariate analy-
sis for the prediction of CRA is applied, the capacity of serum insulin, 
insulin/glucose ratio, and IGFBP-1 levels to predict CRA is eliminated when 
FAT enters into the model due to a strong correlation between these parameters 
with FA! (Table 3, and Figure I). In contrast, leptin levels enter into the model 
in the third step. These results can be interpreted as follows. Insulin is signifi-
cantly higher in CRA patients. An association between decreased insulin sensi-
tivity and hyperandrogenism is well known (Poretsky et al., 1991; Poretsky et al., 
1996). Signal transduction via the insulin receptor has been demonstrated to be 
frequently abnormal in PCOS (Legro et al., 1998). Moreover, IGF-1 as well as 
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insulin have been sho\vn to augment LH-induced androgen biosynthesis by cul-
tured thecal cells (Legro et al., 1998). As insulin binds to the structurally similar 
type I IGF receptor, it has been postulated that high levels of circulating insulin 
stimulate thecal cell androgen production through the type 1 IGF receptors 
(Poretsky et al., 1991; Poretsky et al., 1996). However, this seems to be the case 
only in extreme hyperinsulinism, such as in patients suffering from leprechau-
nism. Moreover, insulin and BMI are the major determining factors of circulat-
ing IGFBP-1 levels in both normoovulatory obese and PCOS women. Insulin 
reduces circulating SHBG (Weaver et al., 1990; Nestler et al., 1991; Yki-Jarvinen 
et al., 1995) and IGFBP-1 levels by inhibiting the production of these proteins in 
the liver ('Weaver et al., 1990; Yki-Jarvinen et al., 1995). Apparently, the liver is 
excluded from reduced sensitivity for insulin stimulation. Accordingly, it has 
been proposed that IGFBP-1 levels may be used as a simple marker for insulin 
resistance (Tiitinen et al., 1993). Several researchers indicatedlo\ver circulating 
levels of IGFBP-1 (Weaver et al., 1990; Zachow et al., 1997; Agarwal et al., 1999), 
but not IGFBP-s (Agarwal et al., 1999), in PCOS patients compared to normal 
cycling women (Lahlou et al., 1997; Agrawal et al., 1998b; Fauser et al., 1991; 
Tiitinen et al., 1993). Moreover, insulin may also inhibit IGFBP-1 production in 
ovarian granulosa cells, by acting through its own receptor (Poretsky et al., 
1996). Circulating serum SHBG concentrations are significantly reduced in 
obese normoovulatory women (Weaver et al., 1990) and in oligoamenorrheic CC-
resistant infertile patients (lmani et al., 1998). Moreover, an increase in circulat-
ing serum SHBG concentration has been reported in ovulatory patients after CC 
medication (Butzov.r et al., 1995) as well as in women vvith PCOS using insulin-
sensitizing agents (Nestler et al., 199/b; Dunaif et al., 1996). An insufficient or 
absent rise in circulating serum SHBG concentrations (v,rith resulting high free 
androgen levels) after CC medication could be held responsible for CC unre-
sponsiveness. 
In the present study total and free IGF-I and IGFBP-3 levels are comparable 
between CC responders and nonresponders. No differences in IGFBP-3 levels 
were previously noted in follicular fluid from PCOS ovaries compared with 
androgen-dominant and estrogen-dominant follicles from normoovulatory 
women (Cataldo et al., 1992; San Roman et al., 1992). In contrast, IGFBP-1 lev-
els are significantly lo\ver in patients remaining anovulatory after CC medica-
tion. As a consequence of decreased hepatic production of serum IGFBP-1 lev-
els, a greater proportion of IGF-I is biologically active (LeRoith et al., 1995). 
Taking into account that serum IGFBP-1 levels increase (Tiitinen et al., 1993) 
and IGF-I levels decrease (Butzow et al., 1995) in oligoamenorrheic women after 
CC medication, it may be suggested that an insufficient rise in serum IGFBP-1 
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levels after CC medication is involved in the follicle grO\:vth arrest in these 
patients. No difference could be observed in pretreatment free !GF-llevels com-
paring responders vs. CRA patients. Overall, FA! is the most significant factor to 
predict ovarian response. It appears that the prediction of insulin and IGFBP-1 
completely depends on its association vvith FAI, in line with recent compelling 
molecular evidence for intrinsic abnormalities in the androgen synthesis path-
way in PCOS thecal cells (Nelson et al., !999). It is likely that decreased !GFBP-
1 is an excellent marker of hyperinsulinemia and that it does not affect the 
endocrine IGF system's effect on follicle grovvth. 
The present study demonstrates a significant correlation bet\veen leptin lev-
els and BMI and VVHR, which is in agreement with previous reports (Laughlin 
et al., 1997; Rouru et al., 1997; Brzechtfa et al., 1996). Serum leptin levels were 
significantly higher in CC nonresponders and enter into the model (instead of 
BMI) in multivariate analyses to predict CRA (Table s). The AUC of the previ-
ously developed prediction model (including FA!, BMI, cycle history, and mean 
ovarian volume) of 0.82 could be slightly impro,·ed to 0.85 by the inclusion of 
leptin rather than BM!. Due to the limited improvement of the AUC and the 
fact that information such as \\-'eight and height of the patient is easy to collect, 
one may prefer to use BMI to predict the probability to be CRA in clinical 
practice. Clearly, the end point for clinical practice should be pregnancy rather 
than ovulation. It has been demonstrated that leptin can directly impair insulin 
action in hepatocytes (Cohen et al., 1996). In addition, leptin directly inhibits 
IGF-I augmentation of FSH-stimulated estradiol production (Zachow et a!., 
1997) as well as LH-stimulated androgen synthesis in vitro (Zachovv et al., 
1991). In vivo observations, however, \\:ould argue against a negative correla-
tion between obesity I elevated leptin levels and androgens. High lcptin levels 
could interfere with the ability of the dominant follicle to produce estradiol, 
both by inhibiting the production of androgen substrate and by decreasing the 
aromatizing capacity of granulosa cells (Agarwal et al., 1999). Moreover, 
changes in estradiol and progesterone during the human menstrual cycle 
may participate in the control of leptin production (Messinis et al., 1999 ). Caloric 
restriction, exercise, and weight-reducing diets may reduce leptin levels 
(Carantoni et al., 1999); result in normalization of insulin sensitivity, gonadotropins, 
and androgen metabolism (l{iclcly el al., 1989); and lead to spontaneous ovulatory 
cycles in up to 50% of \vomen (Hollmann et al., 1996). 
Initial serum inhibin B as well as serum VEGI,- levels \-vere similar comparing 
CC responders and nonresponders. These endocrine parameters had no predictive 
value for ovarian response to CC medication. 
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Figure l Correlations betweenfi·ee mzdrogen indo: (FAI::;:;;; T :r 1001 SHBG) and B1VII, serum 
leptin, insulin, and IGFBP-1 in 182 normogonadotropic oligomnenorrheic infertile patients 
using scatter plot. Open circles represent patients who ovulated following CC, and closed circles 
CC-non responders. 
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TABLE 3. Forward stepvvisc multivariate analyses of parameters of the prediction model plus additional endocrine screen-
ing for prediction of normogonadotropic oligoamenorrheic patients remaining anovulatory during clomiphene citrate 
induction of ovulation 
Analyses: 
Steps: 
StTeClling: parameters 
a) Prediction modele 
FA!d 
BMI (kg/m2 ) 
Mean ovm·icm vol (mL) 
Cycle historye 
b) Additional endocrine paraJuetersf 
Insulin (mU/L) 
ll1sulin/ glucose ratio 
IGFBP-1 (ng/mL) 
Leptin (ng/mL) 
Univariatea 
0 
<0.0001 
0.0003 
0.007 
0.0003 
0.00.5 
O.O:J 
0.01 
0.0003 
Multivariate 
2 
In model In model 
0.03 0.04 
0.12 0.1S 
0.0001 In model 
0.,'32 0.4·5 
O.GG 0.79 
0.82 0.71 
0.01 0.009 
a Step o, Comparison of CC responders vs. CR.A (univariate logistic reg;ression analyses). 
3 ,+b 
In model In model 
<.U·G 0.46 
0.00 In model 
In model In model 
O.D~l 0.9S 
0.6'J. 0.56 
0.7'1· O.G4 
In model In model 
b Final model, Area under the ROC curve, O.S5; multivariate odds ratio (9.0% CI) of" !-<""'AI, 1.19 (1.07-1.32); of cycle history, 0. JG (O.O.':i-0.4·2); of 
!llean ovcn·iclll volume, 1.11 (0.99-1.24); and ofleptin, l.CH (1.01-LOG). This means that, tOr instance, a 1-U increase in a given patient's serum lep-
tin level gives her a 4% hig-her probability to be a CHA. 
c A.s published previously (5). 
dFA.I = T X 100/SHBG. 
e Alllcnorrhca vs. oligomenorrhea. 
/only p;-u·aJnctet·s that are sig-nificantly diffet·ent (see Table 2) are included. 
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Figure 2 Correlations between serum leptin and BZVII, waist-to-hip ratio (ffHR), and serum 
insulin in 182 normogonadotropic oligoamenorrlzeic irifertile patients using scatter plot. Open 
circles represent patients who ovulatedfollowing CC, and closed circles CC-n.on responders. 
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mogonadotropic oligoamenorrheic i"?fertile patients using scatter plot. Open circles represent patients 
who ovulated following CC, and closed circles CC-non responders. 
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The results of this study suggest that circulating inhibin B does not correspond 
to the number of healthy follicles present in polycystic ovaries, characterized by 
follicle maturation arrest and atresia of a proportion of follicles. This is in contrast 
vvith the conclusion of a recent report focusing on a relatively small group of 
patients (Anderson et al., 1998). Recent observations suggest that increased intrao-
varian concentrations of VEGF may be related to increased stroma echogenicity 
and vascularity and increased secretion and pulsatility of LH (Agrawal et a!., 
1998b ). We have not been able to confirm that VEGF levels may represent the 
magnitude of ovarian dysfunction in these women. 
The impact of markers for insulin sensitivity, the IGF system, leptin, inhibin B, 
and VEGF on the prediction of conception after ovulatory CC cycles has also been 
analyzed. None of these parameters predicts the probability of conceiving in 
women who ovulated after CC (data not shown). This stresses again the concept 
previously put forward (lmani eta!., 1999) that follicle growth and oocyte quality 
are differentially regulated. 
In conclusion, the present longitudinal follow-up study suggests that FA!, as a 
marker for the severity of hyperandrogenemia, is the most significant endocrine 
marker of ovarian dysfunction and for the prediction of ovarian response after CC 
medication. Initial serum leptin, insulin, and IGFBP-1 levels are factors in uni-
variate analyses predicting patients \Vho will remain anovulatory after CC. The 
capability of serum insulin and IGFBP-1 to predict CRA disappears when FA! 
enters into the model due to a significant correlation betvveen FAI and these 
endocrine parameters. Finally, leptin is a better marker to predict ovarian response 
to CC medication as compared to BMI. For the assessment of markers useful for 
clinical screening in patients, the present observations predicting ovarian response 
should be combined with factors predicting pregnancies in ovulatory CC women. 
Moreover, the question arises of \vhether factors involved in ovarian response or 
conception after CC medication may also predict individual response to exogenous 
gonadotropins in patients who fail to ovulate or conceive after CC. 
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2.5 A nomogram to predict live birth probability after 
clomiphene citrate induction of ovulation in normogonado-
tropic oligoamenorrheic infertility 
'1.5.1 Introduction 
Anovulation represents the most frequent cause of female infertility, and in most 
\vomen normal serum follicle-stimulating hormone concentrations are found. 
Since its introduction (Greenblatt et al., 1961) clomiphene citrate (CC) has been 
used worldv,ride as first choice medication in the treatment of anovulatory infertil-
ity. Since the early seventies CC treatment \-vas restricted to normogonadotropic 
oligoamenorrheic infertility ('WHO group 2) (World Health Organization. et al., 
1993). A significant proportion of these \vomen, hov,rever, remains anovulatory 
after CC medication. Out of the 7 5% ovulatory CC patients, approximately 50% 
will conceive within 6 CC-induced cycles (lmani et al., 1998; Imani et al., 1999). 
Assessment of pregnancy chances after CC induction of ovulation has been the 
subject of several investigations, all of which focused on the entire group of anovu-
latory patients who start with CC therapy (MacGregor et al., 1968; Gorlitsky et al., 
1978; Shepard et al., 1979; Hammond et al., 1983; Polson et al., 1989; Opsahl et al., 
1996; Kousta et al., 1997). These investigators have failed to identify predictors of 
CC treatment outcome. In contrast, our group focused on prediction of ovulation 
and conception separately (Imani et al., 1998; Imani et al., 1999). This approach in 
life table analysis for prediction of pregnancy chances seems mandatory for the fol-
lov.ring statistical reasons. Discontinuation of CC therapy due to persistent anovu-
lation is clearly an informative selective drop-out since chances for CC treatment 
outcome are different compared to vvomen \Vho continue CC therapy. TherefOre, 
inclusion of both CC responders and CC non-responders in a life table analysis for 
prediction of conception should be avoided. 
\Ve developed two distinct prediction models applying multivariate analyses 
(Imani et al., 1998; Imani et al., 1999). The first model predicts ovarian response 
after CC in the entire group of anovulatory patients on the basis of initial screen-
ing characteristics such as; free androgen index (testosterone/sex hormone-bind-
ing globulin ratio), body mass index (BMI), cycle history (oligomenorrhea versus 
amenorrhea) and mean ovarian volume (Imani et al., 1998; Imani et al., 2000). The 
second model predicts the chances of conception exclusively in those \\,omen who 
have reached ovulatory cycles after CC and includes \\roman's age and cycle histo-
ry (lmani et al., !999). Although scientifically sound, this approach seems diflicult 
to apply in the daily clinical practice. Moreover, the question remains unansvvered 
whether the chances of having a live birth after CC can be predicted prior to the 
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initiation of medication. By combining both prediction models a nomogram may 
be developed predicting chances of a given anovulatory patient to conceive 
resulting in live birth after CC. 
Anovulatory patients present \\rith a wide range of chances to conceive after 
CC. This may be due to differences in the underlying ovarian abnormalities, 
patient's age, body weight, and individual differences in the anti-estrogenic effects 
of CC on cervical mucus or endometrium. Applying a nomogram in the clinic may 
render the ovulation induction protocols more patient tailored and more cost-
effective. Patients with a poor predicted chance to conceive could be advised to 
refrain from CC therapy and start vvith an alternative first line treatment modali-
ty such as \veight reduction, insulin sensitizing agents, or exogenous 
gonadotropins. Particularly in women of advanced age precious time to ascertain 
that CC treatment is ineffective may be used for a more effective approach as the 
first line therapy. We now report the construction of a nomogram to identify char-
acteristics upon initial screening of a large cohort of normogonadotropic anovula-
tory infertile women predicting the individual chance of pregnancy leading to live 
birth after CC induction of ovulation. 
2.5.2 Materials and Methods 
Subjects and study protocol 
Between February 1993 and May 1999, two hundred and fifty nine patients attend-
ing our infertility unit \Vere included in the present study using the follo\ving 
inclusion criteria: (a) oligomenorrhea (bleeding intervals between 35 days and 6 
months) or amenorrhea (bleeding interval > 6 months), (b) serum follicle-stimu-
lating hormone (FSH) levels within normal limits (1-10 IU/L) (World Health 
Organization. et al., 1993; van Santbrink et al., 1995), (c) normal serum prolactin 
and thyroid-stimulating hormone levels, (d) spontaneous menses or positive bleed-
ing response to progestagen withdrawal, (e) body mass index (BMI) (weight divid-
ed by the square of the patients height)> IS kg/m2 , (f) between 19-40 years of 
age, (g) no previous use of ovulation induction agents, (h) a total motile sperm 
count CTMC =ejaculate volume (milliliters) x sperm concentration (106 I mL) x 
percentage of progressive motile sperm] of the partner above I million, (i) nega-
tive history of any tubal pathology, and finally (j) no indication for intrauterine 
insemination. Institutional Review Board approval was obtained from the human 
subjects committee of the Erasmus University Medical Center Rotterdam and 
informed consent \:Vas obtained from all subjects. 
Standardized initial clinical, sonographic, and endocrine screening took place 
prior to initiation of CC ovulation induction, as described previously (Imani et al., 
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1998; lmani et al., 1999; lmani et al., 2000). Clinical screening included age, type of 
infertility, cycle history, BMI, waist-to-hip ratio (\VHR), and previous medication 
and/ or surgery. Transvaginal sonography (TVS) included assessment of the ovar-
ian stroma echogenicity (arbitrarily classified from 1 to 3 per ovary), ovarian vol-
ume (mL) and total number of follicles (both ovaries), as described previously 
(Pache eta!., 1992; van Santbrink eta!., l997b). Sonographic monitoring \\'as per-
formed by a single observer (B. I.). Endocrine screening included serum assays for 
FSH, luteinising hormone (LH), estradiol (E2 ), androstenedione (AD), testos-
terone (T), and sex-hormone binding globulin (SHBG), fasting insulin and glu-
cose, free and total insulin-like growth factor-! (IGF-1), inhibin Band leptin con-
centrations, as described previously (Imani et al., 2000). Hormone assays used and 
the intra and inter assay coefficients of variation valid for this study have all been 
described previously (lmani et al., 1998; lmani et al., 1999; lmani et al., 2000). 
The treatment protocol, assessment of ovarian response and conception after 
CC have also been described previously (lmani et al., 1998; lmani et al., 1999). In 
brief, initial CC doses \Vere 50 mg/day starting on cycle day 3 after a spontaneous 
or progestagen-induced withdravval bleeding. In case of absent ovarian response, 
doses were increased to 100 and 150 mg I day in subsequent cycles. Ovulation 
after CC medication \Vas assessed by sonographic monitoring of follicle grovvth 
and midluteal progesterone > 25 nmol/L. Conception vvas defined as a positive 
urinary pregnancy test (clean·iew, hCG II, Unipath Ltd, Bedford, UK) more than 
3 days after the expected menses. Live birth was defined as delivery of a baby. 
Information regarding deliveries and the health condition of the babies born \\ras 
collected using the hospital records. In the case of home delivery we collected 
information directly from the patient and her general practitioner or mich.vife. 
Data analysis 
The statistical analysis of conception leading to live birth in anovulatory patients 
after CC should take into account the follovving two steps: ovulatory response to 
CC and conception in case of ovulation. Patients remaining anovulatory after CC 
(CRA, = clomiphene resistant anovulation) are considered to have no chance to 
conceive vvith this therapy. Therefore, the cumulative rate of conception leading to 
live birth was calculated by multiplying the chance of achieving ovulation after CC, 
with the estimated Kaplan-Meier (Kaplan et al., 1958) cumulative probabilities for 
conception in the group of ovulatory women after CC. 
A prediction model of the probability of conception resulting in live birth with-
in 6 months after initiation of CC ovulation induction was constructed by combin-
ing the previously published prediction model for the chance to be CRA (lmani et 
al., 1998) with a prediction model for the probability of conception leading to live 
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birth in ovulatory patients after CC. The current study differs from the previous-
ly published model predicting chances for conception (Imani et al., 1999) with 
respect to the starting point of follovv-up (initiation of CC therapy versus first ovu-
lation after CC). In order to implement these findings in clinical practice we 
included months rather than ovulatory cycles and live birth instead of ongoing 
pregnancy in the current analysis. A nomogram was constructed by combining the 
model to predict ovulation in the entire group of \Vomen with the model predict-
ing live birth in ovulatory CC patients. 
To determine the goodness-of-fit of the combined prediction model, patients 
were divided into 5 equal groups according to quintiles of the predicted probabil-
ity of conception leading to live birth. Using a Chi-square test, the mean predict-
eel probability \Vi thin each group vvas compared to the observed probability, calcu-
lated by the H:aplan-::'vfeier method described in the previous paragraph. Data were 
analyzed using the commercially available softvvare package SPSS (Chicago, Ill, 
USA). 
2.5.3 Results 
From the total number of 259 patients fulfilling the in/exclusion criteria and 
treated with CC, 186 (72%) suffered from primary infertility, and 62 (24%) from 
amenorrhea. One hundred and ten patients (43%) were obese (BMI > 27), 160 
patients (62%) presented with an elevated FA! (FA!> 4•.5) and 100 patients (39%) 
with hyperanclrogenemia (T <: 3.2 nmol/L and/ or AD <: 16.3 nmol/L (Fauser et 
al., 1991; van Santbrink et al., 1997b)). In 195 patients (75%) polycystic ovaries 
(mean ovarian volume <: 10.8 mL and/or mean follicle number per ovary<: 10 
(Pache et al., 1992; van Santbrinl< et al., 199'ib)) were diagnosed. One hundred and 
twenty-one patients (47%) presented with elevated initial LH (LH <: 'i.O IU/L (van 
Santbrink et al., 1997b)) serum level. Sixty-five patients (25%) remained anovula-
tory after CC medication despite the maximum CC close (150 mg/clay) and were 
considered as CRA. Eighty-three patients (.52%) presented with ovulatory cycles 
after CC but failed to conceive. 
A total number of 111 (+3%) women conceived after CC treatment and 11 
(10% of conceptions) miscarried. There was one case of ectopic pregnancy and 
one case of intrauterine death. A total number of 98 (38%) patients had a live 
birth. Sixty-seven patients delivered at the hospital and could leave the unit with-
in 24 hours. Nineteen patients ·were hospitalized for pre and postnatal care. In 4 
pregnant women anti-hypertensive medication \\'as required. There was no case 
of maternal or fetal death. In 15 \\-'omen an instrumental delivery and in L'3 
patients a cesarean section \vas performed. At birth the mean ± SD gestational 
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age was 39.3 ± 2.8 weeks and the mean weight of the babies was S !4<2 ± 590 
gram. There was no case of postpartum death in the flrst year after the delivery. 
No case of congenital abnormalities was reported. 
Odds ratios of screening characteristics separately for ovulation in the entire 
population and live birth in ovulatory CC women are presented in Table 1. 
Screening characteristics were included on the basis of significance in previous 
multivariate analysis predicting ovulation 
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Figure 1 Cumulative percentage of women reaching first ovulation and first conception ending 
in a live birth in 259 normogonadotropic oligoamenorrheic irifertile patients treated with CC. 
Solid line =first ovulation after CC (n=I94; 75%); dashed line= first conception ending in a 
live birth (n=98; 38%). 
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TABLE 1. Odds ratios (OR) of initial screening characteristics in relation to the occurrence of O\'Ulation in the entire group of nonnogonadotropic oligoamcnor-
rheic infertile wornen (n= 18+ of 259) m· live birth in ovul<Jtory women after CC (n=98 of J 94) 
Screening c!Jaracteristics 
Clinical 
Age (per yr) a 
Primary vs. secondary infertility b 
Oligomenorrhea vs. amenorrhea a, c, d 
Bleeding intcn·al in case of oligomenorrhea b, e 
i:i-G we<:"ils 
G-9 weeks 
9-2G weeks 
BMI (kg·/m2 ) c 
\Vaist to hip n1tio (\VHR per 0.1 )h 
Endocrine 
Lll \IU/L)b 
FAI J, f 
IIyperandrogenemia (elevated T and I or AD) h 
Insulin (mUlL) b 
Insulin/glucose ratio b 
Inhibin B (ng/L) b 
Free IGF-T (ng/mL) h 
Lcptin (ng/mL) c 
Ultrasound 
PCO versus non-PCO c, g 
Spcnn parameters 
Total motile sperm count I 104 b 
Ovulation Liw· birth in o\'l!latory women 
following CC _____ fl1llowing CC 
1.05 ({UJ8- 1.12) 
1.2.') (0.6'1•- 2 . .'34) 
'L'H (2 . .'3':!·- 8.05) 
8.30 (3.29 -20.98) 
J.G+ ( 1.7.'i- 7.55) 
2.90 ( 1.25- 6.7.'3) 
O.U2 (0.88- 0.96) 
o.6o (o . .-w- o.89) 
0.97 (0.9 J - I.O.'l) 
0.8.'3 (0.7?-i- O.lW) 
O . .'Hi (0.20- 0.65) 
0.95 (0.92- 0.08) 
0.87 (0.77- 0.97) 
1.00 (0.09- 1.01) 
0.01 (0.77- 1.09) 
0.97 (0.95- 0.99) 
0.59 (0.29- J .22) 
0.90 (0.85- 0.94) 
0.71 (0."'1:4- 1. Ui) 
0.77 (0.47- 1.28) 
O.G5 (O . .'J6- 1.18) 
0.87 (0.50- 1.51) 
0.8.'3 (O.-k2- 1.63) 
1.00 (0.97- 1.04) 
1.08 (0.81 - 1.42) 
1.04 ( 1.00- 1.0~1) 
l.OG(l.Ol-l.ll) 
1.67 ( l.IO - 2.5-·:t) 
0.09 (0.97- 1.02) 
0.99 (0.90- 1.08) 
1.00(0.99-1.01) 
1.10(0.9()- 1.25) 
1.02 (1.00-l.O:l) 
O.DB (0.6::1- 1.5'1·) 
1.00 (0.81- 1.23) 
a Characteristics predicting- ronreption in ovulatory CC patients applying multi\'ariate analysis as published pr('viously (lmani et al, JCEi\-f l!J!J!J) 
h Biological releV<-tllt characteristirs for ovarian Jysfuuctiun or !JI'egnanry prediction in nonuoguuadotropi<": ;movulation 
c Chnracteristics predicting ovulation fOllowing CC applying multivariate nne~lysis as published previously (lmani ct a!, JCEM 1908, JCEM 2000) 
d The oligomenorrheic patients nrc+ times more likely (OR= -~<.:J-1,) to ovulnte after CC compared to amenorrheic pntients. llowever the chance !i.w a live birth after CC is 
'2.'J'~{, kss (OR= 0.77) compnrcd to amenorrheic patients. 
~Amenorrhea is reli:-renrc C<Jtcgory fOr the categories of bleeding intcrq] in oligomenorrhea. 
t PAT= T x. 100 I SHBG 
g Polyrystic m·aries =mean ovnrinn \·olume;::: 10.8 mL and/or mean tl)llirk number per ovary;::: 10 (Y<Hl Stanhrinl1 ct a!, Fertil Steril 1997) 
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Figure 2 The impact if cycle histOJJ on cumulative ovulation and live birth mtes in 259 norma-
gonadotropic oligoamenorrheic infertile patients treated with CC. A: solid line = oligomenorrheic 
patients (n = 197); B: dashed line= amenorrheic patients (n = 62). P value represents differences 
appl)'ing LogRank test (A: P < 0.001; B: P value= not applicable in the overall JVHO 2 anovu-
latory patients. P < 0.001 in ovulatory patients following CC). 
(FA!, BM!, cycle history, ovarian volume, leptin), predicting pregnancy in ovula-
tory patients (age, cycle history) and biological relevance for ovarian dysfunction 
(LH, hyperandrogenemia, insulin, insulin/ glucose ratio, inhibin B, free IGF-I) or 
pregnancy prediction (infertility history, bleeding interval in case of oligomenor-
rhea, total motile sperm count). The cumulative rates of first ovulation and first 
conception ending in live birth are depicted in Figure 1. The impact of cycle his-
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tory on cumulative ovulation and live birth rates after CC is depicted in Figure 2. 
Prediction of conception leading to live birth after CC applying a nomogram 
has been depicted in Figure 3. This nomogram comprises hvo separate steps. In 
the left panel the probability of ovulation after CC can be estimated applying FA!, 
BMI, and cycle history (oligomenorrhea versus amenorrhea). Drag and drop the 
chance to ovulate after CC from the left to the right panel. In the right panel the 
predicted probability to conceive \vi thin 6 months after initiation of CC medication 
resulting in live birth is indicated, combining the probability of ovulation after CC 
\Vith age and cycle history (oligomenorrhea versus amenorrhea) of the patient. 
Mean ovarian volume, and serum leptin levels comprise the least predictive con-
tribution to the model (lmani et al., 1998; lmani et al., 2000) and therefore were 
excluded from the left panel of this nomogram. 
The P-values for the Chi-square goodness-of-fit test was 0.4-9, indicating no 
statistically significant lack of fit between the observed and predicted probabil-
ity of live birth within the 5 groups (see also Materials & Methods; data not 
shown). 
2.5.4 Discussion 
Currently, CC represents the first line treatment strategy for all patients with nor-
mogonadotropic anovulatory infertility. The present study confirms that CC is safe 
and convenient vvith limited chances for complications such as multiple pregnancy 
or OHSS. However, only 38% of treated women may conceive after CC resulting 
in live birth which is substantially less than generally assumed. It may represent a 
distinct step forward if patients with even lower chances for live birth after CC 
could be identified in advance. 
Previous attempts by retrospective studies in the entire group of anovulatory 
patients failed to identify factors predicting ovulation (Gorlitsky et al., 1978; 
Shepard et al., 1979; Polson et al., 1989) or conception (Gorlitsky et al., 1978; 
Hammond et al., 1983) (l{ousta et al., 1997) after CC. In contrast, we focused on 
predictors of CC treatment outcome in a prospective fashion in the current longi-
tudinal cohort study. For the first time we used ovulation and conception as sepa-
rate endpoints, taking into account that a significant proportion of patients 
remains anovulatory during CC medication. These \\'omen are not exposed to the 
chances of becoming pregnant. Univariate and multivariate analyses \\-'ere per-
formed in these two separate settings. The first multivariate model consisting of 
FA!, B'v!l, cycle history, and mean ovarian volume predicts chances of remaining 
anovulatory after CC (lmani et al., 1998). The second model consisting of age and 
cycle history predicts chances for conception only in women who respond to CC 
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(lmani et al., 1999). Observed screening characteristics involved in the prediction 
of ovulation after CC medication are distinctly different from predictors of con-
ception in ovulatory CC patients. 
In the current study \-ve combine both prediction models in a nomogram to pre-
dict chances of live birth in the entire group of normogonadotropic anovulatory 
patients. For reasons of its applicability in clinical practice we converted analysis 
to month rather than treatment cycles and used live birth rather than pregnancy 
as the outcome. The estimation of chances to ovulate is a crucial step in evaluating 
the probability of conception resulting in live birth after CC therapy This is the 
reason for the involvement of two steps in the presented nomogram. Cycle histo-
ry is the only factor which is present in both steps. Amenorrheic patients are less 
likely to ovulate after CC medication, but once they ovulate chances for live birth 
are higher compared to oligomenorrheic vmmen. A biologically plausible explana-
tion is that the occurrence of other factors contributing to a reduced fertility is less 
likely since these women never had the chance to conceive. BMI does not influence 
live birth rate in patients \vho ovulate follov..'ing CC. Moreover, live birth rate in 
CC-ovulatory PCO vs. CC-ovulatory non-PCO patients are comparable. 
Interesting!)~ age does not affect chances for ovulation, but is involved in preg-
nancy chances once ovulation has been reached (lmani et al., 1998; lmani et al., 
1999). This is in agreement vvith reports concerning an association betvveen 
reduced treatment outcome after in vitro fertilization and patient's advanced age 
(Scott et al., 1995). 
The major aim \vas to render the present nomogram as easy as possible for use 
in daily clinical practice. Therefore, ovarian volume (which was included in the 
previous multivariate model predicting ovulation (Imani et al., 1998)) has been 
excluded from the present nomogram. The additional predictive contribution of 
this prognostic factor to the model is negligible (a decrease in the area under the 
receiver characteristic curve of the model to predict patients remaining anovula-
tory from 0.82 to 0.80 (lmani et al., 1998)). \Ve also demonstrated previously that 
serum leptin concentrations (an endocrine marker associated \\'ith obesity (Rouru 
et al., 1997)) predict chances of remaining anovulatory after CC (lmani et al., 2000). 
Leptin has also been excluded from the present nomogram since this assay is not 
available in most hospital laboratories. Instead, information for BMI can be gener-
ated easily with only a minor decrease in AUC of the prediction model (0.85 
instead of 0.82). Therefore, serum T and SHBG levels are the only endocrine fac-
tors which should be assessed for the present nomogram. Indeed, both obesity and 
hyperandrogenemia are associated \Vith polycystic ovary syndrome knovvn to 
exhibit low chances for success during CC ovulation induction. Remaining biolog-
ical plausible factors involved in ovarian dysfunction in normogonadotropic 
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anovulation such as LH (Fauser et al., 1991 ), insulin/ glucose ratio's (Poretsky et al., 
1999), inhibin B (Anderson et al., 1998) and free IGF-1 (van Dessel et al., 1999) 
failed to predict ovulation or conception and were therefore excluded from the 
nomogram. 
In summary, the present study demonstrates for the first ti1ne that a nomogram 
can be developed on the basis of initial screening characteristics predicting chances 
of live birth after CC for a given patient. An external validation of the present 
nomogram is mandatory to be able to define a clear cut-off level in the chances for 
live birth after CC for the decision making in routine daily clinical practice. For 
instance, a cut-off level of 20% chance of having a live birth (which comprises 19% 
of the overall WHO 2 anovulatory patients) could be chosen. These patients could 
be advised to refrain from CC therapy and start with an alternative first line treat-
ment modality such as V1ieight reduction, exogenous gonadotropins, insulin sensi-
tizing hormones, or in vitro fertilization particularly in women with an advanced 
age. This vvould render CC ovulation induction strategies more patient tailored 
and could improve overall cost effectiveness. 
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Predirlion qf Ovulation Induction Outcome in Normogonadotropic Anovulatory l!!fertilit:y 
3.1 Introduction 
As indicated before, complications of induction of ovulation applying exogenous 
gonadotropins in the group of normogonadotropic clomiphene resistent 
oligomenorrheic or amenorrheic infertile \vomen are a cause of major concern. 
These complication are mainly OHSS and multiple pregnancy, v,rhich seems to be 
correlated with the dose regimens applied (van Santbrink et al., 199/a), late follic-
ular phase FSH accumulation and I or multifollicular development (Fauser et al., 
1991). Moreover, a large variability exists in the amount of exogenous FSH 
required due to individual differences in ovarian sensitivity for I ... "'SH stimulation-
also referred to as the FSH threshold (Brown et al., 1978)- of these women. This 
has been held responsible for the high incidence of complications resulting from 
the development of multiple dominant follicles which may result in multiple preg-
nancies and sometimes OHSS (Gleicher et al., 2000). 
In an attempt to reduce these complications alternative gonadotropin treatment 
schedules have been developed. These treatment protocols have been described in 
chapter 1.2.Q and 1..3.2. V•le introduced a safe and effective protocol to treat a ne\v 
clomiphene resistent patients applying exogenous gonadotropins for induction of 
ovulation. An initial dose-finding cycle according to a low-dose step-up protocol prior 
to subsequent step-dO\vn cycles was applied to identify patients vvith extreme lov,r or 
high FSH threshold. The starting does of FSH in the subsequent cycle was initiated 
according to a step-dO\vn close regimen \:vith initial starting dose of 1/ 2 ampoule 
above the effective close (FSH response dose) in the preceding low-dose step-up cycle. 
Prediction of FSH threholcl (FSH response dose) in normogonadotropic 
clomiphene resistent oligomenorrheic or amenorrheic infertile women has been 
the focus of the first part of the present chapter. Subsequently, in the last part of 
the present chapter \Ve report on prediction of multifollicular development, con-
ception during exogenous gonadotropins fOr induction of ovulation applying step-
clown dose regimen. 
3.2 Prediction of the individual follicle-stimulating hormone 
threshold for gonadotropin induction of ovulation in 
normogonadotropic anovulatory infertility: 
An approach to increase safety and efficiency 
3.2.1 Introduction 
Chronic anovulation is a common cause of infertility in \vomen, the majority of 
\Vhom have irregular menstrual cycles and norma] serum FSH concentrations 
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CWorld Health Organization [WHO], group 2) (World Health Organization. et 
al., 1993). Approximately 60% of these women are diagnosed as polycystic ovary 
syndrome (PCOS), dependent on inclusion criteria used (van Santbrink et al., 
1997b). Treatment of f1rst choice in \VHO 2 is anti-estrogen medication, com-
monly clomiphene citrate (CC) (Franks et al., 1995). Approximately 50% of WHO 
group 2 anovulatory \VOmen who have failed to ovulate or conceive after CC med-
ication can be successfully treated vvith exogenous gonadotropins (Franks eta!., 
1995; Fauser eta!., 1997). Currently, low-dose step-up (\Vhite et al., 1996) or step-
down (van Santbrink et al., 1995; van Santbrink et al., 1997a) regimens are used to 
reduce the probability of multiple pregnancies and ovarian hyperstimulation syn-
drome (OHSS) compared to initially introduced high dose gonadotropin proto-
cols (Fauser et al., 1997). 
Exogenous gonadotropins elicit significantly increased ovulation rates (up to 
90%) compared to CC (White et al., 1996; lmani et al., 1998) and result in similar 
conception rates (55%) in case ovulatory cycles are obtained (van Santbrink et al., 
1995; \Vhite et al., 1996; lmani et al., 1999). However, a large variability exists in 
the amount of exogenous FSH required due to individual differences in ovarian 
sensitivity for FSH stimulation -also referred to as the FSH threshold (Brown et 
al., 1978)- of these women. This has been held responsible for the high incidence 
of complications resulting from the development of multiple dominant follicles 
which may result in multiple pregnancies and sometimes OHSS (Gleicher et al., 
2000). The increased incidence of multiple gestation has significant social, eco-
nomic, and health consequences (Callahan et al., 1994). 
The narrovv range of FSH serum concentrations resulting in either mono or 
multi-follicular grovvth has been a major concern. Thus, intense monitoring of 
patients undergoing gonadotropin induction of ovulation is mandatory to adjust 
the FSH dose according to the individual ovarian response. One method of fme-
tuning the required FSH levels and reducing complications is by starting with a 
lov,r dose of FSH and gradually increasing the dose until ovarian response is 
observed (White et al., 1996; Fauser et al., 1997), a protocol currently referred to 
as the "lovv-dose, step-up" regimen. However, this can be a time-consuming proce-
dure, especially for patients who exhibit a high FSH threshold. 
Another treatment strategy~ developed by our group, is the "step-down" regi-
men (van Santbrink et al., 1995; Fauser et al., 1997; van Santbrink et al., 1997a) 
which involves a relatively high initial dose of FSH followed by subsequent deere-
mental steps. This approach more closely mimics physiological conditions in 
norma-ovulatory women (van Santbrink et al., 1995). However, the initial standard 
FSH dose may be too high for those women with a low FSH threshold level which 
could induce imminent ovarian hyperstimulation requiring cancellation of stimu-
so 
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lation (Fauser et al., 1997). Adjusting the starting dose in women with a low FSH 
threshold would certainly reduce the incidence of multiple dominant follicle devel-
opment and related complications during the step-dovvn regimen. 
The ability of clinicians to choose an appropriate starting dose of FSH for a 
given patient could considerably improve treatment outcome in both low-dose 
step-up or step-down regimens and render this treatment modality safer and more 
efficient. Clinicians, vvho prefer to use a low-dose step-up regimen, may start \vith 
a higher FSH starting dose in patients with a predicted high FSH threshold. These 
patients may reach adequate ovarian stimulation in a shorter period of time vvith 
fe\ver requirements for ovarian response monitoring and less gonadotropin prepa-
rations administered in doses below the FSH threshold. In contrast, women with 
a low predicted FSH threshold may start with lower initial dose of FSH to mini-
mize complication or cancellation rates especially v.1hen a step-dovvn protocol is 
applied. The present study was designed to develop a model, which uses pre-treat-
ment clinical, endocrine, and sonographic screening characteristics of normogo-
nadotropic anovulatory \vomen \vho did not ovulate or conceive after preceding 
CC medication, to predict the individual FSH response dose for gonadotropin 
induction of ovulation. 
3.2.2 Materials and Methods 
Subjects and study design 
Ninety women attending our infertility unit between June 1997 and September 
1999 were included in the present study, using the following criteria; (a) oligomen-
orrhea (bleeding intervals between 35 days and 6 months) or amenorrhea (bleed-
ing interval> 6 months), (b) serum FSH levels within normal limits (1-10 !U/L), 
(van Santbrink et al., 1995; Schipper et al., 1998) (c) normal serum prolactin and 
thyroid-stimulating hormone levels, (d) spontaneous menses or positive bleeding 
response to progestagen withdrawal, (e) body mass index (BMI) (weight divided 
by square height) > 18 kg/m2 , (f) age between 19-40 years, and (g) previously 
being treated unsuccessfully with CC (failure to ovulate, or failure to conceive in 
six ovulatory CC-cycles) in our fertility unit. Institutional Review Board approval 
\Vas obtained from the human subjects committee of the Erasmus University 
Medical Center Rotterdam and informed consent was obtained from all subjects. 
Standardized initial clinical, sonographic, and endocrine screening (as 
described previously (lmani et al., 1998; lmani et al., 1999)) took place prior to ini-
tiation of exogenous gonadotropin induction of ovulation using a low-dose step-
up regimen during the first stimulation cycle. Clinical screening included age, 
duration and history (primary vs. secondary) of infertility, cycle history, ovarian 
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response to previous CC medication, BMI, waist-to-hip ratio (WHR), any other 
previous medication and/ or surgery. Transvaginal sonographic (TVS) screening 
included assessment of the ovarian stroma echogenicity (arbitrarily classified from 
I to 3 per ovary), ovarian volume (mL) and total number of follicles (both ovaries), 
as described previously (Pache et al., 1992; van Santbrink et al., 1997b). 
Sonographic monitoring was performed by a single observer (B.I.), using an ultra-
sound machine (model EUB-415, Hitachi Medical Corp., Tokyo, Japan) with a 6.5-
MHZ transvaginal transducer. Endocrine screening included serum assays for 
FSH, luteinizing hormone (LH), estradiol (E0 ), androstenedione (AD), testos-
terone (T), and sex-hormone binding globulin (SHBG), fasting insulin and glu-
cose, free and total insulin-like growth factor-! (IGF-1), !GF-bincling protein-! 
(IGFBP-1), IGFBP-3, inhibin Band leptin concentrations, as described previous-
ly (lmani et al., 2000). 
Hormone assays used for this study have all been described previously (Imani 
et al., 1998; Imani eta!., 2000). Intra- and in teras say coefficients of variation \\-'ere 
less than 6.1% and 9.9% for insulin, less than 1.0% and 1.9% for glucose, less than 
IO.S% and 10.7% for free IGF-l, less than S.+% and 8.2% for IGF-1, less than 5.2% 
and 6.0% for !GFBP-1, less than 3.9% and 1.9% for !GFBP-3, less than S% and 
14% for inhibin B, and less than 3.6% and 4.6% for leptin, respectively. 
Treatment protocol and monitoring of ovarian response 
A low-dose step-up regimen using either daily intra-muscular (IM) injections of 
urinary FSH (Metrodin HP®, Serono Benelux BV, The Hague, The Netherlands) 
or subcutaneous (SC) injections of recombinant FSH (Gonal-F®, Serono Benelux 
BV) was applied starting on clay S-5 after a spontaneous or progestagen-induced 
withdrawal bleeding. The starting dose of FSH was one 7 5 !U per day. The first 
increase in the FSH dose by SS IU per day \\'as based on absence of ovarian 
response (i.e. sonographic visualization of a follicle 2 10 mm (Pache et al., 1990; 
van Santbrink et al., !995)) after 7 days of medication. The FSH close was kept 
constant for the follovving seven days and subsequently increased by .98 IU per 
day in case ovarian response ,,ras still Jacking. Monitoring was performed every 
other day. In case of sufficient ovarian response, the FSH dose remained unaltered 
until administration of human chorionic gonadotropin (hCG) (Pregnyl®, NV 
Organon, Oss, The N etherlancls ). A single close of 5,000 IU of hCG was adminis-
tered IM on the clay one or two follicles 2: IS mm were visualized. In case three 
or more follicles 2 16 mm vvere present, stimulation was cancelled and hCG with-
held. Ovulation vvas assessed after hCG administration by the sonographic visu-
alization of collapse of the dominant follicle and mid-luteal progesterone (P) lev-
els above 25 mnol/l. l\o luteal support was provided. 
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Data analysis 
All patients were followed during the first gonadotropin-induced cycle. \Ve used 
the F test for AN OVA and Chi-square test for comparison of FSH response dose 
bet\veen variables. To assess the univariable relation bet\veen the initial screening 
parameters and FSH response dose, Pearson's correlation coefficients were com-
puted. Multiple linear regression was used for multi variable analysis, with FSH 
response dose as a continuous outcome variable. Initial screening parameters sig-
nificant in the uni·variable analysis, vvere entered into the multiple regression 
model in a fonvard stepv,rise fashion. 
The overall predictive performance of the final model was assessed by multiple 
R2 . This number expresses the fraction of the total variance of FSH response dose 
that is explained by the regression modeL The average error of the model \\rhen 
used for prediction of the FSH response dose of new patients was assessed by the 
Root Mean Squared Error (RMSE). R2 and RMSE were computed on the same 
data that were used for developing the model. A bootstrapping procedure with 200 
replications was therefore used to estimate the amount of over-optimism. From 
this, corrected R2 and RMSE were calculated. P = 0.05 was deemed as threshold 
level for statistical significance. Data were analyzed using the commercial1y avail-
able software package SPSS (Chicago, IL, USA). 
3.2.3 Results 
Of the 90 women who failed to conceive after CC, 4·0 (44%) patients were 
considered to be CRA and the remaining 50 (56%) women were CC failures 
(CCF) (CC-induced ovulatory cycles without conception). During ovulation 
induction by exogenous FSH using a lovv-dose step-up regimen, all patients 
developed a follicle beyond 1 0-mm diameter and visualization of ongoing dom-
inant follicle growth beyond 10 mm was observed at a dose of 75 IU/d in 33 
(37%), 112.5 IU/d in 27 (so%), 150 IU/d in 16 (18%), 187.5 IU/d in 10 (ll%) 
and > 187.5 IU/d in only 4 (1·%) patients, respectively. A total number of 5 
cycles (5.5%) have been cancelled due to multiple follicle development(> S fol-
licle beyond 16 mm). 
Distribution of CRA or CCF, and amenorrheic or oligomenorrheic patients 
related to the FSH dose administered on the day of ovarian response are depicted 
in Figure 1. Initial clinical, endocrine, and sonographic characteristics of the over-
all study group and separately for patients \Vho reached an ovarian response at a 
daily dose of 75, 112.5, 150, or> 187.5 IU/day are presented in Table 1. Cycle his-
tory (amenorrhea or oligomenorrhea), bleeding interval (arbitrary classified in 4 
categories), ovarian response to CC medication (CRA or CCF), BMI, \VHR, T, 
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SHBG, free androgen index (FA! = 100 x T I SHBG), insulin, insulin/ glucose 
ratio, free IGF-1, !GFBP-1, and leptin serum levels were all significantly different 
and correlated with the FSH response dose. 
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Figure 1 Distribution of 90 normogonadotropic anovulator)' infertile women in 4 different FSH 
response dose groups (7 5, 112.5, ISO, or:;?: 187.5 IU Ida)) during ovulation induction by exoge-
nous FSH using a low-dose step-up regimen. T'hefollowing initial prognostic factors have been 
depicted: Ovarian response to the preceding CC medication (CRA or CCF; A) and cycle histoJ)' 
(amenorrhea or oligomenorrhea; B). A: P < 0.001 (CCF vs. CRA). B: P <0.001 (oligomenorrhea 
vs. amenorrhea) 
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The result of univariate and multivariate analysis for prediction of the FSH 
response dose is depicted in Table 2. The multiple R2 of model step 1, 2, 3 were 
0.29, 0.42, and 0.51 respectively. The multiple R2 of the fmal model was 0.54, and 
the average prediction error (RMSE) was 30.6. The bootstrapping procedure 
revealed that the corrected values of R2 and RMSE were 0.39 and 35.4, respec-
tively This means that we may expect the model to explain 39% of the between 
women variability in FSH response dose, and that the standard error of the pre-
dicted value is about 35 IU /L. The following equation for the predicted FSH 
response dose has been developed; [4 BMI (kg 1m2)] + [32 CRA (yes= 1 or no 
= o)] + [7 free IGF-1 (ng/mL)] + [6 FSH (IU/L)J- 51. The scatter plot between 
observed and predicted FSH response doses using this model is depicted in Figure 
2. Box and Whisker plots of2 initial screening parameters (significant at P < 0.01 
in univariate analysis) of patients separated in four different groups of FSH 
response doses are depicted in Figure S. 
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TABLE 1. Clinical, endocrine, and ultrasound characteristics (mean ± SD) during initial screening of 90 normogonadotrop-
ic anovulatory infertile women who did not ovulate or conceive after previous clomiphene citrate medication. Observations 
are also separated for patients vvho reached an ovarian response by the daily administration of 75, 112.5, 150, ~ 187.5 IU 
exogenous FSH (FSH response dose) applying a low-dose step-up regimen for induction of ovulation. 
Overall group FSH response close pa 
11 = 90 75 IU/cl 112.5 IU/cl 150 IU/cl <: 187.-S IU/cl value 
37% (n = .'33) so% (n = 27) 18%(n=1G) 1.'5% (n = 14<) 
Screening parameters 
Clinical 
Age (years) 29 ± 4 29 ± .'3 29 ± 4 29 ± ,') 29 ± 3 
P1·illlary infertility% (n) GG% (.59) 67% (22) GS% (17) 6S% (10) 71%(10) 
Bleeding interval in ·1· categories < 0.001 b 
5-6 weeks,% (n) 19(XJ(17) 30%(12) II% (3) o% (I) 7% (1) 
6-9 weeks,% (n) 28% (2.'5) 30% ( 10) .'37% (10) 19% (:3) 14% (2) 
9-2G weeks,% (n) 16% (1.'5) 12% (4) 19% (.'5) 2.o% (4) 14% (2) 
Amenorrhea,% (n) s7% (ss) 21% (7) ss% (9) 50% (8) G·l·% (D) 
Ovc:u·i;:m response to CC (CHA) •H·% (•1·0) 21% (7) 'H% (11) os% (10) 86%(12) < 0.001 b 
BMI (kg/m2) 26.5 ± 5.5 23.0 ± 4·.4· 27.4· ± 4.5 28.8 ± 4·.3 30.3 ± 6.6 < 0.001 
\Vaist to hip ratio (VVHR) 0.81 ± 0.08 0.78 ± 0.06 0.81 ± 0.08 0.87 ± 0.11 0.8.'5 ± 0.06 0.003 
Endocrine 
Ll I (IU/L) 8.1 ± 4.7 8.4 ± .'5.1 7.3 ± 'J..9 8.9 ± +.2 8.1 ± 4.0 
FSH (lUlL) 5.1 ± 1.5 'k8 ± l.G 5.3 ± 1.'} 5.1 ± 1.7 5.1 ± 1.6 
E2 (pmoi/L) 236 ± lOti 2<1·2 ± 130 213 ± 104· 258 ± 71 211-2 ± 73 
AD (nmoi/L) 13.9 ± 6.7 12.9 ± 4·.9 12.7 ± 4•.8 16.4· ± 10.0 16.0 ± 8.4· 
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T (nmoi/L) 2.5 ± 1.0 2.'1· ± 0.8 2.3 ± 0.9 ~l.l ± 1.1• 2.G ± 0.7 
SllRG (nmol/L) 4B ± 25 61 ± 26 'l<J ± 23 38 ± 22 30 ± 17 
FA! (T x 100 I SHRG) 7.1 ± .15.4 4.7 ± 2.7 6.9 ± 5.2 11.5±8.2 8.0 ± 3.5 
Insulin (mUlL) 12 .. 'l ± 8.2 8.7 ± 4.2 12.6 ± 5.7 15.6 ± 8.6 16.9 ± 14.6 
Glucose (mmol!L) ·1<,.'3 ± 0.7 +.2 ± 0.8 4.0 ± O.F) 4.0 ± 0.9 4.4 ± 0.9 
Insulin/ glucose ratio 3.0 ± 2.1 2.1 ± 1.0 2.9 ± L'J 4.2 ± 2.4 4.1 ± D.G 
Inhibin B (ng/L) 164· ± 134· 196 ± H5 l•H·±I2G 115 ± 101 183 ± 1·1·8 
IGF-1 (ng·/mL) 244 ± 80 25B ± 65 237 ± 88 2:J8 ± 87 232 ± 92 
Free IGF-f (ng/mL) 2.8 ± 1.7 2.6 ± L4 2.5 ± 1.4· 2.B ± 1.9 3.9 ± 2.4 
IGFBP-1 (ng/mL) 2'1· . .'3 ± 17.0 .'34·.0 ± 17.7 21.7 ± 14.7 16.8 ± 14.2 U5.8 ± 12.1 
IGFilP-s (ng/mL) 3,'l{:i9 ± 757 3,cJ.98 ± 7.18 3,392 ± 776 .'1,.'51.'l ± 980 .'3,.10.'3 ± 4.'H 
Leptin (ng/mL) 20.0 ± 15.0 10.4· ± 5.0 22.3 ±I J/1· 2G.O ± 16.9 .'ll.3 ± 22.'} 
Ultrasound 
Total stroma scon:c 4.2 ± 1.2 4.0± 1.1 4.3 ± 1.3 4.8± 1.1 4·.1 ± 1.4 
Mean ovarian Yolume (mL) 10.7 ± 'i-.2 10.0 ± S.G 9.9 ± 2.0 12.1 ± .'5.4 12.4 ± 6.2 
Mean tOllicle number 15 ± 6 H± 5 15 ± 5 IS± 8 H·± 8 
a P value ofF test for AN OVA tOr continuous variables, and P val tiC of Chi-square test f()r categorical variables 
b FSH response dose differs among tOur categories of bleeding interval 
c Arbitn1rily defined as one to three per nvary (both ovaries added) 
0.024 
0.002 
< 0.001 
O.OOG 
0.002 
0.09 
< 0.001 
< 0.001 
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TABLE 2. Fonvard stepwise multivariate analyses of initial screening parameters for prediction of the FSH response dose 
during FSH induction of ovulation applying a low-close step-up regimen in 90 normogonadotropic anovulatory infCrtile 
vvomcn who failed to ovulate or conceive fOllmving CC 
Analyses Univariate a Multivariate b 
Steps 0 2 3 
Screening parameters 
Clinical 
Amenorrhea (n = 33) d ().~32 e 0 . .'39 e 0.21 O.l.S 
Ovarian response to CC medication (CRA) 0.49 r: 0.4.'3 e In model In model 
BMI (kg/m2) 0.54· e In model In model In 111odd 
Endocrine 
FSII (IU/L) 0.06 0.19 O .. 'W e 0.2d" 
FA! (T x 100 I SHBG) o.nl -0.02 -0.16 -0.10 
Insulin (mUlL) 0.35 e O.H 0.1 J 0.09 
Free IGF-l (ng/mL) 0 .. '3.'3 e 0.42 e 0.3H e In model 
IGFRP-1 (ng/mL) -O.SG e -0.06 -0.06 -0.09 
Leptin (nglmL) 0.53 e 0.25/ 0.'20 0.11 
UltrasouJHl 
Mean ovarian volume (mL) 0.17 0.14 0.02 -0.00 
a Pearson's correlations (step o, univariate). Only variables significant in univariate analysis were used in this annlysis. 
b Partial correlations, corrected for pnnunelers entered into the model (step 1 - '-", multiv<~ri8te) 
c Finnl model, multiple R2 = 0 .. '5+ 
d Amenorrhea was used a.s candidate \'ariable instead of bleeding interval in '1· categories (as in Table 1) for case of interpretation 
e Significant at P < CUl1 
f Significant at P < O.O,S 
t} [" 
0.12 
In model 
In model 
In model 
-0. 1'1• 
0.10 
In model 
-0.10 
0.13 
0.03 
Pt·cdicted FSJ-f response dose c<Jlculated by a fOrmula based on 4 selected v<~riables in the fin<~lmodel: [ 4· 13M I (kg- 1m2)] + [32 CHA (yes = 1 or 
no= o)] + [7 free IGF-1 (nglmL)] + [G FSII (lUlL)]- 51. As an example, a new <tmcnorrhcic iniCrtile patient who did not respond to CC med-
ication presented with the following findings: BMI = 30.75, initial free IGF-1 = 2.9 nglml, and initial St..Tttlll FSJI = G.S lUll. The predicted FSH 
response dose is 123 + 32 + 20 + +1- 51= 165 IU I day which equals 2.2 ampoules I day. 
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Figure 2 Scatter plot of the observed and predicted FSH response dose by the -model ([4 B1VII (kg 
1m2)]+ [32 CRA 6·es = 1 or no= o)] + {lfree IGF-I (nglrnL)] + [6 FSH (lUlL)]- 51) 
during ovulation induction by exogenous FSH using a low-dose step-up regimen in 90 normogo-
nadotropic anovulatory iriffrtile patients. PS =the 5th percentile and P95 =the 95th percentile of 
predicted probability. 
3.2.4 Discussion 
The present study v,ras designed to evaluate vv·hether initial clinical, endocrine and 
sonographic characteristics of normogonadotropic o1igoamenorrheic infertile 
vvomen \\'hO failed to ovulate or conceive after CC induction of ovulation could pre-
dict the amount of exogenous FSH required for ovarian response during a lovv-
dose step-up regimen. The aim of this stimulation protocol is to apply the lov,.'est 
possible daily dose of exogenous gonadotropins to gradually surpass the individ-
ual FSH threshold in order to achieve follicular maturation and subsequent ovula-
tion. This concept was introduced by Brown (Brown et aL, !978) and indicates that 
each woman has a given threshold requirement for FSH belov,r which fOllicular 
development does not occur. After sufficient ovarian stimulation by exogenous 
FSH, the dominant follicle may be selected in these anovulatory patients (van 
Santbrink et aL, !997a). Distinct differences in the individual FSH threshold level 
Prediction r!f uogenous gonadotropin m:mlation induction outcomt 
may be held responsible for the relatively high incidence of complications such as 
multiple gestations or OHSS (Schoemaker et al., 1993). 
The FSH threshold may represent the severity of ovarian abnormalities in 
these patients. Up to so% of normogonadotropic anovulatory \VOmen do not 
respond to increased endogenous FSH stimulation brought about by CC adminis-
tration suggesting a high FSH threshold (Imani et al., 1998; lmani et al., 2000). 
These patients are characterized as obese, hyperandrogenic, amenorrheic women 
with an augmented ovarian volume (lmani et al., 1998; lmani et al., 2000). 
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Figure 3 Two initial screening paratneters of 90 nonnogonadotropic anovulator)' infertile 
patients separated in 4 different F SH response dose groups (7 5, 112.5, 150, or "C 187.5 IU I daJ0, 
during ovulation induction by exogenous FSH using a low-dose step-up regimen. Data are pre-
sented as box and whisker plots: Boxes encompass values between the 25th and the 75th percentile, 
horizontal lines represent median values, and "whiskers" give the 95% range of values. The foLlo-
wing initial prognostic factors have been depicted: BlVIJ (A) and Free IGF-1 (B). P values repre-
sent differences applying ANOVA (A• P < 0.001; B, P <0.004). 
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The present study demonstrates that BMI and I or serum leptin levels, cycle 
history (oligomenorrhea vs. amenorrhea), ovarian response to CC medication (CCF 
vs. CRA), initial serum FSH, free IGF-I and IGFBP-Jlevels were significantly cor-
related with the individual FSH response dose. In a multivariate analysis BMI, 
ovarian response to CC medication, initial serum free IGF-I and FSH level entered 
into the final model. The combination of these parameters shovved good predictive 
probability within the t!nal model with an R 2 of 0.54. BMI seems to be the most 
significant factor. The dose formula based on BMI alone is as follows• Predicted 
FSH response dose= 4.5 x BMI (kg/m2 ) + 1.5 with a R2 of0.29 compared to 0.54. 
Predictive power lost is 0.25 if a single parameter (BMI) is used (data not shown). 
Overweight amenorrheic patients require significantly higher FSH doses. BMI 
and initial serum leptin levels appear to be the most prominent predictors of the 
FSH response dose which is likely to be caused by an augmented ovarian FSH 
threshold in the patients. Differences in absorption and distribution of exogenous 
FSH in obese women may also be involved (Mannaerts el al., 1993). A direct rela-
tionship betvv·een body vveight and the amount of exogenous gonadotropins needed 
to induce ovulation in low-dose step-up cycles has previously been reported (Chong 
et al., 1986; Hamilton-Fair ley et al., 1992). Previous reports from our group on pre-
diction of ovarian response during CC induction of ovulation also stressed the 
importance of BMI and leptin (Imani et al., 1998; Imani et al., 2000). Although only 
BMI enters into the final model, leptin v·mulcl enter in case information regarding 
BMI is not available (data not shown). This may be due to significant correlations 
between serum leptin levels and BMI, free IGF-I and CRA (Imani et al., 2000). 
Leptin, the hormone product of the obesity gene (Zhang et al., 1994), inhibits 
IGF-I augmentation of FSH-stimulatecl estradiol production in vitro suggesting a 
direct action at the ovarian level (Agarwal et al., 1999). However, the present find-
ings are consistent with a limited direct role of leptin in the pathophysiology of 
PCOS. Serum leptin levels are positively correlated with fasting insulin levels in 
PCOS \vomen and are not altered compared to normo-ovulatory women (Laughlin 
et al., 1997). A positive influence of insulin on fasting leptin levels (independent of 
adiposity) bas been reported in PCOS, suggesting that the opposing effects of 
hyperinsulinemia (stimulatory) and insulin resistance (inhibitory) may negate the 
impact of insulin excess and account for the maintenance of normal leptin levels 
(Laughlin et al., 1997). In addition, weight reduction in obese women with PCOS 
may result in normalization of insulin resistance, androgen metabolism, and alle-
viation of ovarian abnormalities (Clark et al., 1995). These observations underline 
the crucial role of body weight for ovarian function. 
The present study demonstrates for the first time that the ovarian response to 
preceding CC medication predicts ovarian response during subsequent stimulation 
9! 
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by exogenous FSH. This finding confirms the concept previously proposed by our 
group indicating that CRA patients may suffer from a more serious ovarian abnor-
mality which is more resistant to stimulation by FSH (lmani et al., 1998; lmani et 
al., 2000). Patients who ovulated after CC but failed to conceive exhibit a lower 
FSH threshold and may subsequently require lower dose of exogenous FSH to 
reach sufficient ovarian stimulation. 
Both free IGF-1 and IGFBP-1 levels were previously shown to be signifi-
cantly different in PCOS patients compared with norma-ovulatory controls (van 
Dessel et al., 1999). In the current study, free IGF-I predicts the FSH threshold 
level in anovulatory \:vomen independent from other assessed factors. Free IGF-
I as \\,ell as fasting serum insulin levels are significantly higher in patients who 
have a higher FSH response dose, whereas serum IGFBP-1 is significantly 
lower. In fact, free IGF -I as well as insulin have been shovvn to directly augment 
theca cell androgen production in vitro (Legro et al., 1998) and may therefore 
play important roles in perpetuating ovarian dysfunction in PCOS. This may 
also increase FSH requirements to induce follicle development. IGFBP-1 was 
also significantly lower in patients remaining anovulatory after CC, as shown 
previously (lmani el al., 2000). Free !GF -I is not a commonly performed assay in 
daily clinical practice. Hovvever, the FSH response dose formula based on elimi-
nation of free IGF-I and substitution of insulin or insulin I glucose ratio did not 
improve R2 of the model. Predicted FSH response close= 3.5 x EM! (kg/m2) + 
35.6 x CRA + 6.7 x FSH + 2.6 x insulin I glucose ratio- 351.5 with a R2 of 0.49 
instead of R2 of the prediction model (0.54) which uses fi·ee IGF-1. R2 lost is 5 
by using a model which uses serum insulin I glucose ratio instead of free IGF -I 
(data not shown). 
In the present study, initial serum FSH levels predict the FSH response dose in 
anovulatory patients suggesting that baseline I ... ~SH levels are also associated with 
the FSH threshold in these women, despite the fact that concentrations are below 
the threshold. This is in line with previous observations in norma-ovulatory 
women where maximum early follicular phase FSH concentrations also represent 
the FSH threshold (Schipper et al., 1998). 
lnhibin B is produced by healthy antral follicles in the early follicular phase of 
normal menstrual cycle (Groome et al., 1996). Therefore inhibin B may represent 
the number of healthy follicles in polycystic ovaries and may serve as a marker for 
the severity of ovarian dysfunction in anovulatory patients. However, this con-
tention is not supported by the current observations since inhibin B does not pre-
dict the FSH threshold. 
Amenorrheic or severely oligomenorrbeic patients exhibit a higher FSH 
response dose. ,..fhis finding is in agreement with previous observations regarding 
~)'] 
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ovarian response after CC (Imani et al., 1998) suggesting that the cycle abnormality 
may reflect the severity of ovarian dysfunction in anovulatory patients. This easy 
to collect information seems to be a major prognostic factor in prediction of ovar-
ian response to FSH stimulation by either CC or exogenous FSH. 
To our knowledge this is the first time a model has been developed to predict 
the individual FSH response dose in anovulatory patients on the basis of initial 
screening characteristics. By choosing the appropriate starting dose chances of 
OHSS or multiple gestations may diminish. However, this contention should be 
confirmed in subsequent prospective trials. Obese, amenorrheic, CRA vvomen 
exhibit a higher FSH response dose. The starting dose of exogenous FSH should 
be higher in these \VOmen in order to reach sufficient ovarian stimulation. 
Monitoring of ovarian response for an extended period of time may be prevent-
ed in patients receiving FSH doses below the threshold. This approach may 
increase patient convenience and render treatment more efficient. In contrast, 
non-obese, oligomenorrheic, CCF women exhibit significantly lower FSH 
response close. The great majority of these vvomen may reach sufficient stimula-
tion by a fixed daily dose of 50-75 IU/day Adjusting the initial FSH dose, par-
ticularly in step-do\vn regimens, may render this treatment modality safer in 
women with a low FSH threshold. The step-down regimen has initially been 
developed with a fixed starting dose of !50 IU/d (van Santbrink et al., 1995). 
Although this initial dose is adequate for the majority of patients, stimulation 
should be cancelled in some cases due to hyperresponse. Currently, this repre-
sents the major drawback of the step-down approach (Fauser et al., 1997). It 
would be a distinct step forward in the further development of this decremental 
regimen in case patient characteristics could identify women in advance who 
would benefit from a lower starting dose of FSH. 
In conclusion, it is possible to predict the individual FSH response dose in 
anovulatory infertile \vomen using BMI, ovarian response during preceding CC 
medication, and serum free IGF -I and FSH concentrations. The possibility to 
predict the individual FSH threshold may increase safety, efficiency and patient 
convenience of low-dose regimens for gonadotropin induction of ovulation by 
the proper assessment of the appropriate starting close for a given patient. This 
may represent a distinct step forward. Time-consuming lo\'v dose increments 
may be overcome by starting with a high dose in \vomen vvith an augmented 
FSH threshold. In contrast, starting with an individualized dose in step-down 
regimens may reduce chances for hyperresponse in \Vomen \vith a low FSH 
threshold. These approaches should be further evaluated in prospectively 
designed comparative trials. 
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3.3 Prediction of Chances for success or Complications in 
Gonadotropin Ovulation Induction Using a Step-down 
Protocol in Anovulatory Infertility 
3.3.1 Introduction 
Exogenous gonadotropin preparations have extensively been used since their 
introduction into clinical practice in 1958. Next to ovarian hyperstimulation for 
assisted reproduction these preparations have been used fOr induction of ovulation 
in anovulatory infertile patients who failed to ovulate or conceive during preced-
ing anti-oestrogen medication (Schwartz et al., 1981; Lunenfeld et al., 1985; Insler 
et al., 1988; Kelly et al., 1990; Fauser et al., 199.3c; Franks et al., 1994; Fauser et al., 
1997). Exogenous gonadotropins elicit increased ovulation rates (up to 90%) com-
pared to clomiphene citrate (CC) \\,..ith comparable cumulative conception rates 
(65%) (van Santbrink et al., 1995; 'White et al., 1996; Imani et al., 1998; lmani et al., 
1999). Hov.rever, this treatment modality is associated v,rith higher chances for 
complications such as ovarian hyperstimulation syndrome (OHSS) and multiple 
pregnancies (Fauser et al., 1997). 
Distinct individual differences in the amount of FSH required to elicit an ovar-
ian response (referred to as the "FSH threshold") has been proposed to be the main 
factor in hyperresponse and severe complications in some patients (Bro\vn et al., 
1978). Various low-dose gonadotropin protocols have been introduced recently in 
order to reduce the chances for complications. The lovv·-dose step-up regimen aims 
at slowly and prudently surpassing the FSH threshold (vVhite et al., 1996), where-
as the low-dose step-dovvn protocol (van Santbrink et al., 1995; van Santbrink et al., 
1997a) aims to mimic the physiological conditions during the luteo-follicular tran-
sition of spontaneous ovulatory cycles (van Santbrink el al., 1995). 
VVe previously designed a prospective longitudinal follO\-v-up study attempting 
to develop model predicting individual outcome of ovulation induction using pre-
treatment clinical, endocrine and sonographic screening characteristics in normog-
onadotrophic anovulatory \Vomen. Analyses was performed separately for CC 
(lmani et al., 1998; Imani et al., 1999; Imani et al., 2000) and FSH (lmani et al., 
200!a). An equation has been introduced to predict the individual FSH response 
dose for gonadotropin induction of ovulation (Imani et al., 200la). Body \veight, 
ovarian response to CC, and cycle history (amenorrhea) \vere the major factors pre-
dicting augmented FSH threshold. It \Vould be of distinct clinical significance in 
case initial screening characteristics could also predict clinical outcome of 
gonadotropin ovulation induction (i.e. chances for success or complications). Some 
previous studies suggested that the occurrence of polycystic ovaries (\Vhite et al., 
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1996), overweight (Hamilton-Fairley et al., 1992) and duration of stimulation I 
total amount of exogenous FSH (van Santbrink et al., 1997a) may be important fac-
tors during ovarian stimulation applying exogenous FSH (Fauser et al., 1997). The 
present prospective fOllow-up study \vas designed to investigate whether pre-
treatment clinical, endocrine, and sonographic screening characteristics of nor-
mogonadotrophic anovulatory women, predict individual chances for complica-
tions (i.e. multi-follicular growth) or success (conception) prior to initiation of this 
treatment strategy. 
3.3.2 Materials and Methods 
Subjects 
One hundred and fifty two vvomen attending our infertility unit March 1993 and 
December 1999 \vere included in the present study using the following criteria: 
a) oligomenorrhea (bleeding intervals betvveen 35 days and 6 months) or amen-
orrhea (bleeding interval> 6 months), b) serum FSH levels within normal limits 
(1-10 IU/L) (van Santbrink et al., 1995; Schipper el al., 1998) and normal serum 
prolactin and thyroid-stimulating hormone levels, c) spontaneous menses or pos-
itive bleeding response to progestagen withdra\val, cl) being previously treated 
unsuccessfully in our fertility unit with CC medication (failure to ovulated, or fail-
ure to conceive in ovulatory CC-cycles) (Imani et al., 1998; Imani et al., 1999; 
Imani et al., 2000), e) body mass index (BMI) (weight divided by square height)> 
18 kg/m2, f) between 19-40 years of age, g) a total motile sperm count (TMC = 
ejaculate volume (ml) x sperm concentration (1o6hnl x percentage of progressive 
motile sperm) of the partner above 1 million, i) negative history for any tubal 
pathology plus negative chlamydia antibody titer, or negative hysterosalpingog-
raphy or laparoscopic inspection, and ultimately j) no indication for intra-uterine 
insemination. Study approval was obtained from the human subjects committee of 
the Erasmus Medical Center and informed consent vv·as obtained from all sub-
jects. 
Standardised initial clinical, sonographic, and endocrine screening took place 
prior to initiation of exogenous gonadotropins using a low-dose step-up regimen, 
as described previously (Imani et al., 2000). Clinical screening included age, infer-
tility duration and history (primary vs. secondary), cycle history, ovarian response 
to previous CC medication, BMI, waist-to-hip ratio (\VHR), any other previous 
medication and/ or surgery. TransYaginal sonographic (TVS) screening included 
assessment of the ovarian stroma echogenicity (arbitrarily classified from 1 to 3 
per ovary), ovarian volume (ml) and total number of follicles (both ovaries), as 
described previously (Pache et al., 1991; Pache et al., 1992; van Santbrink et al., 199/b ). 
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Sonographic monitoring was performed by a single observer (B.l.), using an 
ultrasound machine (model EUB-415, Hitachi Medical Corp., Tokyo, Japan) with 
a 6.5-MHZ transvaginal transducer. 
Hormone assa)'S 
Endocrine screening included serum assays for FSH, prolactin, thyroid-stimulat-
ing hormone, luteinising hormone (LH), oestradiol (E2), androstenedione (AD), 
testosterone (T), and sex-hormone binding globulin (SHBG), as described previ-
ously (Imani et al., 1998; lmani et al., 1999). In addition, serum was also assayed for 
fasting insulin and glucose, free and total!GF-1, IGFBP-1, IGFBP-3 and leptin 
concentrations as described previously (lmani et al., 2000). The method of blood 
vvithdrawal, the assays used and the intra- and inter assay coefficients of variation 
valid for this study have all been previously described (lmani et al., 1998; lmani et 
al., 1999; lmani et al., 2000 ). 
Study protocol 
The treatment protocol and assessment of ovarian response were as follO\vs. 
Exogenous FSH was initiated on day 3-5 after a spontaneous or progestagen-
incluced withdrawal bleeding. A low dose step-up regimen for induction of ovula-
tion using either daily intra-muscular (IM) injections of urinary FSH (Metrodin 
HP®, Serono, Serono, Switzerland) or sub-cutaneous (SC) injections of recombi-
nant FSH (Gonal-F®, Serono) was used for the stimulation of follicle growth and 
assessment of the individual FSH response dose (lmani et al., 2001a). Monitoring of 
dominant follicle development (i.e sonographic visualisation of a follicle 2 10 mm 
(Pache et al., 1990; van Santbrink et al., 1995) was performed every 2 or S days until 
human chorionic gonadotropin (hCG) (Pregnyl®, Organon, Oss, The Netherlands) 
was administered. A single l.M. dose of 5,000 IU hCG was administered on the day 
upon which one or two follicles ~ 18 mm could be visualised. In case three or more 
follicles 2 16 mm were present, stimulation was cancelled. Ovulation after hCG 
administration was determined by the sonographic signs of the collapse of the dom-
inant follicle and mid-luteal progesterone (P) levels above 25 mnol/1. 
Low-dose, step-up protocol 
The starting dose of FSH was one ampoule (7 5 IU) per day. The first increase in 
FSH close by half an ampoule (37,5 IU) per day was based on the absence of sana-
graphic visualisation of a follicle 2 10 mm after 7 clays. The FSH dose was 
increased subsequently by half an ampoule (37,5 !U) per day for the following 7 
days in case an ovarian response was still lacking. In case of suff1cient ovarian 
response, exogenous FSH dose was unaltered until administration of hCG. No 
96 
Prediction [!/'Ovulation Induction Outcome in Nonnogonadotropic Anovulatm:y Iryfertilit; 
luteal support was provided. The effective FSH response dose in some patients \vas 
7 5 IU I day. This dose of FSH was sustained until the day hCG could be adminis-
tered. 
Step-down protocol 
The starting dose of FSH was chosen on the basis of one of the two following cri-
teriao I) Three categories of body mass index ( 18-22, 23-28, >29) have been used 
based on initial experience of our group before 1996. We started directly with step-
down protocol using either 11/ 2, 2, or 21/ 2 ampoules per day (n=58 patients). The 
first decrease in dose by half an ampoule (37,5 IU) per day was based on visualisa-
tion of a follicle growth 2: 10 mm in diameter as described previously (van Santbrink 
et al., !997a). A further dose decrease (each time by 37,5 IU/day) was performed 
every 3 days in case follicular growth continued to a minimum dose of one ampoule 
(7 5 IU) per day until the day hCG could be administered. The initial dose was 
increased by half an ampoule ( 37,5 !U) per day in case ovarian response remained 
absent after 5 days. If follicular growth remained absent over the following 10 days 
(2 incremental steps of 37,5 IU/day), further medication was withheld and the cycle 
was cancelled. No luteal support was provided. 2) From 1996 an initial low-dose 
step-up cycle have been applied in our clinic to evaluate individual FSH response 
dose (n=94 patients). Arbitrarily we used a dose of half an ampoule (37,5 IU) per 
day of FSH above the response dose to start the subsequent step-down cycle. 
Fzxed dose 1 ampoule I day protocol 
The effective FSH response dose in this group of patients during the !ow-dose 
step-up induction cycle was 1 ampoule/ day. Thus, the starting dose of FSH was 1 
ampoules (7 5 IU) and kept constant till the day of sonographic visualisation of a 
follicle;:: 10 mm. This dose was sustained until the day hCG could be administered. 
The initial dose \vas increased by a 1/ 2 ampoule/ day if an ovarian response 
remained absent after 5 days. If follicular growth remained absent over the fol-
lowing 10 days (2 incremental steps of a 1/ 2 ampoule/day), further medication was 
withheld and the cycle was cancelled. No luteal support was provided. 
Data analysis 
We used univariate and multivariate logistic regression analyses for comparison of 
patients who developed multiple large dominant follicles (more than I follicle> 15 
mm) (van Santbrink et al., 1997a). The multivariate odds ratio is provided for the 
factors significant in the multivariate analyses. For instance multivariate odds ratio 
(95% CI) of serum AD= 1.05 (1.02-1.08) (TableS). This means a !-unit increase 
in a given patient's serum AD level gives her a 5% higher probability of develop-
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ing multifollicular growth after exogenous gonadotropin induction of ovulation. 
Univariate and multivariate Cox regression vvas used for life table analysis of 
conception rates during exogenous gonadotropin induction of ovulation. The 
number of gonadotropin induced cycles was the time variable for multivariate 
analyses. Censoring was defined as defmitive discontinuation of gonadotropin 
therapy without conception or end of follow-up. The Log Rank test has been used 
to denote statistical significance in life table analyses. A P-value of 0.05 was cho-
sen as threshold level fOr statistical significance. The multivariate analysis \vas 
performed vvith the method of fonvard stepv,rise selection to gain a better insight 
in the interdependence between initial screening parameters. The prognostic 
impact of variables vvas expressed as a fecundability ratio, \:vhich is equivalent to 
the hazard ratio in survival analysis. Data were analysed using the commercially 
available software package SPSS (Chicago, IL, USA). 
3.3.3 Results 
A total number of one hundred and fifty two patients fi.Ilfilled the in/exclusion cri-
teria and were treated with exogenous gonadotropin induction of ovulation. Initial 
clinical, endocrine, and sonographic screening characteristics of the overall group 
of anovulatory infertile patients, the group with mono or multi-fOllicular develop-
ment, and those \Vho did or did not conceive are depicted in Tables 1 and 2. 'I'he 
results of univariate analyses for comparison bet\veen these groups of patients 
(\:vomen vvho did or did not reach a monofollicular development and those \Vho did 
or did not conceive) have been also depicted in Table 1 and Table 2. In 198 (45%) 
cycles multi-follicular growth occurred and in 50 (II%) cycles no human chorion-
ic gonadotropin (hCG) was given and the stimulated cycle was cancelled due to 
multi-follicular growth and potential risks for multiple pregnancy or ovarian 
hyperstimulation syndrome (OHSS). Ovarian response to the preceding CC treat-
ment, initial serum LH, FSH, T, and mean number of follicles \vere significantly 
different for patients \vho developed mono vs. multi-follicles during ovarian stim-
ulation applying step-down dose regimen. The results of the fonvard step-wise 
multivariate logistic regression analyses of the patients who did or did not devel-
op a single dominant follicle are depicted in Table S. 
SeYenty-nine \vomen (52%) conceived. Ten miscarried (13%) and the remaining 
ongoing pregnancies ended in 67 singleton, one tv,rin, and one triplet pregnancy. 
The life table analysis ofCCR of the overall group of patients is depicted in Figure 
I. A cumulative conception rate (CCR) of 60% was reached within 6 induced cycles 
(Figure 1). In univariate Cox regression analyses, patients age, initial serum free 
IGF-I and IGF-I were significantly different between patients who did or did not 
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conceive following gonadotropin induction of ovulation (Table 2). Multivariate 
Cox regression analyses of screening parameters for prediction of conception fol-
lowing gonadotropin induction of ovulation has been depicted in Table 4•. 
Woman's age, initial serum IGF-1 and T entered the final model (AUC = 0.69). 
Age (cut-off of so yr), ovarian response during preceding CC medication (CC-
responders vs. non-responders), and initial serum LH level (cut-off level of 0. 7 
IU/L) in univariate analyses for CCR are depicted in Figure 1. 
The impact of predicted FSH response dose on treatment outcome (the num-
ber of dominant follicle maturation and conception) has been depicted in Figure 2. 
The impact of initial screening characteristics as a prognostic factor in 152 nor-
mogonadotropic anovulatory infertile patients on prediction of a single dominant 
fOllicle maturation has been depicted in Figure 3. 
" 2 1oo 1 
~ ao J 
' ;;. ~ 60 : 
u 40. 
l 
~ 20: 
' ' u 0 Go cycl.s o 
Number •• R;,, 152 1 ffl 77 55 J9 31 17 :2 
Numberofevoo\s 21 23 15 10 J 
2 100 
• 
"' 80 
CCF 
c (n = 79) ~ 
.2 p"' 0.8 1< 60 
• ~ 
0 40 CRA 0 
~ 20 {n = 68) 
'3 
E 
0 
0 
Gl cycles 
il100 
~ 
& 80 
§ 
li 60 
Age< 30 yrs 
(n = 94) 
~ 40 / P<0.001 / /-Age>= 30 Yl<> 
(n =58) ~ 20 / 
ro / 
s o~'<'-'--~-------~ 0 
"' 'Q;" 100 
;:; 
80 
c 
.g_ 60 
~ 8 40 
l 20 
p::: 0.9 
4 
Gl cycles 
NormallH (< 7.0) 
(n = 78 
High LH (>""7.0) 
(n = 74) 
~ "'--------~ 
6 4 
Gl cycles 
Figure 1 Lif'e table analysis of cumulative conception rates (CCR) in 152 normogonadotropic oli-
goamenorrheic infertile patients who fO.iled to ovulate or conceive following preceding CC medica-
tion and were treated with ovulation induction by exogenous l,'"'SH applying a step-down dose regi-
rnen. CCR's (induding absolute number of patients at risk and nurnber 9[ events, conceptions) are 
presented fOr the total study group (11pper left paneQ (vertical lines represents 95% Confi"dence 
Interval;,). Univariate analysis 9[ cumulative conception rates in the same patients. Initial screening 
parameters which have been depicted are as fOllows: 1) Patient's age (cut-riff level at 30 _years) (upper 
right panel). 2) Ovarian response to preceding CC medication (CRA vs. CCF) (lower lift paneQ. 3) 
Initial serum LH concentrations (cut-riff level 9[7.0 IU IL) (lower rz~r;;lzt paneQ. n represents the ini-
tial number 9[ patients at risk. P =Log Rank test P value. 
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Figure 2 Predicted FSH response dose as a prognostic factor in 152 normogonadotropic anovula-
tOF)' irifertile patients who failed to conceive fOllowing preceding CC medication and were treated 
with ovulation induction b)' ex·ogenous FSH appl)•ing a step-down dose regimen. Data are presen-
ted as box and whisker plots: Boxes encompass values between the 25th and the 75th percentile, ho-ri-
zontal lines represent median values, and "whiskers" gi·ve the 95% range cif values. Two treatment 
outcome have been depicted: Dominant fOllicle development in three categories (A) and conception 
(B). P > o.os applying ANOTl/1. 
3.3.4 Discussion 
The present study was designed to evaluate vvhether initial clinical, endocrine and 
sonographic characteristics of 152 clomiphene resistant or failure anovulatory 
infertile women may predict the chance of treatment outcome during 
gonadotropin induction of ovulation applying a step-dovvn dose regimen. Although 
gonadotropin ovulation induction have been the focus of vast number of investigators 
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during the last four decades, a prospective follow-up study to predict the chance of 
ongoing pregnancies during this treatment strategy is lacking. Our group, hmvever, 
focused on a prospective follow-up study in entire VVHO 2 anovulatory infertile 
women since 1993. Several prediction models have been developed. These models 
may be used to predict CC ovulation induction outcome (ovulation, ongoing preg-
nane)~ or live birth) as ·well as the amount of the exogenous gonadotropin required to 
reach an ovarian response in vvomen \vho failed to ovulate or conceive following CC 
(lmani et al., 1998; Imani et al., 1999; Imani et al., 2000; Imani et al., 200la; lmani et al., 
20mb). In brief, obese amenorrheic hyperandrogenic women are more likely to 
remain anovulatory following CC. Hmvever, fi'om those women vvho reach a sufficient 
ovarian response, young amenorrheic \Vomen are more likely to conceive leading to a 
live birth after CC (lmani et al., 1998; lmani et al., 200lb). It has been recently report-
eel that the amount of exogenous FSH necessary for a sufficient ovarian response dur-
ing exogenous gonadotropins can be predicted in ·women v,rho failed to ovulate or con-
ceive follovving CC applying four initial screening parameters of the following equa-
tion: The individual FSH response dose (IU/d) = (4· A+ 32 B + 7 C + 6 D)- 51 in 
which A = body mass index (BMI; kg /m2), B = clomiphene resistant anovulation 
CRA (yes = 1 or no = o), C = initial free insulin-like growth factor-! (fi·ee IGF-l; 
ng/mL), and D =initial serum FSH (IU/L) (Imani et al., 2001a). 
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Figure 3 The impact if bod)' mass index, predicted FSH response dose, serum androstenedione, and 
mean follicle number on follicle development following gonadotropin ovulation induction appl)'ing 
step-down regimen in 152 normogonadotropic oligoarnenorrheic iJifertile patients who failed to 
ovulate or conceive following preceding CC. 
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TABLE I. Initial clinical, endocrine, and ultrasound screening characteristics (n1ean ± SD) of 152 normogonadotropic anovu-
latory infertile women, separately for cycles with mono (n = 244·) or multi-follicular (n = 198) growth after FSH induction of 
ovulation using a step-down dose regimen. 
Screening parameters 
Clinical 
Age (yrs) 
Amenorrhea (n) 
BMI (kg/m2) 
V/aist-to-hip ratio (WHR) 
CC resistant anovulation (n) 
Predicted FSH response dose (IU) 
Endocrine 
LH (IU/L) 
FSH (IU/L) 
E:2 (pmol/L) 
AD (nmol!L) 
T (nmoi/L) 
SHBG (nmoi/L) 
FA! (T x 100 I SHBG) 
Insulin (mU/L) 
Overall gToup 
(n patient= 152) 
29 ± '1· 
52 
26.9 ± 6.0 
0.8 ± 0.1 
es(wo%) 
120 ± 33 
fLO ± 4.il 
'k9 ± 1.5 
2·t·3 ± 124• 
15.6 ± 7.S 
2.6±1.1 
48.8 ± 27.~3 
7.4 ± G.1 
l'l·.'i• ± 10.2 
Mono-
fOllicular 
grm·vth 
(n cycle = 244) a 
29 ± 4 
6H (24%)~' 
2G.B ± .'i.7 
0.8±0.1 
10 2 ( 4<3 (x) r~ 
120 ± :33 
7.9 ± 1·.G 
5.1 ± U:i 
254±151 
15.2 ± 6 .. '3 
2.6 ± 1.0 
51.1 ±'26.8 
7.0 ± 5.5 
1'1·.1 ± 10.2 
Multi-
follicular 
gTowth 
(n cycle = 198) a 
29 ± 4 
G2 (~32%)* 
2G.··t· ± 5.7 
0.8±0.1 
106 (.1,'3%)* 
120 ± ~3~3 
8.8 ± '}.2 
4·.8 ± 1.:3 
267 ± 1:3,1 
18.1 ± 9.1 
2.9 ± 1.2 
60.6 ± 2·J..S 
i.ti ± 5.6 
15.0± 11.1 
p b AUC b 
NS 
NS 
NS 
NS 
0.02 O.fJG 
NS 
0.03 0.58 
0.04 0 .. 15 
NS 
< 0.001 0 .. 59 
< 0.001 0.00 
NS 
NS 
NS 
l 
s. g 
""' ~~· 
c ;;; 
C/,3 
~ 
s-
.g 
;:::· 
a 
e 
c 
" ~· 
;::;· 
~ 
" § a 
c 
" 0 ~ 
0 
~ 
Insulin/glucose t·atio 3.4 ± 2.3 3.'1· ± 2.3 3.7 ± 2.'\• 
Inhibin B (ng/L) 159 ± 117 164 ± 123 1B2 ± 127 
IGF-l (ng/mL) 2.'3 1 ± S2 220 ± 84· 214 ± 78 
Free JGF-I (ng/mL) 2.7 ± 1.7 2 .. '5 ± 1.6 2.7 ± 1.5 
!GFBP-1 (ng/mL) QrJ..(J ± 18.1 -:n.o ± 1.s 2SA ± 17 
!GFBP-J (ng/mL) 3,'1-06 ± 7'-~9 3,359 ± 77S 3,295 ± !59.'3 
Lcptin (ng/mL) 20.5 ± 10 20.8 ± 16 20.6 ± 15 
Ultrasound 
Totnl stroma scorec .'3.8 ± 1.2 .S.H ± 1.2 :-3.7 ± 1.2 
Mean ovarian volume (mL) 10.8 ± 4.6 10.8 ± 4.6 10.2±4.6 
Mean follicle number 14· ± 6 1'1· ± G H·± G 
a Cycles with poor response (n=2D cycles; absent follicle growth beyond H< rwn) were excluded. 
b P vcllue of univariate logistic regres.siot1 analyses, and area under the ROC curve. 
c Arbitrarily defined as one to three per ovary (both ovaries added). 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.07 0.56 
d Polycystic ovaries defined as mean ovarian volume :;::: 1 O.R mL and/ or 111ean fOllicle number per ovary :;::: 10 (van Stanbrinh ct al, Perfil Steril 19U7) 
;t· Prevalence (%) of characteristics with the specific group of vmmen. 
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TABLE 2. Initial clinical, endocrine, and ultrasound screening characteristics (mean ± SD) and sperm parameters (median 
and range) of 152 clomiphene resistant or failure anovulatory infertile ·women, separated for patients v,rho did or did not con-
ceive after exogenous gonadotropin induction of ovulation using a step down regimen. 
Conceived Did not pa AUC a 
COllCClVC 
(n ::::: 79; 52rX1) (n::::: 73; 4,8%) 
Screening parameters 
Clinical 
Age (yrs) b * 29 ± /1· 28 ± /1· 0.02 0.61 
Infertility duration (yrs) 2.7 ± 1.7 3.2 ± 2.2 NS 
Primary infertility (n) 57 (5.'3%) 50 ( 4·7%) NS 
Amenorrhea (ll) 28(-'+%) 24(4G%) NS 
BMI (kg/m2) 2G.'I· ± 0.2 27.5 ± 5.8 NS 
\Vaist-to-hip ratio (VVHR) 0.8 ± 0.1 0.8 ± 0.1 NS 
CRA (n) .'35 (51%) 33 ( 49%) NS 
Predicted FSH t·csponse dose (IU) 11.9 ± .'3.'3 121 ± .'3.'3 NS 
Endocrine 
LH (IU/L) 8.'[• ± 5.0 7.7 ± '1-.2 NS 
FSH (lUlL) 1·.9 ± 1.5 5.0 ± 1.5 NS 
E2 (ptnoi/L) 232 ± 125 256 ± 122 NS 
AD (nmol/L) 1.'5.7 ± S.S L5.4 ± 7.0 NS 
T (nmol/L) 2.5 ± l. 1 2.G±l.l O.a!=.l 0.58 
SHBG (nmol/L) 4G.9 ± 26.9 ,00.[) ± 27.8 NS 
FA! (T x 100 I SHBG) 7.'1- ± 5.9 7.5 ± 6.3 NS 
"' 
' ~ 
" 
"" ~ ,, 
g 
~ 
'~ ~ 
it 
1 
0 
~ 
" i! 
0 
t 
" 0 
0 
8 
" 
' 
0 
e;., 
Insulin (mU/L) 1D.1±11.4 
Insulin/glucose t·atio .'l.S ± 2 .. '5 
fnhibin B (ng/L) lUG± 101 
IGF-l (ng/mL) 251 ± 81 
Free fGF-I (ng/mL) S.O ± 1.7 
IGFBP-1 (ng/mL) 24.!) ± 18.6 
IGFIH'-3 (ng/mL) .'l477 ± G4!) 
Leptin (ng/tnL) 20.1 ± 1D 
Ultrasound 
Total stroma scorec 3.7± 1.1 
Mean ovarian volume (mL) 10 .. '5 ± 4.1 
Mean follicle number H± G 
Total motile sperm count (TMC) 67 (1-GG1) 
%Normal morphology 25 (8-90) 
13.8 ± 8.9 
3.2 ± 2.1 
163 ± 1.33 
209 ± IH 
2.4 ± 1.7 
2'1<.5 ± 17.7 
3327 ± 8'1•8 
20.9 ± 17 
;}.9 ± 1 .. '3 
Il.2 ± 5.1 
H± 7 
39 (1-428) 
23 (1-48) 
NS 
NS 
NS 
0.000 
0.0'1· 
NS 
().08 
NS 
NS 
NS 
NS 
NS 
NS 
0. ()1 
O.OG1 
0.56 
a P vnlue of univariate logistic regression analyses cmd area under the ROC curve of initial pat·amctcrs fOr comparison of cycles with mono or 
multifollicualr gTowth fOllowing exogenous gonadotropin induction of ovulation using a step down regimen 
b *corresponds to P value of univariate Cox regression analyses tOr comparison of patients who did or did not conceive f{)Jlowing exogenous 
gonadotropin induction of ovulation(*= P < 0.05, ** = P < 0.01). 
c Arbitrat·ily defined as one to three per ovary (both ovaries added). 
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Prediction qfe.rogenous gonadotropin ovulation induction outcome 
In the present study, the predicted FSH response did not predict treatment outcome 
during gonadotropin induction of ovulation applying step-down dose regimen i.e 
multi-follicular development, cycle cancellation or ongoing pregnancy (Table I and 
Figure 2). The major factor involved in prediction of exogenous FSH requirement 
for ovarian response - obesity - is not a predictor for multi-follicular growth. 
Factors associated with obesity such as BMI, \VHR or serum leptin level do not 
predict treatment outcome following exogenous FSH induction of ovulation apply-
ing step-dov,rn regimen. Previous reports from our group indicated that obesity and 
cycle history (amenorrhea vs. oligomenorrhea) are strong predictors of patients 
remaining anovulatory following CC (lmani et al., 1998). These factors also predict 
patient's exogenous FSH requirement for initiation of an ongoing follicle grmvth in 
FSH-induced cycles applying a low-dose step-up regimen (lmani et al., 200la). 
Cycle history (amenorrhea vs. oligomenorrhea) had no impact on exogenous FSH 
treatment outcome in the present study. The remaining factors of the model for pre-
diction of FSH response dose, such as CIL>\ or serum free IGF-1 level, predict 
exogenous gonadotropin induction of ovulation outcome. CRA. v.rith a lovv initial 
serum FSH level exhibit more chance to develop a multi-follicular growth com-
pared to CCF patients with a normal FSH serum concentration. Serum fi·ee IGF-1 
-which entered in multivariate model for prediction of FSH response dose -pre-
dicts patients \\'ho have higher chance to conceive during gonadotropin ovulation 
induction in univariate analyses. These findings may indicate that impact of an aug-
mented FSH threshold does not necessarily indicate higher chance of multi-follicu-
lar growth or conception of the cycle during step-down cycles. This may be due to 
serum endogenous FSH accumulation pattern differences between low-dose step-
up vs. step-down regimen (van Santbrink et al., 1997a). 
Initial serum AD and mean follicle number entered into the model predicting 
the chance of multiple follicle development during gonadotropin induction of 
ovulation. Hyperandrogenic patients vvho present with an increased number of 
unstimulated follicles during pelvic ultrasound screening are more likely to devel-
op multiple follicle growth and consequently cancellation of the cycle. In univari-
ate analyses, initial serum LH level which predict CC medication outcome, is a 
predictor for multiple follicle development during exogenous gonadotropin 
induced cycles applying step-down close regimen. CRA patients, however, exhib-
it a high chance of multi-follicular development compared to CCF during exoge-
nous FSH induction of ovulation. Patients with low initial serum FSH level tend 
to develop multiple follicle growth. \Ve used our strict criteria for defmition of 
PCO and/or hyperandrogenemia in our study. Both these factors predict multiple 
follicle growth during exogenous gonadotropin ovulation induction applying 
step-down protocoL 
]()(j 
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Initial serum LH, LH/FSH ratio, AD, and T levels are significantly higher and, 
in contrast, serum FSH level is lmx.,er in patients who exhibit higher chance of 
multiple follicle development during gonadotropin ovulation induction applying 
step-down regimen. Patients vvho remain anovulatory follo\ving CC, women \vho 
present with increased number of follicles during assessment of initial pelvic ultra-
sound screening prior to ovarian stimulation, and patients defined as exhibiting 
PCO are at high risk to develop multiple follicle development during exogenous 
FSH induction of ovulation. When a multivariate analysis for prediction of multi-
ple follicle development chances is applied, initial serum AD and mean follicle 
number are entered into the model (see TableS). The impact of initial serum AD 
level is the highest and the area under the receiver operating characteristics of the 
present model is 0.60. Serum SHBG or FA! level does not predict patients who are 
at high risk for multiple follicle development during ovarian stimulation applying 
exogenous gonadotropin. However, predictive power of serum FAT is the highest 
in our report on prediction of CRA patients \vho suffer from severe ovarian dys-
function (Imani et al., 1998; Imani et al., 2000). The impact ofFAl is clue to signif-
icance of both serum SHBG and T in prediction of patients remaining anovulato-
ry following CC. Predictors of ovarian response between these two ovulation 
induction strategies differs presumably due to differences between mechanism and 
mode of action of CC compared to exogenous FSH. 
Initial serum insulin, insulin/glucose ratio, or inhibin B level had no predictive 
value for prediction of chances for multiple follicle development during exogenous 
gonadotropin induction of ovulation. V-/e have not been able to confirm that ele-
vated level of these endocrine parameters may represent the magnitude of ovarian 
hypersensitivity for multiple follicle development during exogenous administra-
tion gonadotropin for ovulation induction applying a decremental dose regimen. 
In the present study, cumulative conception rate (CCR) of %65 have been 
reached \vi thin eight consecutive gonadotropin ovulation induction cycles. This is 
in agreement \Vith our previous report on CCR in CC-induced ovulatory cycles 
(Imani et al., 1999) and is similar to reports on spontaneous conception chances in 
normoovulatory women (Tietze et al., 1968). This is also comparable to conception 
rates reported in the literature regarding exogenous gonadotropin induction of 
ovulation applying a low-dose step-up regimen (Hamilton-Fairley et al., 1991; van 
Santbrink et al., 1995) or a step-down protocol (van Santbrink et al., 1995). 
Applying an initial close-finding low-dose step-up cycle prior to step-down cycles, 
the starting dose for the first step-down cycle has been individualised and adjust-
ed which has led to overall singleton pregnancies in \vomen whom this approach 
has been applied. Moreover, strict cancellation criteria were used in patients with 
multiple follicle development or an imminent chance for multiple pregnancy. 
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Applying the present modified step-down close regimen one may expect overall 
singleton pregnancy chances with no decrease in CCR. 
In the present study initial serum IGF-1, age, and serum free IGF-1 were sig-
nificantly different comparing patients \:vho conceived vs. those v,rho did not con-
ceive during exogenous gonadotropin induction of ovulation applying decremen-
tal dose regimen. Multivariate analyses revealed a final model including initial 
serum IGF-I, age, and serum T. The area under the receiver operating character-
istics curve of the present model reached 0.69 (data not shown), which is compa-
rable \Vith that in the previous model predicting conception in CC-induced ovula-
tory cycles (0.68) (Imani et al., !998). The predictive power of initial serum IGF-I 
\vas the highest. Age entered in the second step. However, the predictive pov,rer of 
age in the present model is comparable with the impact of age in the model report-
ed by our group for prediction of ongoing pregnancy following ovulatory CC-
induced cycles. One year increase in patient's age reduces her chance for ongoing 
pregnancy of approximately 9 percent (footnote Table 4 ). To our knowledge, this 
is the first time a model is introduced for prediction of chances for ongoing preg-
nancy during gonadotropin induction of ovulation. The impact of age as the major 
factor for prediction of chances for conception follov,,..ing spontaneous, FSH-
incluced or CC-incluced cycles has previously been reported. It should be taken into 
account that a significant number of young amenorrheic patients have reached live 
birth during the preceding CC-inducecl ovulatory cycles (Imani et al., 2001 b). This 
may indicate that predictive power of age would have been higher in case step-
dmvn regimen was applied as the first line treatment modality instead of CC. The 
predictive power of serum free IGF -I for prediction of ongoing pregnancy vvas sig-
nificantly reduced when serum IGF-I entered into the model in the first step due 
to significant correlation betv.reen these tvvo parameters. 
The present study demonstrates for the first time that patients \vho remain 
anovulatory following CC have comparable chance for conception during 
gonadotropin induction of ovulation compared to \\'Omen vv·ho failed to conceive 
despite the preceding 6 to 8 consecutive CC-induced ovulatory cycles. CRA exhib-
it no chance of conception clue to persistent anovulation whereas CCF ovulate but 
do not conceive presumably due to impaired endometrial receptivity following 
consecutive ovulatory CC-incluced cycles. During gonadotropin induction of ovu-
lation, however, CCF benefit from comparable chance for ongoing pregnancy com-
pared to CRA. Endometrial receptivity of women who respond to CC might be 
impaired due to its effect after long term exposure. However, this reduced fecund-
ability rate may be enhanced once exogenous FSH preparations are applied. 
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TABLE 3. Forward stepwise multivariate analyses of initial screening characteristics fOr the prediction of developing multi-
follicular growth after FSH induction of ovulation using a step down regimen in 152 nonnogonadotropic anovulatory infer-
tile patients (425 cycles). 
Analyses steps 
Screening parameters 
Clinical 
CHA 
Endocrine 
LH (lUlL) 
FSH (lUlL) 
AD (nmol/L) 
T (nmoi/L) 
Ultrasound 
Mean follicle number 
a Univariate logistic regression < 0.10 
h Final model, Area under the ROC curve = 0.6 
r Multivariate odds ratio (!-J5(% CI) = 1.05 ( 1.02-l.OH). 
dMultivariate odds ratio (9.S% CI) = 1.0:3 (1.00-1.07). 
Univariate a 
() 
0.02 
0.03 
0.04 
< 0.001 
< 0.001 
0.07 
Multivariate 
2 b 
0.12 0.22 
0.24 0.4{) 
0.22 O.J2 
In model In model c 
0.26 0.67 
0.05 rn model d 
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TABLE 4. Forvi1ard stepwise multivariate analyses of screening parameters for prediction of conception follovving exogenous 
gonadotropin induction of ovulation using a step down regimen in 152 clomiphene resistant or failure anovulatory infertile 
patients. 
Analyses steps 
Screei1i11g parameters 
Clinical 
Age (yrs) 
Infertility duration (yrs) 
Primary infertility (n) 
CRA 
Endocrine 
Lll (IU/L) 
T (nmoi/L) 
!(W-1 (ng/mL) 
Free IGF-1 (ng/mL) 
a Univariate Cox regression < 0.10 
Univariate a 
0 
0.02 0.02 
0.8 0.8 
0.9 0.9 
0.6 0.8 
0.8 0.7 
0.09 0.08 
0.006 In model 
0.04 0.13 
Multivariate 
2 3 b 
In model In model 
0.7 0.8 
0.8 0.7 
0.2 0.8 
0.9 0.2 
0.03 In model 
In model In model 
0.3 0.2 
b Final model, multivariate fecunclability ratio (95% Cl) of IGF-l = l.OCH (1.00 1-1.006), of age= 0.91 (0.85-0.97), and ofT= 
0.74 (0.57-0.87). This mean that a 1 year increase in a given patient's age reduces her monthly probability of conception fOl-
lowing exogenous gonadotropin induction of ovulation by 9%. 
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Prediction qf Ot-'lllation Induction Outcome in Nornwgonadotropic Anovu!atmy Infertility 
Unidentified factors may play a role in determining endometrial receptivity dur-
ing the windo\v of implantation in normal condition or in CCF patients \vith 
impaired endometrial receptivity after long term exposure to CC. In the present 
study, CRA patients are more likely to develop multiple follicle growth thus 
more chance for cancellation of the exogenous FSH-induced cycle. Moreover, 
some reports indicate impaired chance of conception in these ,,,omen due to 
detrimental effect of hyperandrogenemia on oocyte quality. To our surprise, 
CRA patients exhibit comparable chance of conception during exogenous 
gonadotropins compared to CCF who are more lil~:ely to be normoandrogenic. 
\\le did not observe any detrimental effect of augmented serum LH level for 
the chances of ongoing pregnancy. Initial serum LH level predicts chances for 
multiple follicle development but not ongoing pregnancy in the present study. 
\Ve were unable to observe any significant increase in the chance of spontaneous 
miscarriages in patients with an elevated initial serum LH level. Reports in the 
literature are contradictory. Our finding is in contrast vvith previous reports 
indicating a higher percentage of miscarriages in these patients. Hov;,rever, on the 
basis of these observations one may not have hard conclusion due to the limited 
number of miscarriages in the present study. Initial serum insulin, insulin/ glu-
cose ratio, or inhibin B had no predictive value fOr prediction of chances for 
ongoing pregnancy during exogenous gonadotropin induction of ovulation. 
Moreover, TMC does not predict chances of conception during exogenous FSH 
induced cycles. This is agreement \Vith our report on predictors of CC ovulation 
induction outcome (lmani et al., 1999). 
In conclusion, the present longitudinal follov,r-up study suggests that 
clomiphene resistant anovulatory women who exhibit an elevated serum AD 
level in combination with an augmented number of fOllicles prior to ovarian 
stimulation are at high risk for multiple follicle development during 
gonadotropin ovulation induction applying a step-dmvn regimen. They exhibit a 
higher chance for cancellation of the FSH-induced cycle. Applying a low-dose 
step-up cycle prior to step-dov,rn cycle, the starting FSH dose for step-clovn1 
cycle vvas adjusted. Moreover, applying strict cancellation criteria the complica-
tion rates \-vere minimised. However, CCR of 65% v.ras reached \-vithin 8 stimu-
lated cycles, which is comparable to CCR reported in the literature. \Ve report 
merely singleton pregnancies. Moreover, young CRA or CCF ,,ramen vvho exhib-
it an elevated serum IGF-I level and normal T level are at high risk to reach an 
ongoing pregnancy. CRA patients are at high risk for cancellation of the cycle 
due to multiple follicle growth. CRA patients are more likely to exhibit multi-
follicular development during ovarian stimulation applying exogenous FSH due 
to hyperandrogenemia. Hovv·ever, they exhibit a comparable chance of reaching 
Ill 
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ongoing pregnancy compared to CCF. Patients, who failed to conceive despite 
ovulatory CC-induced cycles, benefit a good chance of pregnancy during exoge-
nous FSH induction of ovulation. This indicates that assisted reproduction tech-
niques should not be introduced in women vvho ovulated but failed to conceive 
following CC. Gonadotropins should be considered as ovulation induction strat-
egy with high chances of pregnancy particularly in young, CRA or CCF patients 
who exhibit an elevated level of IGF-I. Only those women who are more likely 
to fail to conceive due to impaired fertility chances (advanced age or high chance 
of hyperresponse during exogenous FSH stimulation), should be devised to ben-
efit from alternative treatment options such as assisted reproductive techniques. 
Prospective studies should be performed to evaluate significance of these param-
eters for prediction of treatment outcome follo\ving assisted reproductive tech-
niques such as in vitro fertilisation in those patients \vho failed to conceive dur-
ing exogenous gonadotropin induction of ovulation applying a modified step-
do\vn regimen. 
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Studies presented in this thesis \\rere set up attempting to identify clinical, 
endocrine and ultrasound features upon initial screening to predict outcome of 
ovulation induction in normogonadotropic anovulatory infertile vvomen. This 
approach in a very heterogeneous group of patients might render clinical inter-
vention more cost effective by allowing individualized treatment strategies. T'his 
line of thinking requiers a paradigm shift from diagnosis to prognosis. The search 
for etiological factors in cross sectional studies is inherently weak. This new lon-
gitudinal approach may provide useful information regarding the pathophysiology 
of underlying ovarian abnormalities in this heterogeneous patient population. I.e. 
factors involved in the response of ovaries to stimulation by endogenous or exoge-
nous FSH may indeed be directly related to ovarian dysfunction. In this respect, 
ovulation induction can be considered an extended challange test. 
Currently, CC represents the first line treatment strategy for all patients \vith 
normogonadotropic anovulatory infertility. CC is safe and convenient with limited 
chances for complications such as multiple pregnancy or OHSS. However, only 
38% of treated women may conceive follovving CC resulting in live birth \vhich is 
substantially less than generally assumed. As indicated earlier, a great majority of 
patients do not respond to maximum close of CC administered. It may represent a 
distinct step forward if patients remaining anovulatory following CC therapy or 
patients with extreme low chance for live birth despite ovulatory CC cycles could 
be identified prior to initiation of therapy. Ineffective and time-consuming CC 
medication could be prevented and alternative treatment modalities could be 
applied. This may be helpful, particularly for women of advanced reproductive age. 
I-."'or the first time, our group has focused on ovulation and conception in sepa-
rate steps. Two multivariate prediction models have been introduced in the treat-
ment of anovulatory infertility applying CC. The first multivariate model consist-
ing of FA!, BMI, cycle history, and mean ovarian volume predicts chances of 
remaining anovulatory following CC (Imani et al., 1998). The second model con-
sisting of age and cycle history predicts chances for conception only in \vomen 
who respond to CC (lmani et al., 1999). These two models were subsequently 
implemented in a nomogram. The first part of the nomogram, depicted in left side 
of the nomogram chart, is to predict the chances of ovulation following CC apply-
ing three initial screening characteristics, FAI, BMI, and cycle history. As indicat-
ed earlier, FAI is the most significant endocrine marker of ovarian dysfunction and 
for the prediction of ovarian response follov,ring CC. External validation of the 
present nomogram is mandatory to allm:v the definition of a clear cut-off level in 
the chances for live birth after CC for the decision making in routine daily clinical 
practice. These patients could be advised to refrain from CC therapy and start with 
an alternative first line treatment modality such as weight reduction, exogenous 
lJ(J 
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gonadotropins, insulin sensitizing hormones, or in vitro fertilization, particularly 
in vvomen of advanced age. This v..'Ould render CC ovulation induction more 
patient-tailored and could improve overall cost effectiveness. 
Complications of induction of ovulation applying exogenous gonadotropins in 
the group of normogonadotropic clomiphene resistent oligomenorrheic or amen-
orrheic infertile vvomen are a cause of major concern. These complications are 
mainly OHSS and multiple pregnancy, which seem to be correlated with the close 
regimens applied (van Santbrink et al., 199/a), late follicular phase FSH accumula-
tion and I or multifollicular development (Fauser et al., 1997). The initial starting 
dose of FSH for any given patient is a crucial point since it might be inapropriate-
ly too high or too lO\v, in the majority of patients who exhibit a too lovv or a too 
high FSH threshold level. In these patients, stimulation should be cancelled clue to 
hyperresponse. Currently, this represents the major drawback of the step-down 
approach (Fauser et al., 1997). By choosing the appropriate starting FSH dose 
chances of OHSS or multiple gestations may be restricted. 
As second step in the present study we focused on prediction of FSH response 
dose which reflects FSH threshold level. The individual FSH response dose in 
anovulatory infertile vvomen can be predicted using BMI, ovarian response during 
preceding CC medication, and serum free IGF -I and initial FSH concentrations. 
The possibility to predict the individual FSH threshold may increase safety, effi-
ciency and patient convenience of lovv-dose regimens for gonadotropin induction 
of ovulation by the proper assessment of the appropriate starting dose for a given 
patient. This may represent a distinct step fon\'ard in the clinic. Time-consuming 
low dose increments may be overcome by starting \\rith a high dose in women with 
an augmented FSH threshold. In contrast, starting with an individualized dose in 
step-down regimens may reduce chances for hyperresponse in \Vomen with a lovv 
FSH threshold. FSH threshold may represent the severity of ovarian abnormali-
ties in these patients. Indeed, ovarian response to preceding CC medication pre-
dicts ovarian response during subsequent stimulation by exogenous I, .... SH. This 
fmding confirms the concept previously proposed by our group indicating that 
CRA patients may suffer from a more serious ovarian abnormality vvhich is more 
resistant to stimulation by FSH (lmani et al., 1998; lmani et al., 2000). Patients who 
ovulated following CC but failed to conceive exhibit a lower FSH threshold and 
may subsequently require lower dose of exogenous FSH to reach sufficient ovari-
an stimulation. 
Next, a model has been introduced to predict the chance of multiple follicular 
development in gonadotropin induced cycles applying decremental dose regimen. 
Multivariate analyses revealed a final model including initial serum AD level, 
being a CRA and the total number of follicles prior to initiation of stimulation. 
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Further \vell-designed prospective randomised studies are required to investigate 
\Vhether alternative treatment options such as "ovarian drilling" or "insulin sen-
tising agents" are cost effective in patients predicted applying this model. In the 
present study a CCR of %65 have been reached \Vithin eight consecutive 
gonadotropin ovulation induction cycles. 
Overlooking the findings dicussecl in this thesis the following recommendations 
for future studies can be made: 
Extensive validation of these prediction models should be performed in other, 
independent patient populations. 
Further follov .. ' up studies should be performed in the current series of patients 
after unsuccessful ovulation induction undergoing in vitro fertilization. Can 
ovarian response to hyperstimulation and chances for success and complica-
tions be predicted" (Mulders et al., In preparation) 
\Ve should go back to the literature and investigate whether confirmation of the 
importance of factors identified in our multi-variate analysis for ovarian patho-
physiology and outcome of ovulation induction can be found. (Mulders et al., In 
preparation) 
A flov,r chart for the health economic approach of classical ovulation induction 
may be designed on the basis of the current findings. (Eijkemans et al., In 
preparaton) 
A multi-variate analysis should be performed for the prediction of classical ovu-
lation induction outcome (CC and FSH combined). (Eijkemans et al., In prepa-
ration) 
Alternative treatment approaches may be explored in women \vith predicted 
lov-.' success chances vvith conventional ovulation induction, such as: 
- FSH as first treatment in women \Vith low chances for life birth following CC 
treatment. 
- The application of insulin sensitizing agents or aromatase inhibitors as 
adjunctive or first line therapy in low chance patients. 
- The surgical/laser approaches as adjunctive or first line tretament in low 
chance patients 
-In vitro fertilisation as first line treatment in low chance patients. 
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Summary 
Chapter L The first chapter of the present thesis has focused on classification of 
anovulatory infertility, the treatment strategies, ovulation induction protocols, 
success and complication rates reported in the literature, and an insentive for the 
development of a nev.r classification ofVVHO 2 anovulatory infertility \vhich in fact 
is the most common form of anovulation in vvomen of I·eproductiYe age. '\iVe also 
briefly described the objective of the present thesis which has been the prediction 
of treatment outcome in these patients. Therefore, vve have discussed several sta-
tistical aspects of development of a prognostic model in longitudinal follo\v-up 
cohort studies. 
Chapter 2: In the first part of Chapter 2 \vas have focused on identification of cer-
tain criteria assessed during standardized initial screening ·which could predict the 
response to ovulation induction \vith clomiphene citrate (CC) in 201 patients pre-
senting \Vith oligomenorrhea or amenorrhea and infertility. Serum FSH levels 
\\-'ere vvithin the normal range (l-10 IU/L). First ovulation with CC was used as 
the end point. After a complete follow-up (in the case of a non-response, at least S 
treatment cycles \Vith daily CC doses up to 150 mg), 156 patients (78%) ovulated. 
"I'he free androgen index (FAI = testosterone/ sex hormone-binding globulin 
ratio), body mass index (B:\11), cycle history (oligomenorrhea vs. amenorrhea), 
serum androgen (testosterone and/or androstenedione) levels, and mean ovarian 
volume assessed by transvaginal sonography \vere all significantly different (P < 
0.0 l) in responders fi~om those in non-responders. FAI \-vas chosen to be the best 
predictor in univariate analysis. The area under the receiver operating character-
istics curve in a multivariate prediction model including FAI, BMI, cycle history, 
and mean ovarian volume \vas 0.82. These observations may add to ongoing dis-
cussion regarding etiological factors involved in ovarian dysfunction in these 
patients and classification of normogonadotropic anovulatory infertile \VOmen. 
In the second part of this chapter vve have tried to identify whether clinical, 
endocrine, or ultrasound characteristics assessed by standardized initial screening 
of normogonadotropic oligo/amenorrheic infertile patients could predict concep-
tion in 160 \Vomen \'vho reached ovulation after clomiphene citrate (CC) medica-
tion. First conception (defined as a positive urinary pregnancy test) \\-'as the end 
point for this study. A cumulative conception rate of/3% \vas reached \vi thin 9 CC-
inclucecl ovulatory cycles. Patients \Vho did conceive presented more frequently 
with lower age (P < 0.0001) and amenorrhea (P < 0.05) upon initial screening. In 
a univariate analysis, patients Yvith elevated initial serum LH concentrations 
(>7.0 IU/L) had a higher probability of conceiving (P < 0.01). In a multivariate 
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analysis, age and cycle history (oligomenorrhea vs. amenorrhea) \vere identified as 
the only significant parameters for prediction of conception. These observations 
suggest that there is more to be gained from CC ovulation induction by younger 
women presenting v,.·ith profound oligomenorrhea or amenorrhea. Screening char-
acteristics involved in the prediction of ovulation after CC medication in normog-
onadotropic oligo/ amenorrheic patients (body \veight and hyperandrogenemia, as 
shown previously) are distinctly different from predictors of conception in ovula-
tory CC patients (age and the severity of cycle abnormality). This disparity sug-
gests that ovarian response and oocyte quality (chances for conception in ovulato-
ry cycles) may be differentially regulated. 
The third part of the present prospective longitudinal follovv-up study \Vas 
designed to identify \'1-'hether additional endocrine screening characteristics, all 
potentially involved in ovarian dysfunction in 182 normogonadotropic oligoamen-
orrheic infertile \\'Omen, are associated with ovarian response, which may improve 
overall prediction of CC-resistant anovulation. Screening included serum assays 
for fasting insulin and glucose, insulin-lil<e growth factor I (IGF-1), IGF-binding 
protein-! (!GFBP-1), !GFBP-s, free !GF-1, inhibin B, leptin, and vascular 
endothelial grov .. .-th factor. Forty-tv ..·o women (22% of the total group) did not ovu-
late at the end of follow-up (a total number of 525 cycles were analyzed). Fasting 
serum insulin, insulin/glucose ratio, IGFBP-1, and leptin vvere all significantly 
different in univariate analyses (P ~ 0.02), comparing CC responders vs. nonre-
sponders. Forward stepv-.rise multivariate analyses in combination with factors 
reported earlier for prediction of patients remaining anovulatory after CC revealed 
a prediction model including l) free androgen index (E;\I = testosterone/ sex hor-
mone-binding globulin ratio), 2) cycle history (oligomenorrhea or amenorrhea), 3) 
leptin level, and 4) mean ovarian volume. These data suggest that decreased insulin 
sensitivity, hyperandrogenemia, and obesity- all associated with polycystic ovary 
syndrome - are prominent factors involved in ovarian dysfunction, preventing 
these ovaries from responding to stimulation by raised endogenous FSH levels due 
to CC medication. By using leptin instead of body mass index or \\-'aist to hip ratio, 
the previous model for prediction of patients remaining anovulatory after CC med-
ication could be slightly improved (area under the curve f!·mn 0.82-0.85). This may 
indicate that leptin is more directly involved in ovarian dysfunction in these 
patients. The capability of insulin and IGFBP-1 to predict patients \Vho remain 
anovulatory after CC disappears when FAI enters into the model due to a signifi-
cant correlation between FAI and these endocrine parameters. This suggests that 
markers tOr insulin sensitivity (e.g IGFBP-1 and insulin) are associated with 
abnormal ovarian function through its correlation with androgens, whereas leptin 
is directly involved in ovarian dysfunction. 
Summa!)' 
The objective of the last part of chapter 2 is to establish whether initial screen-
ing characteristics of normogonadotropic anovulatory infertile women predict live 
birth after clomiphene citrate (CC) induction of ovulation. In this prospective lon-
gitudinal single centre study included 259 couples. Main outcome vvas conception 
leading to live birth after CC. Ninety eight ( 38%) patients conceived after CC lead-
ing to live birth. The cumulative live birth rate vvithin 12 months \Vas 4•2% for the 
total study population and 56% for the ovulatory \vomen after CC. Factors pre-
dicting chances for live birth include; free androgen index (testosterone sex hor-
mone-binding globulin ratio), body mass index, cycle history (oligomenorrhea ver-
sus amenorrhea) and \\'oman's age. In conclusion, it is possible to predict the indi-
vidual chances of live birth after CC using two distinct prediction models com-
bined in a nomogram. Applying this nomogram in the clinic may be a step forward 
in optimizing the decision-making process in the treatment of normogonadotrop-
ic anovulatory infertility. Alternative first line treatment options could be consid-
ered for some women vvith limited chances for success. 
Chapter So The objective of the third and last chapter of the present thesis has 
been prediction of the gonadotropin induction of ovulation outcome. In the first 
part of the present prospective longitudinal clinical study we focused on prediction 
of FSH response (threshold) dose in normogonaclotropic, anovulatory infertile 
women undergoing gonadotropin induction of ovulation. Ninety clomiphene cit-
rate (CC) resistant (CRA) or CC-failure (CCF) normogonaclotropic o!igoamenor-
rheic infertile patients \\·'ere included. A lov·.:-close step-up regimen for daily exoge-
nous FSH administration was applied. Main outcome measures has been the FSH 
close on the clay of ovarian response (follicle growth beyond 10 mm diameter). The 
following equation has been developed applying a multivariate analyses to predict 
the individual FSH response dose (between 75 and> 187 !U/d) before initiation 
oftherapyo [4 body mass index (BMI; kg /m2)] + [32 CRA (yes= 1 or no= 0)] 
+ [7 initial free insulin-like growth factor-! (free !GF-l; ng/mL)J + [6 initial 
serum FSH (IU /L)j - 51. Standard error of the predicted dose = 35 IU. In con-
clusion, the individual FSH response close for gonadotropin induction of ovulation 
in anovulatory infertile v,romen can be predicted on the basis of initial screening 
characteristics. The prediction model developed in this study may increase safety 
and efficiency of low-dose gonadotropin protocols (both step-up or step-clown) by 
the proper assessment of the appropriate starting dose for a given patient. 
The objective of the second part of the present chapter, has been to evaluate 
\Vhether standardised initial screening may predict treatment outcome (mono vs. 
multi-follicular development and conception) follov·:ing gonadotropin induction of 
ovulation. One hundred and fifty two women who previously failed to ovulate or 
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conceive following clomiphene citrate (CC) induction of ovulation were included. 
The main outcome parameters included number of developing follicles assessed by 
ultrasound, cycle cancellations and conception (positive urinary pregnancy test) 
after exogenous gonadotropins. In an univariate logistic regression analyses to 
predict the probability of multiple dominant(> 15 mm) follicle development (n = 
198, 45%), ovarian response to the preceding CC treatment, initial serum LH, 
FSH, testosterone (T), androstenedione (AD), and sonographic appearance of 
polycystic ovaries were significant different. A multivariate model to predict the 
chances of generating multiple dominant follicles could be developed with an area 
under the receiver operating characteristic curve (AU C) of 0.6, including T and 
mean follicle number. A total number of 79 patients conceived (52%) and 69 
women had a live birth (4<5%). A cumulative conception rate (CCR) of 60% was 
reached vv·ithin 6 induced cycles. In univariate Cox regression analysis patients age 
and initial serum insulin-like growth factor-! (IGF-l) were significant different (P 
< 0.05). Comparing those ''"'omen 1vho did versus those 1vho did not conceive in a 
multivariate Cox regression analyses ·women's age, initial serum IGF -I and T 
entered into the final model, which had an AUC of 0.69. In conclusion, it is possi-
ble to predict the individual treatment outcome- chances for a successful stimula-
tion of monofollicular gro1vth and conception - follovving gonadotropin induction 
of ovulation applying a step-down dose regimen. The present tv.w prediction mod-
els (in combination with the previous model predicting the individual FSH 
response dose) may render gonadotropin ovulation induction more patient tailored 
by reducing chances for complications and optimizing chances of achieving a sin-
gleton pregnancy. 
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Sawenvatting 
Samenvatting 
Hoofdstuk l: Het eerste hoofclstuk van dit proefschrift is gericht op de klassifl-
catie van anovulatoire infertiliteit, ver.schillende behandelingsstrategieen en ovu-
latie inductie protocollen en successen en complicaties zoals beschreven in de lit-
eratuur. Het doel van de 6 studies beschreven in dit proefschrift ~ predictie van 
uitkomsten van ovulatie incluctie bij vonnven met normogonaclotrope, anovula-
toire infertiliteit- \\-'ercl aangegeven. Statistiche aspecten van de ontwikkeling van 
predictie modellen in longitudinale follow-up studies worden beschreven. 
Hoofdstuk 2: In het eerste cleel van hoofdstuk 2 lag de focus op identificatie van 
bepaalde criteria (verkregen tijdens een gestandaardiseerde initiele screening) die 
voorspellend zouden kunnen zijn voor de respons op ovulatie inductie met 
clomifeen citraat (CC) bij 201 patienten met oligomenorroe of amenorroe en infer-
tiliteit. Serum FSH spiegels waren binnen de normale range ( 1-10 IU /l). De eerste 
ovulatie met CC were! gebruikt als eindpunt. N a een complete follow-up (in geval 
van geen respons, tenminste 3 behandelingscycli met een dagelijkse CC dosering 
tot 150 mg) waren 156 patienten (78%) ovulatoir. De vrije androgeen index (FA! 
= free androgen index = ratio testosteron/ sexhormoon bindend globuline ), BMI 
(body mass index), cyclus anamnese (oligomenorroe versus amenorroe), serum 
androgeen spiegels (testosteron en/of androsteenclion), en bet gemiddelcle ovari-
um volume (bepaald met behulp van transvaginale echografie) \\'aren allen signif-
icant verschillend (P < 0.01) tussen patienten met en zonder respons op CC. De 
FAI vverd gekozen als de beste voorspeller voor ovariele respons in de univariate 
analyse. De "area onder de ROC (receiver operating characteristics) curve" in een 
multivariaat predictie-model met FAI, BMI, cyclus anamnese, en gemiddeld ovar-
ium volume vvas 0.82. Deze bevindingen zijn wellicht van belang voor de voort-
durende discussie over etiologische factoren betrokken bij ovarium dysfunctie bij 
deze patienten en voor de classificatie van normogonadotrope anovulatoire infer-
tiele vrouwen. 
In het tweede dee! van het hoofdstuk hebben we geprobeercl om klinische, 
endocriene of echo karakteristieken (bepaald bij gestandaardiseerde initiele screen-
ing van normogonadotrope infertiele patienten met oligo/amenorroe) te identifi-
ceren die voorspellend zijn voor conceptie bij 160 patienten die ovuleerden na CC 
medica tie. De eerste conceptie (gedefinieerd als een positieve urine zwangerschap-
stest) was het eindpunt van deze stuc\ie. De cumu]atieve zwangerschapskans van 
73% wercl bereikt binnen 9 CC-gelnduceerde ovulatoire cycli. De patienten die 
zwanger werden, hade! en vaker een jongere leeftijd (P < 0.000 I) en amenorroe (P 
< 0.05) bij de initiele screening. In de univariate analyse hadden patienten met een 
Predit1io11 qj" Ovulation Jndurlion Ou/comt in Normogrmadotropic Anont!atory ]i!fi:rtili(y 
verhoogde initiele LH serum spiegel (> 7.0 IU/1) een grotere kans op Z\vanger-
schap (P < 0.01). In de multivariate analyse v.rerden leeftijd en cyclusanamnesc 
(oligo- of amenorroe) geYdentificeerd als de enige significante parameters voor de 
predictie van conceptie. Deze bevindingen suggereren dat er bij ovulatie inductie 
met CC meer winst valt te behalen bij jongere \TOU\ven met ernstige oligomenor-
roe of amenorroe. De screenings l.;:arakteristieken die betrokken z\jn bij de preclic-
tie van ovulatie na CC medicatie bij normogonadotrope patienten met 
oligo/ amenorroe (BMI, en hyperanclogenemie, zie eerder) zijn duidelijk verschil-
lend van de voorspellers van conceptie in ovulatoire CC patienten (leeftijd en mate 
van cyclusstoornis ). Dit onclerscheid suggereert dat de FSH drempel (hoeveelheid 
F'SH nodig voor stimulatie van follikelgroei en ovulatie) en oocyt kwaliteit (kans 
op conceptie in ovulatoire cycli) verschillend worden gereguleercl. 
Het derde deel van de huidige prospectieve longitudinale follovv-up studie \'vas 
ontv,rorpen om te beoordelen of additionele endocriene screenings parameters, 
allen potentieel betrokken bij ovariele clysfunctie in 182 normogonadotrope infcr-
tiele vrouv1ren met oligo/ amenorroe, correleerden met O\'ariele respons, zodat 
wellicht de totale predictie van CC-resistente anovulatie kan vv·orclcn verbeterd. Bij 
de screening waren analyses voor nuchtere insuline en glucose, IGF -I (insulin-like 
growth factor 1), IGFBP-1 (IGF-binding protein-!), IGFBP-3, vrij IGF-I, inhib-
ine B, leptine, en "vascular endothelial growth factor" inbegrepen. Tvvee-enveertig 
\TOu\ven (22% van de totale groep) ovuleerclen niet aan het eind van de follo\v-up 
(in totaal \verden 325 cycli geanalyseercl). Het nuchtere serum insuline, de insu-
line/glucose ratio, IGFBP-1, en leptine waren allen significant verschillencl in uni-
variate analyses (P ~ 0.02) tussen de patienten met en zonder ovariele respons. 
Met "forv.rard stepvvise" multivariate analyses, in combinatie met de factoren die 
eerder zijn aangegeven voor de predictie van patiCnten die anovulatoir blijven na 
CC, kwam een predictiemodel tot stand met 1) FA!, 2) cyclusanamnese, 3) leptine 
serum spiegel, en 4) gemicldeld ovarium volume. Deze data suggereren dat een ver-
laagde insuline sensitiviteit, hyperandrogenemie, en obesitas (allen geassocieerd 
met polycysteus ovarium syndroom), prominente factoren zijn betrokken bij ovar-
iele dysfunctie, en voorkomen dat de ovaria van clezc patienten reageren op stimu-
latie door verhoogde endogene FSH spiegels ten gevolge van CC medicatie. Door 
leptine te gebruiken in plaats van BMI of taille/heup ratio, kon bet eerdere model 
voor predictie van patienten die anovulatoir bleven na CC meclicatie enigszins ver-
beterd \'vorden ("area under the curve" van 0.82 naar 0.85). Dit kan betekenen dat 
leptine directer betrokken is b\j ovarium clysfunctie bij deze patienten. De compe-
tentie van insuline en IGFBP-1 om patienten te voorspellen die anovulatoir b1ijven 
na CC verdvvijnt zodra FAI het model blnnenkomt ten gevolge van een significante 
correlatie tussen I'~\ I en deze endocriene parameters. Dit suggereert dat markers 
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voor insuline sensitiviteit (zoals IGFBP-1 en insuline) geassocieerd zijn met 
abnormale ovarium functie door hun correlatie met androgenen, terwijl leptine 
direct betrokken is by ovarium dysfunctie. 
Het doe! van het laatste dee! van hoofdstuk 2 is om vast te stellen of initiele 
screenings karakteristieken van normogonadotrope anovulatoire infertiele patien-
ten voorspellend zijn voor de geboorte van een levend kind na de inductie van ovu-
latie met CC. In deze prospectieve longitudinale studie \verden 259 paren 
bestudeerd met een voorgeschiedenis van infertiliteit, oligo/ amenorroe, normale 
FSH (follikel stimulerend hormoon) concentraties en geen eerdere behandeling 
met enige medicatie voor ovulatie inductie. De belangrijkste uitkomst vvas concep-
tie na CC leidend tot de geboorte van een levend kind. Negenentachtig (38%) 
patienten werden Z\-vanger na CC leidend tot de geboorte van een levend kind. Het 
cumulatieve percentage levende geboortes binnen 12 maanden was 42% voor de 
totale studie-populatie en 56% voor de ovulatoire vrouwen na CC. De factm-en die 
de kans op de geboorte van een levend kind voorspellen zijno FA!, BMI, cyclu-
sanamnese (oligo- of amenorroe) en de leeftijd van de vrou\V. Concluderend, het is 
mogelijk om de individuele kansen voor de geboorte van een levencl kind na CC 
gebruik te voorspellen in hvee verschillende predictie modellen, gecombineerd in 
een nomogram. De toepassing van dit nomogram in de kliniek kan een stap 
vooruit zijn in het verbeteren van het besluitvormingsproces in de behandeling 
van normogonadotrope anovulatoire infertiliteit. Voor sommige vrouwen met lage 
kansen op succes kunnen alternatieve eerstelijns behandelings opties worden over-
vvogen. 
Hoofdstuk So Het seen laatste hoofdstuk van dit proefschrift behandelt het voor-
spellen van de uitkomst ovulatie-inductie met gonadotrofines. In het eerste deel 
van de huidige prospectieve longitudinale studie hebben we ons gericht op voor-
spellen van de FSH response-(drempel) dosis in normogonadotrope anovulatoire 
infertiele vrouwen die gonadotrofine-ovulatie incluctie ondergingen. Negentig 
normogonadotrope anovulatoire vrouvven die clomifeencitraat (CC)- resistent 
(CRA) waren en CC- behandelde vrouwen die vvel ovuleerde, maar niet zwanger 
werclen (CCF), werclen geincludeerd. Voorafgaand aan de behandeling wercl een 
g·estandaardiseerde screening gedaan \Vaarbij klinische-, endocriene en echografis-
che parameters werden vastgelegd. Vervolgens werd in een lm\1-dose step-up pro-
tocol clagelijks exogeen gonaclotrofme toegediend. De FSH dosis op de dag van 
ovariele response (follikel groei > 10 mm in diameter) werd gezien als de FSH-
response dosis. Met behulp van een multivariate analyse is de volgende formule 
ontwikkeld met als cloel om de individuele FSH-responsedosis te berekenen 
voorafgaand aan een behandelingo [4 body mass index (BMI; kg /m2)] + [32 CRA 
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Ua = 1 or nee = o)J + [7 initial vrije- insulin-like growth factor-! (free IGF-1; 
ng/mL)] + [6 initial serum FSH (IU/L)~- 5!. Standaard error van de voorspelde 
dosis is S5IU/L. Concluderend kan worden gesteld dat de individuele FSH-
respons dosis voor gonadotrofine ovulatie inductie in normogonadotrope anovula-
toire infertiele vrouvven kan worden voorspeld op basis van screenings-parame-
ters. Het in deze studie ontwikkelde preclictie-model kan veiligheicl en efficientie 
van een low-close gonadotrophine protocol (zowel step-up als step-dovvn) ver-
hogen door de juiste start dosis te bepalen bij een individuele patient. 
In het tweede dee! van het huidige hoofdstuk wordt gekeken of klinische, 
endocriene, of echografische bevindingen tijdens de gestandaarcliseerde screening 
voorafgaancle aan de behandeling, de uitkomst van de behandeling (mono- vs 
multi-folliculaire groei en conceptie) kunnen voorspellen bij gonadotrofine ovu-
latie inductie. Honclerdtv,.·eeenvijftig vrouvven werden gei"ncludeerd. Gekeken vvercl 
naar het aantal groeiende follikels bij echografiscb onderzoek, bet aantal afgebro-
ken cycli en conceptie (positieve urinaire Z\vangerschapstest). Bij een univariate 
logistieke regressie analyse ter voorspelling van ontvvikkeling van multipele dom-
inante follikelgroei (>15 mm in diameter) bleek ovariele response op de vooraf-
gaande CC bebandeling, initieel LH, FSH, Testosteron (T), Androstendion (AD) 
en echografische PCO beelcl significant te verschillen. Een multivariate model 
werd ontwikkeld om de kans voor bet optreden van multipele dominante follikel-
groei te voorspellen met behulp van de initiele serum Testosteron en het aantal 
follikel op de dag van screening. In totaal werden 79 patienten zwanger (52%) 
\Vam·van 69 ( 4·5%) vrouv,.·en van een levendgeboren kind bevielen. Een cumulatieve 
conceptie rate (CCR) van 60% werd bereikt binnen 6 bebandelcycli. In een uni-
variate Cox-regressie analyse werden leeftyd, initiele IGF-I en T toegevoegd aan 
het model waarbij een AUC van 0.69% kon worden bereikt. Concluderend lykt bet 
mogelijk de individuele behandeluitkomst - de kansen voor succesvolle monofol-
liculaire groei en conceptie - bij een 10\v-dose step-down gonadotrofine ovulatie-
inductie protocol te voorspellen. Deze twee predictiemodellen kunnen deze beban-
deling gebuikvriendelijker maken en ons helpen om de kans op complicaties tijdens 
de behandeling te minimaliseren en de kansen op een eenlingzvvangerschap te ver-
groten. 
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